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ABSTRACT 
 Human diseases caused by an excess of protein function can often be treated with small 
molecules that bind and inhibit the corresponding proteins. In contrast, there are many currently 
incurable human diseases that are caused by missing protein ion transporters, including cystic 
fibrosis and microcytic anemia. Like many other human diseases caused by missing proteins, 
these diseases are difficult to treat, and new approaches are needed. Some small molecules can 
perform ion transporter-like functions, suggesting the possibility of replacing missing protein ion 
transporters with small molecule mimics. Closely replicating the functions of ion selective and 
tightly regulated protein transporters with small molecules is challenging. However, robust 
protein networks comprised of pumps and channels drive targeted ions in targeted directions 
throughout the spectrum of living systems. We hypothesized that relatively unselective and 
unregulated small molecule mimics of missing protein transporters might be capable of 
collaborating with the corresponding protein ion pumps to restore physiology.  
 The ion channel-forming natural product amphotericin B (AmB) was first identified as a 
small molecule that could enable testing of this hypothesis. AmB is the prototypical small 
molecule capable of ion channel formation and can permeabilize both yeast and human cells to 
potassium and other ions. We observed vigorous and sustainable restoration of yeast cell growth 
by replacing potassium ion transporters with AmB. We next tested whether AmB could restore 
physiology in cystic fibrosis (CF) human lung epithelia. We observed restoration of key makers 
of physiology in CF epithelia upon treatment with AmB. Chemical inhibition experiments 
demonstrated evidence for collaboration between AmB and protein ion pumps in both yeast and 
human epithelia.  To fully harness the ion channel property of AmB in the setting of protein 
deficiencies, a detailed understanding of how AmB interacts with membranes is required. 
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 For over 50 years, AmB has remained the powerful but toxic last line of defense in 
treating life-threatening fungal infections in humans with minimal development of microbial 
resistance. For decades, the dominant theory has been that AmB primarily exists in the form of 
small ion channel aggregates that are inserted into lipid bilayers and thereby permeabilize and 
kill yeast cells. Using solid-state NMR (SSNMR), we determined that AmB exists primarily in 
the form of large, extramembranous aggregates that kill yeast by extracting ergosterol from lipid 
bilayers. These findings suggest a roadmap for separating its toxic and ion channel activities. In 
this vein, the AmB channel is proposed to be funnel shaped, with the narrowest region near the 
C3 hydroxyl. Based on this model, we hypothesized that removal of the C3 hydroxyl would 
impact ion channel activity. The C3 alcohol was removed via synthesis in only 9 steps from 
AmB, resulting in C3deOAmB. Single ion channels of C3deoxyAmB in planar lipid bilayers 
revealed that C3deoxyAmB is still capable of ion channel formation, but its conductance is 
significantly reduced relative to AmB. This is consistent with models that place the C3 hydroxyl 
at a critical point for ion conductance and provide a potential site to tune ion selectivity.  
 Encouraged by the results in yeast and CF lung epithelia, we hypothesized that a small 
molecule might be able to restore physiology in iron transporter deficiencies. We used iron-
deficient yeast to screen for small molecules that could restore growth. We identified the small 
molecule hinokitiol (Hino) as capable of restoring growth in yeast lacking iron transporters. We 
then tested Hino in human colorectal epithelia lacking an iron transporter and observed Hino-
mediated restoration of transepithelial iron transport. Together, these results illuminate a 
mechanistic framework for pursuing small molecule replacements for deficient protein ion 
transporters that underlie a range of challenging human diseases. 
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Chapter 1 
Deficiencies of Protein Function and the Prospect of Molecular Prosthetics 
1-1 DEFICIENCIES OF PROTEIN FUNCTION 
In the classic paradigm of pharmacology, small molecules bind to proteins and inhibit 
their functions.1 This approach can be highly effective for diseases caused by an excess of 
protein function but is generally ineffective for those caused by a deficiency. The latter can 
sometimes be treated by directly replacing the missing protein, such as the use of insulin to treat 
diabetes, human growth hormone to treat growth failure, and recombinant enzymes to treat 
lysosomal storage diseases. In other cases, gene therapy may prove to be a viable strategy, with 
promising results recently reported in severe combined immunodeficiency disorders2 and Leber’s 
congenital amaurosis.3 Despite the important progress in these areas, however, many human 
diseases caused by deficiencies of protein function remain incurable. 
Deficiency of a chloride channel protein (cystic fibrosis transmembrance conductance 
regulator, CFTR) causes cystic fibrosis, the most common  fatal  genetic  disease affecting    
more than 70,000 young people worldwide.4,5 While tremendous progress has been  made  with  
the genotype-specific drug Ivacaftor to improve lung function in 4% of patients,6 there persists a 
major unmet medical need for the remaining 96% of cystic fibrosis patients 7,8 In  human lung      
epithelia, basolateral pumps and channels such as the sodium-potassium-chloride cotransporter    
(NKCC) create electrochemical gradients to drive anions through passive CFTR channels 
(Figure 1.1A).9,10 This leads to normal airway surface liquid (ASL) height and composition  
needed for healthy lung function.11  
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In addition, more than 25 hereditary diseases result from deficiencies of iron transporters 
or regulatory proteins including hypochromic, microcytic anemia12-16 caused by deficiencies of 
divalent metal transporter 1 (DMT1).17-21  DMT1 promotes the uptake of non-heme iron in 
duodenal enterocytes through H+/Fe2+ symport (Figure 1.1B) and drives erythropoiesis, releasing 
endosomal iron in developing erythrocytes.22-24 
 
1-2 THE PROSPECT OF MOLECULAR PROSTHETICS  
Small molecules often possess advantageous features that make them exceptionally 
effective and practical as therapeutics. Specifically, relative to proteins, peptides, and 
oligonucleotides, small molecules are more often evasive of the immune system, inert to 
peripheral metabolism, cell permeable, orally bioavailable, and cost effective to produce, purify 
Figure 1.1: Schematic for deficiencies of protein function. A.) In one of the leading models, the basolateral 
Na+/K+ ATPase pumps create an electrochemical driving force for chloride movement into the cells, and CFTR 
promotes the passive release of chloride to the apical surface. This, in turn, hydrates the surface leading to 
normal mucociliary motion. Lack of CFTR prevents chloride efflux leading to dehydration, lack of mucociliary 
motion, and chronic infections synonymous with cystic fibrosis. B.) DMT1-deficient gut epithelia exhibit 
reduced dietary iron absorption across the apical membrane resulting in decreased transport to the basolateral 
fluid via FPN1. 
3 
 
and store. Because of these features, small molecule-based strategies for addressing diseases 
caused by protein deficiencies could be especially impacting. In this vein, there are important 
examples of small molecules that can increase the functions of proteins, including ligands for 
various endogenous receptors,25 activators of enzymes,26-28 pharmacological chaperones,29 
disrupters of protein-protein interactions,30,31 and small molecule dimerizers.32 There are also 
promising cases in which small molecules increase the expression of proteins with nonsense 
mutations33 or activate riboswitches.34 All of these approaches, however, require inducible 
macromolecules. With the goal of overcoming this important limitation, it is intriguing to 
consider the possibility that small molecules might also possess untapped potential to 
autonomously replicate the functions of deficient proteins, thereby operating as prostheses on the 
molecular scale. 
If the restoration of physiology requires that a small molecule perfectly replicate the 
function of a missing protein, it is challenging to envision this approach being successful. 
However, living systems tend to be robust,35-38 and this an imperfect small molecule mimic of a 
missing protein might be able to restore physiology (Figure 1.2). Specifically, robustness enables 
living systems to thrive despite many genetic and/or environmental perturbations. The basis for 
this robustness is an excess of capacity to perform many of the functions required for physiology 
(Figure 1.2left). This robustness is achieved via a number of different mechanisms, including 
functional redundancy, feedback control, and modularity.35 If a protein is missing, the capacity to 
perform the corresponding function can drop below the threshold required for normal physiology 
resulting in a phenotype, such as growth deficiency in a cell or disease in a human. However, 
robustness implies that the level of residual functional capacity in such an organism is substantial 
(Fig. 1.2, middle). This is especially evident in transmembrane ion movement where robust 
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protein networks comprised of pumps and channels drive targeted ions in targeted directions 
throughout the spectrum of living systems.39 This analysis leads to the intriguing hypothesis that 
a small molecule that only partially mimics the function of that missing protein could collaborate 
with the respective protein ion pumps to restore physiology (Figure 1.2, right). 
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Chapter 2 
Probing the Atomistic Underpinnings of Amphotericin B’s Antifungal and Ion Channel 
Activity 
For over 50 years, amphotericin B (AmB) has remained the powerful but highly toxic last 
line of defense in treating life-threatening fungal infections in humans with minimal 
development of microbial resistance. Understanding how this small molecule kills yeast is thus 
critical for guiding development of derivatives with an improved therapeutic index and other 
resistance-refractory antimicrobial agents. In the widely accepted ion channel model for its 
mechanism of cytocidal action, amphotericin forms aggregates inside lipid bilayers that 
permeabilize and kill cells. Using solid-state NMR (SSNMR) spectroscopy and transmission 
electron microscopy (TEM), we determined that amphotericin exists primarily in the form of 
large, extramembranous aggregates that kill yeast by extracting ergosterol from lipid bilayers. 
These findings reveal that extraction of a polyfunctional lipid underlies the resistance-refractory 
antimicrobial action of amphotericin and suggests a roadmap for separating its cytocidal and 
membrane-permeabilizing activities. 
In addition, AmB is also the archetype for small molecules that form ion channels in 
living systems. Molecular modeling studies predict that AmB self-assembles in lipid membranes 
with the polyol region lining a channel interior that funnels to its narrowest region at the C3-
hydroxyl group. This model predicts that modification of this functional group would alter 
conductance of the AmB ion channel. To test this hypothesis, the C3-hydroxyl group was 
synthetically deleted, and the resulting derivative, C3deoxyAmB (C3deOAmB), was 
characterized using multidimensional NMR experiments and single ion channel 
electrophysiology recordings. C3deOAmB possesses the same macrocycle conformation as AmB 
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and retains the capacity to form transmembrane ion channels, yet the conductance of the 
C3deOAmB channels is 3-fold lower than that of AmB channels. Thus, the C3-hydroxyl group 
plays an important role in AmB ion channel conductance, and synthetic modifications at this 
position may provide an opportunity for further tuning of channel functions. 
 SSNMR experiments and analysis were performed by Dr. Mary Clay. Cell-based assays 
were performed by Katrina Diaz. Bowei Hu synthesized C3deOAmB. Solution NMR studies 
were performed with Dr. Stephen Davis, Bowei Hu, and Lisa Della Ripa. Dr. Stephen Davis 
performed planar lipid bilayer experiments. Portions of this chapter were adapted from Anderson 
et al., Amphotericin forms an extramembranous and fungicidal sterol sponge, Nature Chemical 
Biology, 2014 and Davis et al., C3-OH of Amphotericin B Plays an Important Role in Ion 
Conductance, Journal of the American Chemical Society, 2015.  
2-1 CURRENT UNDERSTANDING OF AMPHOTERICIN B’S ANTIFUNGAL ACTIVITY 
 The incidence of life-threatening systemic fungal infections continues to rise in parallel 
with expanding populations of immunocompromised patients.1 Substantially exacerbating this 
problem is the concomitant rise in pathogen resistance to almost all clinically approved 
antifungal agents. In contrast, AmB (Figure 2.1A) has served as the gold standard treatment for 
systemic fungal infections for over five decades with minimal development of clinically 
significant microbial resistance.2 This exceptional track record reveals that resistance-refractory 
modes of antimicrobial action exist, and the mechanism by which AmB kills yeast is one of 
them. However, because of the often dose-limiting toxicity of this natural product, mortality rates 
for systemic fungal infections persist near 50%.3 Improving the notoriously poor therapeutic 
index of this drug and the development of other resistance-refractory antimicrobial agents thus 
represent two critically important objectives that stand to benefit from a clarified molecular 
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description of the biological activities of AmB. Moreover, an advanced understanding of the 
biophysical interactions of this natural product within living systems would enable more 
effective utilization of its remarkable capacity to perform ion channel-like functions.  
For decades, the prevailing theory has been that AmB primarily exists in the form of 
small ion channel aggregates that are inserted into lipid bilayers and thereby permeabilize and 
kill yeast cells (Figure 2.1B).4-23 
Figure 2.1: Models for the structure and function of AmB in the presence of lipid bilayers. A.) Structures of 
AmB, Erg, POPC and paramagnetic probes 5-DOXYL-PC and 16-DOXYL-PC. 5-DOXYL and 16-DOXYL 
position a paramagnetic functional group at depths of ~12 Å and ~25 Å within the lipid bilayer, respectively. B.) 
The classic ion channel model for the structure and function of AmB. C.) Surface adsorption model. D.) A new 
sterol sponge model, in which AmB primarily exists in the form of large extramembranous aggregates that 
extract Erg from lipid bilayers. 
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An extensive series of structural and biophysical studies, including those employing planar lipid 
bilayers,4-10 liposome permeability,9-13,17 Corey-Pauling-Kulton (CPK) modeling7-9 UV/Vis 
spectroscopy,9-11,13,21 circular dichroism,10,11,13,21 fluorescence spectroscopy,9,11 Raman 
spectroscopy,10 differential scanning calorimetry,9,10,21 chemical modifications,11-14,17 atomic 
force microscopy,21 transmission electron microscopy,20 computer modeling,11,15 electron 
paramagnetic resonance,10 surface plasmon resonance,22 solution NMR spectroscopy,11 and 
SSNMR16-19 spectroscopy are all interpreted through the lens of this ion channel model. 
Importantly, this model suggests that the path to an improved therapeutic index requires selective 
formation of ion channels in yeast versus human cells,10-20 that the search for other resistance-
refractory antimicrobials should focus on membrane-permeabilizing compounds,24 and that the 
ion channel-forming and cytotoxic activities of AmB cannot be separated.  
2-2 AMPHOTERICIN FORMS AN EXTRAMEMBRANOUS AND FUNGICIDAL STEROL 
SPONGE 
Recent studies show that the channel forming capacity of AmB is not required for 
fungicidal activity, whereas binding ergosterol (Erg) (Figure 2.1A) is essential.25-27 However, the 
structural and biophysical underpinnings of this rare type of small molecule-small molecule 
interaction and its connection to cell killing all remained unclear. Sterols, including Erg in yeast, 
play many essential roles in eukaryotic cell physiology, including functional regulation of 
membrane proteins, microdomain formation, endocytosis, vacuole fusion, cell division, and cell 
signaling.28-31 We thus hypothesized that sequestering Erg and thereby precluding its 
participation in multiple cellular functions may underlie the fungicidal action of AmB.  
Guided by this hypothesis, we considered three possible models for the primary structure 
and function of AmB in the presence of Erg-containing phospholipid membranes (Figure 2.1B-
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D): (i) In the classic channel model, AmB primarily exists in the form of small (~1 nm) ion 
channel aggregates inserted into the membrane, perpendicular to the membrane surface, with Erg 
molecules interdigitated between AmB molecules (Figure 2.1B).7-9,11,12,15-19,22,23 (ii) In an 
alternative surface adsorption model, AmB is primarily positioned in the intermediate/headgroup 
region, oriented parallel to the plane of the membrane, sequestering Erg to the membrane surface 
(Figure 2.1C).9,22 (iii) In a new sterol sponge model, AmB primarily exists as large 
extramembranous aggregates that extract Erg from lipid bilayers (Figure 2.1D). In the latter two 
models, we envisioned that membrane-permeabilizing ion channels represent relatively minor 
contributors to both the structure and cytocidal activity of AmB.  
Distinguishing among these models required determining the location of AmB relative to 
lipid bilayers and the corresponding location of Erg in the absence and presence of AmB. 
Making these determinations turned out to be exceptionally challenging due to the lack of high-
resolution methods for probing small molecule/membrane interactions.9-13,15,17-21 We thus 
developed an experiment based on the NMR paramagnetic relaxation enhancement (PRE) of 13C 
nuclei caused by lipid-appended spin labels.32-34 13C nuclei proximal to a stable radical, such as 
4,4-dimethyloxazolidine-N-oxyl (DOXYL), experience large enhancements of their longitudinal 
relaxation rates (R1 = 1/T1). Due to the high gyromagnetic ratio of the electron spin, the PRE is 
detectable for distances up to ~20 Å. Harnessing this phenomenon, we designed a magic-angle 
spinning (MAS) SSNMR PRE experiment based on 16-DOXYL-PC and 5-DOXYL-PC to 
interrogate proximity to the hydrophobic core and intermediate/headgroup region, respectively 
(Figure 2.1A). Importantly, the three models under consideration (Figure 2.1B-D) predict distinct 
PRE effects for AmB. The ion channel model predicts large PREs with both spin labels; the 
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surface adsorption model predicts large PREs only with 5-DOXYL-PC; and the sterol sponge 
model predicts little or no PRE effects with either spin label. 
To execute this experiment with maximized signal-to-noise ratio, we prepared highly 
enriched U-13C-AmB via development of an improved biosynthetic protocol.18 By using 
uniformly labeled 13C glucose (U-13C-glucose) as the primary carbon source, we developed a 
robust procedure for attaining >80% 13C incorporation, the highest 13C enrichment yet reported 
for this natural product. This highly enriched U-13C-AmB enabled confident assignment of 13C 
resonances and high sensitivity PRE measurements even at high lipid-to-AmB ratios. 
We next identified a physiologically relevant lipid bilayer system in which we could 
execute the targeted experiments. Recent structure-function studies with AmB reveal that, in 
contrast to liposomes comprised of fully saturated lipids, liposomes derived from 
monounsaturated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and Erg yield 
results that mirror those obtained with live yeast cells.25,27 Also unlike membranes derived from 
fully saturated lipids, the plasma membranes of yeast and bilayers derived from POPC:Erg are 
both in the liquid crystalline state at 23 °C.35,36 In yeast, POPC is highly abundant, and Erg is the 
most common sterol.37 Moreover, at the minimum inhibitory concentration for AmB against both 
Saccharomyces cerevisiae and Candida albicans, there is at least as much AmB as there is Erg.25 
We thus prepared lipid bilayer samples throughout this study with molar ratios of at least 10:1 
POPC:Erg; for those samples containing AmB, we used at least 1 equivalent of AmB (relative to 
Erg). These bilayers exhibited proper phase behavior and retained this behavior upon addition of 
DOXYL spin labels (Figure 2.2). 
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To first confirm the position of each spin label in the bilayer, we determined the 
respective PREs on 13C resonances in natural abundance POPC lipids with 5 mol% of each 
DOXYL spin label (Figure 2.3A). Consistent with the structure of POPC membranes,35 bilayers 
doped with 5% 16-DOXYL-PC demonstrated a maximal PRE at the termini of the POPC fatty 
acid chains, and the PRE decreased as the distance from the center of the membrane increased 
(Figure 2.3A). The incorporation of 5-DOXYL-PC alternatively yielded maximal PREs in the 
intermediate and headgroup regions of the lipid bilayer and much smaller, yet still readily 
observable, effects at the membrane interior. Thus, these two spin label probes enabled confident 
and complementary interrogation of the inner most and outermost regions of a lipid bilayer in a 
straightforward SSNMR experiment.  
We next prepared samples with U-13C-AmB in POPC/Erg bilayers and used a series of 
13C chemical shift correlation experiments (including CTUC-COSY,38 DARR,39 and SPC540) to 
assign de novo the 13C resonances of AmB (Figure 2.4). We then performed PRE measurements 
in the presence of 16-DOXYL-PC or 5-DOXYL-PC spin probes. The results were striking and 
unambiguous. As predicted by the extramembranous sterol sponge model, and inconsistent with 
Figure 2.2: 1H T2 values of the bulk fatty acyl CH2 peaks of molar ratios of A.) 10:1 POPC:Ergosterol B.) 10:1 
POPC:Ergosterol  +  5%  5-DOXYL-PC and C.) 10:1 POPC:Ergosterol  +  5% 16-DOXYL-PC liposomes as a 
function of temperature. The data were acquired on a 600 MHz spectrometer over a calibrated temperature range 
of -8 to 28 °C 
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both the membrane-inserted ion channel and surface adsorption models, we observed no 
significant PREs to any 13C resonances of AmB with either probe (Figure 2.3B). Thus, the 
majority of AmB in these samples is >20 Å away from the membrane-embedded spin labels. 
 
A series of additional SSNMR experiments further revealed that AmB exists in the form 
of large aggregates that are more closely associated with water than lipids. The longitudinal 
relaxation times (T1 values) for AmB were substantially longer than those of the lipids, 
consistent with large and relatively immobile aggregates of AmB (Figure 2.3C and 2.3D). 
Figure 2.3: AmB primarily exists as large extramembranous aggregates. A.) PRE values have magnitude proportional to 
1/r6, where r is the distance from spin label to NMR-detected nucleus. POPC controls demonstrated this proportionality in the 
presence of 5 mol% 5-DOXYL-PC (black) or 16-DOXYL-PC (gray). B.) [U-13C] AmB demonstrated no PRE effects ≥0.03 
s−1 in the presence of either 5-DOXYL-PC (black) or 16-DOXYL-PC (gray) paramagnetic probes. Substantial differences 
were observed between longitudinal (T1) 13C relaxation times for sites in C.) POPC and D.) AmB. E.) Selected 1H-13C two-
dimensional spectra were collected with a 1 ms T2 filter and 1H-1H spin diffusion times of 1 ms, 100 ms and 400 ms; cross-
peaks were from lipid acyl chains (red) and water (blue) to the [U-13C] AmB polyene region. F.) The polarization transfer 
was quantified as a function of spin diffusion time from water and lipid to [U-13C] AmB polyene. PRE values were derived 
from the difference between 13C R1 relaxation rates measured via inversion recovery for diamagnetic samples and samples 
containing 5-DOXYL-PC and 16-DOXYL-PC. Error bars were determined by χ2 analysis. 1H-13C spin diffusion data were 
normalized relative to maximum intensity observed for both lipid and water cross-peaks for a given 13C site after correcting 
for 1H T1 relaxation. Error bars were derived from the signal-to-noise ratio of the observed cross peak. Spectra were acquired 
at 14.1 T (600 MHz, 1H frequency) at 20 °C, 10 kHz MAS. 
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SSNMR spin-diffusion experiments, designed for the purpose of probing membrane protein 
topology,41 revealed that lipid-AmB correlations reached maximum intensity only at very long 
mixing times (~400 ms) for all resolvable carbons on AmB (Figure 2.3E, 2.3F) indicating that 
the majority of the lipids were >15 Å away from the AmB. In contrast, we observed strong 
correlations between water and AmB within just 25 ms, consistent with intimate proximity of the 
AmB aggregates to water. 
 
To further probe these aggregates and distinguish between an intramembranous vs. 
extramembranous location, we also performed transmission electron microscopy analysis of 
large unilamellar vesicles (LUVs) comprised of the same ratio of POPC:Erg ± AmB. In the 
absence of added AmB, we observed well-formed LUVs (Figure 2.5A). When AmB was added, 
we observed large extramembranous aggregates (Figure 2.5B). These aggregates were associated 
with one or more LUVs, suggesting an interaction between the surfaces of the aggregate and the 
lipid bilayer. When we added the same amount of AmB to the same volume of buffer devoid of 
Figure 2.4: 13C-13C 2D spectra of (1.44 ms SPC5 mixing) of 10:1:1 POPC:U-13CAmB:Erg (red) and 10:1:1 
POPC:U-13C-AmB:Erg with 5 mol% 5-DOXYL-PC used to make site-specific assignments of the AmB and 
confirm that the addition of the DOXYL spin labels has no significant effect on AmB. Spectrum was acquired 
on a 600 MHz spectrometer, at 20 °C with and MAS rate of 10 kHz, and 75 kHz SPINAL 1 H decoupling.53 
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LUVs, similar aggregates of AmB were observed (Figure 2.5C). These observations were 
consistent with the spontaneous formation in aqueous buffer of large AmB aggregates that 
externally associate with the surface of lipid bilayers. 
 
Importantly, parallel potassium efflux experiments revealed readily observable 
membrane permeabilization upon adding the same concentration of AmB to suspensions of the 
same POPC:Erg LUVs (Figure 2.5D). This observation was consistent with a minor fraction of 
AmB existing in the form of membrane-permeabilizing ion channels that are too small to be 
visualized by TEM. This analysis was also consistent with all of our SSNMR data, in which the 
limits of detection permit up to 5% of the AmB existing in the membrane. 
With the structural aspects of the sterol sponge model confirmed, we aimed to test the 
functional prediction that these large extramembranous aggregates of AmB extract Erg from 
lipid bilayers. We first performed a modified SSNMR PRE experiment in which we analyzed 
13C-skip-labeled Erg (13C-Erg, Fig. 2.6A)19 in spin label-containing bilayers as a function of 
AmB:13C-Erg ratio (Figure 2.6A). This labeling pattern provided sufficient sensitivity that the 
ratio of POPC to Erg was increased to 40:1, readily enabling titrations of the AmB:Erg molar 
Figure 2.5: Direct visualization of large extramembranous aggregates of AmB by TEM. A.) POPC/Erg 10:1 
liposomes. B.) POPC/Erg 10:1 liposomes with 1 equivalent (relative to Erg) of added AmB. C.) AmB only. D.) 
AmB promotes robust K+ efflux from 200 nm LUVs composed of 10:1 POPC:Erg. This activity mirrors both the 
in vitro and in vivo efflux activity of AmB previously reported by our laboratories.25,27 10 mol% AmB was added 
as a DMSO solution (final AmB concentration of 1 µM) at t = 1.5 min, and efflux is reported as a percentage of 
total efflux observed upon addition of Triton X-100. The observed plateau at 60% efflux is likely reflective of 
equilibrium between the bulk solution and the vesicle interior. Scale bars, 200 nm. 
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ratio while retaining the biophysical properties of the lipid bilayer. Thus, we prepared bilayers 
comprised of POPC:Erg* 40:1 ± 5 mol% 16-DOXYL with or without increasing amounts of 
natural abundance AmB. AmB had minimal effect on the POPC PRE (Figure 2.7A-D). In 
contrast, we observed a progressive decrease in the 13C-Erg PRE as the amount of AmB 
increased, indicating that Erg increasingly occupied a position outside the lipid bilayer (Figure 
2.6A, Figure 2.7A). In the absence of AmB (AmB:13C-Erg 0:1), we observed substantial PREs 
for the resolved 13C signals of 13C-Erg; for several sites, such as Erg-18, Erg-21, Erg-22, Erg-24 
and Erg-26/27, the PRE is ~1.5 s-1 or greater, and relatively short (<1.5 s) 13C T1 values. These 
findings were consistent with the structure of Erg-containing membranes in which the Erg was 
inserted into the hydrophobic core of the bilayer,35 with the isopropyl tail most deeply inserted 
and therefore most proximate to the 16-DOXYL label. These conformation-specific PREs for 
13C-Erg decreased markedly upon the addition of AmB (Figure 2.6A, Figure 2.7A). Specifically, 
with increasing amounts of natural abundance AmB (AmB:13C-Erg ratios of 1:1, 4:1, 8:1), we 
observed a progressive decrease, with at least a three-fold reduction in observed PRE in the 
AmB:13C-Erg 8:1 sample. These results support the interpretation that, in the presence of 
increasing amounts of AmB, Erg increasingly occupied a position outside the lipid bilayer 
membrane. 
Additional SSNMR experiments also supported this conclusion and further demonstrated 
that the extracted Erg is physically bound to the extramembranous aggregates of AmB. As the 
ratio of AmB:13C-Erg increased, Erg resonances, but not those of POPC, demonstrated 
inhomogeneous broadening,19 consistent with a transition from a mobile state to an immobile 
state (Figure 2.7E). 
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Figure 2.6: AmB extracts Erg from lipid bilayers. A.) Samples prepared using 40:1 POPC/ [13C]Erg ± 5 mol% 16-DOXYL-
PC showed a progressive decrease in PRE effects of resolved Erg resonances as the ratio of AmB/[13C]Erg increased. B.) The 
two-dimensional 13C-13C DARR spectrum of [13C]Erg (250-ms mixing, 10:1:1 POPC/AmB/[13C]Erg) changed in the 
presence of AmB, exhibiting new cross-peaks. C.) The 1H-13C polarization transfers from water (blue) and lipid (red) to Erg-
7 were substantially different in the absence (closed circles and squares, dashed line) and presence (open circles and squares, 
solid line) of AmB. D.-F.) Expansions of the olefin-to-methyl spectral region for two-dimensional [1H]-13C-[1H-1H]-13C 
spectra42,43 of D.) only [13C]Erg (328 h signal averaging time), E.) only [U-13C]AmB (187 h) and F.) both [13C]Erg and [U-
13C]AmB (187 h). Error bars in A.) were derived from χ2 analysis of inversion recovery trajectories. The 1H-13C spin 
diffusion data in C.) were normalized relative to the maximum intensity observed for both lipid and water cross-peaks for a 
given 13C site after correcting for 1H T1 relaxation, and error bars were derived from the signal-to-noise of the observed 
cross-peak. Spectra were acquired at 14.1 T (600 MHz 1H frequency). Data in A.-C.) were acquired at 10 kHz MAS, at 20 °C 
and 10 °C, respectively. The [1H]-13C-[1H-1H]-13C spectra D.-F.) were acquired at 10 °C, 11.628 kHz MAS; processed with 
40-Hz and 75-Hz line broadening in the direct and indirect dimensions, respectively; and were drawn with contour threshold 
set to four times the r.m.s. noise. 
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The average 13C T1 relaxation values for 
13C-Erg also followed the expected trend, 
increasing with the AmB:13C-Erg ratio (Figure 2.7B). 2D 13C-13C correlation spectra further 
revealed several 13C-Erg resonances that shifted significantly upon the addition of AmB (Figure 
2.6B), and resolved bound state resonances exhibited significantly higher linewidth and T1 
values than those of the corresponding unbound state. In the absence of AmB, we observed very 
strong lipid-Erg correlations and no water-Erg correlations (Figure 2.6C),41 whereas in the 
presence of AmB we observed strong water correlations to all resolved Erg sites, with 
polarization transfer rates similar to those observed for AmB (Figure 2.6C). We also repeated 1D 
and 2D chemical shift, linewidth, and T1 analyses of 
13C-Erg in the presence of amphoteronolide 
Figure 2.7: The addition of AmB to POPC:Erg liposomes has a large effect on Erg, but a relatively small effect on POPC. 
The combination of the decrease in A.) PRE and substantial increase in the B.) longitudinal relaxation times (T1) of Erg are 
consistent with the formation of an AmB:Erg complex that is separated from the lipid bilayer. Note the small relative change 
in the POPC C.) PRE (~20% on average) and D.) 13C T1values (~ 10% on average). (40:1 POPC:13C-Erg (black), 40:1:1 
POPC:AmB:13C-Erg (orange), 40:4:1 POPC:AmB:13C-Erg (blue), and 40:8:1 POPC:AmB:13C-Erg (red) liposomes ±5 mol%  
16-DOXYL-PC.) Only methane (CH) and methylene (CH2) sites that do not shift significantly (< 0.5 ppm) upon addition of 
AmB are shown. E.) 1D 13C spectra of 13C-Erg titrated with natural abundance AmB. As a function of AmB:Erg ratio, the 
13C-Erg resonances broaden from an average linewidth of 0.3 ppm to >1.0 ppm, consistent with formation of an AmB-Erg 
complex. SSNMR experiments were performed on a 600 MHz spectrometer, at 20 °C with an MAS rate of 10 kHz and 75 
kHz 1H decoupling.53 
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B (AmdeB), a synthesized derivative of AmB that lacks the mycosamine appendage and does not 
bind Erg,25,27 and observed no 13C-Erg chemical shift perturbations and only very small changes 
in linewidths and T1 values (Figure 2.8).  
To definitively probe whether the extracted Erg is bound to the AmB aggregate, we 
prepared an additional series of samples in which 13C labels were placed on (i) only Erg (Figure 
2.6D), (ii) only AmB (Figure 2.6E), and (iii) both AmB and Erg (Figure 2.6F). (1H)-13C-(1H-1H)-
13C spectra42,43 for the first two samples showed only the anticipated intramolecular correlations 
(Figure 2.6D, 2.6E), while the sample containing labels on both AmB and Erg revealed many 
new intermolecular AmB-Erg cross peaks (Figure 2.6F), consistent with Erg aligned parallel to 
the polyene region of AmB and directly confirming the formation of a small molecule-small 
molecule complex.  
We also measured the 1H-13C dipolar couplings for resolved sites in both AmB and Erg 
using the T-MREV recoupling sequence44 (Figure 2.9) and Erg (Figure 2.10) to determine the 
relative mobility of these sites. In the absence of AmB, Erg was mobile as evidenced by the low 
order parameters, but in the presence of AmB, the order parameters shifted to the same rigid 
lattice limit observed for AmB. Furthermore, we observed line widths of >110 Hz for both AmB 
and Erg in the sterol sponge. Thus, AmB extracts Erg from lipid bilayers into large, 
extramembranous aggregates. 
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Figure 2.8: As a control experiment we also examined the effect of AmdeB, a derivative of AmB lacking the 
mycosamine appendage that does not bind Erg.25,27 There were no chemical shift perturbations observed upon 
the addition of AmdeB, as shown in A.) the overlay of 13C-13C 2D DARR (500ms mixing) spectra of 40:1 
POPC:13C-Erg (black), 40:8:1 POPC:AmdeB:13C-Erg (red).  This is in contrast to the dramatic changes observed 
with the addition of AmB to POPC:13C-Erg membranes. Furthermore there were only slight perturbations of the 
B.) 13C linewidth, and C.) 13C longitudinal (T1) relaxation times in comparison to those changes induced by the 
addition of an equivalent amount of AmB (40:8:1 POPC:AmB:13C-Erg (blue)). Spectra were acquired on a 14.1 
T (600 MHz 1H frequency) spectrometer, at 20 °C with an MAS rate of 10 kHz and 75 kHz 1H decoupling.53 
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Finally, we tested the validity of the sterol sponge model in cells. First, we probed 
whether AmB extracts Erg from the cell membrane of yeast by adapting an ultracentrifugation-
based membrane isolation assay45 to quantify the amount of Erg in the membranes of live 
Saccharomyces cerevisiae cells in the absence and presence of AmB. As shown in Figure 2.11A, 
AmB very effectively extracted Erg in a time-dependent fashion. In contrast, we observed no Erg 
extracting effects with the non-Erg-binding derivative AmdeB. 
 
Figure 2.9: The T-MREV dipolar lines shapes and order parameter measured select AmB resonances in 10:1:1 
POPC:U-13C-AmB:Erg MLVs (black, experimental solid line, simulation open circle) confirm that sterol sponge 
is rigid. Spectra was acquired on a 600 MHz spectrometer, at 20 °C with and MAS rate of 8.333 kHz, and 85 
kHz TPPM 1H decoupling59, using N=4 T-MREV.44  
 
Figure 2.10: The substantial broadening of the T-MREV dipolar lines shapes and order parameter measured for 
select Erg resonances in 40:0:1 (black, experimental solid line, simulation open circle) and 40:4:1 
POPC:AmB:13C-Erg  (red, experimental solid line, simulation open circle) further confirms the absorption of 
Erg by the AmB Sterol sponge. Spectra was acquired on a 600 MHz spectrometer, at 20 °C with and MAS rate 
of 8.333 kHz, and 85 kHz TPPM 1H decoupling,59 N=4 T-MREV.44 
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Further experiments demonstrated that the Erg-extracting activity of AmB was 
responsible for its cell killing effects. As shown in Figure 2.11B, we observed no cell killing 
with DMSO or AmdeB, whereas AmB promoted robust cell killing with a time course that 
paralleled Erg extraction. In addition, methyl-beta-cyclodextrin (MBCD), a cyclic 
oligosaccharide known to extract sterols from membranes,46 similarly demonstrated both Erg 
extracting and cell killing activities (Figure 2.11C and 2.11D). Finally, the sterol sponge model 
predicts that AmB aggregates pre-saturated with Erg will lose the ability to extract Erg from 
membranes and kill yeast. Enabling this hypothesis to be tested, we found conditions that 
promoted the formation of stable and soluble aggregates of AmB and Erg. As predicted, treating 
cells with this preformed AmB-Erg complex resulted in no Erg extraction (Figure 2.11C), and no 
cell killing (Figure 2.11D).  
The sterol sponge model provides a new foundation for better understanding and more 
effectively harnessing the unique biophysical, biological, and medicinal properties of this small 
molecule natural product. Based on the classic ion channel model, many efforts over the past 
several decades to improve the therapeutic index of AmB focused on selectively permeabilizing 
yeast versus human cells.11,13 This approach has not yielded a clinically viable derivative of the 
natural product. The sterol sponge model suggests that an alternative approach will be more 
effective. Specifically, analogous to the now clarified mechanism of antifungal activity, the 
extraction of cholesterol by large extramembranous aggregates of AmB may be primarily 
responsible for toxicity to human cells. This, in turn, suggests that the goal should be to 
maximize the relative binding affinity of AmB aggregates for Erg versus cholesterol. 
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This insight is already guiding development of the first derivatives of AmB that are toxic to yeast 
cells but not human cells and thus hold exceptional promise for yielding an improved therapeutic 
index.47  
A high-resolution structure of the large, extramembranous AmB aggregate, with and 
without bound Erg and cholesterol, would powerfully enable the discovery and/or further 
development of such derivatives. Importantly, the results described herein provide a strong 
platform for determining such a structure. Specifically, the large extramembranous aggregate of 
AmB, confirmed to reproducibly and stably form in the presence of POPC bilayers, represents an 
excellent substrate for SSNMR analysis, and the common relaxation properties of AmB and Erg 
are consistent with the existence of a stable complex. Moreover, the 2D (1H)-13C-(1H-1H)-13C 
Figure 2.11: AmB extracts Erg from and thereby kills yeast cells. A.) AmB extracted Erg from the membranes of S. 
cerevisiae cells in a time-dependent manner, whereas AmdeB showed no Erg-extracting activity. The percentage of Erg 
remaining in the cell membranes was normalized to that measured in DMSO only treated controls. B.) Cell killing paralleled 
Erg extraction in AmB-treated cells. AmdeB showed no cell-killing effects. C.) Erg extraction after 120 min of incubation. 
500 mM MBCD extracted Erg from the membranes of S. cerevisiae cells, whereas a preformed 5 μM AmB/25 μM Erg 
complex did not. The percentage of Erg remaining in the cell membranes was normalized to that in DMSO only and 25 μM 
Erg in DMSO only treated controls, respectively. D.) Cell killing after 120 min incubation was observed for yeast treated 
with 500 mM MBCD but not for yeast treated with 5 μM AmB/25 μM Erg complex. Data represent mean ± S.E.M. for at 
least three independent experiments. *P < 0.02; **P < 0.002; NS, not significant. 
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spectra of the complex derived from U-13C-AmB and 13C-Erg exhibit intermolecular AmB-Erg 
correlations with intensities indicating internuclear distances of ~6 Å or less. We further note 
that comparison of 13C-13C 2D spectra of 10:1 POPC:U-13C-AmB and 10:1:0 POPC:U-13C-
AmB:Erg shows that the structures of the AmB aggregates in the absence and presence of Erg 
are very similar (Figure 2.12A). There are, however, some intriguing changes in the AmB 
resonances corresponding to the mycosamine appendage upon the binding of Erg (Figure 2.12B). 
These changes will be the subject of future investigations.  
 
We anticipate that further SSNMR studies, including those applied to derivatives of AmB 
and/or Erg/cholesterol with site-specific or skip-pattern isotopic labels, will enable us to define in 
high resolution the structure of this extramembranous aggregate and the interface between these 
small molecules. Such information may reveal the structural underpinnings of the small 
preference of AmB to bind Erg over cholesterol and further guide the development of derivatives 
of AmB that maximize this binding preference and thus the therapeutic index.47 In this vein, we 
note that the pattern of chemical shift perturbations observed for Erg in the absence and presence 
Figure 2.12: 13C-13C 2D spectra of (1.44 ms SPC53 mixing) of 10:1:1 POPC:U-13CAmB:Erg (red) and 10:1:0 
POPC:U-13C-AmB:Erg (blue) at 600 MHz with SPINAL 1H decoupling.53 A.) Irrespective of the presence of 
Erg, the peak positions do not change substantially. B.) However interesting changes in the mycosamine 
resonances upon the binding of Erg are observed. 
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of AmB are consistent with tight association between AmB and the A and B rings of the sterol. 
Interestingly, the B ring of cholesterol, to which AmB binds but less strongly than ergosterol,27,47 
is more sterically bulky than that of Erg, because it possesses an extra degree of saturation. 
Moreover, lanosterol, to which AmB does not bind,27 possesses both the same extra degree of 
saturation in the B ring and a sterically bulky gem dimethyl group on the A ring. While further 
studies are required to provide a detailed picture, our current data begin to support a structural 
rationale for the differential binding of AmB to Erg (strong), cholesterol (weak), and lanosterol 
(no binding). More broadly, relative to small molecules that bind proteins, small molecules that 
bind other small molecules in a biologically relevant fashion are very rare. A high-resolution 
structure of this prototypical AmB-Erg complex may enable rational pursuit and study of other 
biologically important small molecule-small molecule interactions.  
The sterol sponge model also offers a new rationale for the paucity of clinically relevant 
microbial resistance that is a hallmark of AmB as a therapeutic. Because the extraction of Erg 
renders yeast membranes Erg-deficient, AmB may simultaneously perturb all cellular processes 
that depend on membrane Erg.28-31,48 This likely includes many different membrane proteins that 
directly bind Erg,28-31 and simultaneous mutation of all such proteins in a manner that alleviates 
this Erg dependence is highly improbable. It has also remained unclear why, in contrast to the 
rarity with which AmB resistant mutants are found in patients, it is relatively easy to generate 
AmB-resistant yeast mutants in cell culture experiments.49 The sterol sponge model provides a 
rationale for this dichotomy. AmB-resistant mutants generated in cell culture generally possess 
modified sterols in their membranes, e.g., lanosterol50 (and/or other biosynthetic precursors to 
Erg) to which AmB does not bind.27 It was previously assumed that such changes in sterol 
content minimize antifungal potency by minimizing membrane-permeabilizing activity.9,10,13,49 
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The sterol sponge model alternatively suggests that, because AmB does not bind or extract 
lanosterol, this modified sterol remains in the membrane to serve as a surrogate binding partner 
for sterol-dependent proteins. Due to the structural differences between lanosterol and Erg 
described above, however, the former is likely only a minimally effective substitute, resulting in 
reduced activity of many proteins that require specific interactions with Erg to function properly. 
This, in turn may translate into substantially reduced pathogenicity of the resulting yeast 
mutants. Consistent with this notion, strains of yeast with modified sterol content have markedly 
reduced pathogenicity in animal models.49 Such strains may routinely emerge in patients treated 
with AmB, but, due to their reduced pathogenicity, cannot thrive and/or are rapidly cleared by 
the immune system of the host. A recently reported alternative series of studies provide 
complementary support for this conclusion.49  
The clarified picture of the structural and functional underpinnings of AmB activity 
provided by the sterol sponge model also illuminates a rational roadmap for separating the ion 
channel forming and cytotoxic activities of AmB. Small, membrane-spanning ion channel 
aggregates likely exist as minor components in equilibrium with the large extramembranous 
assemblies of AmB characterized herein. This proposal is consistent with the weak AmB-lipid 
correlations observed in the SSNMR spin diffusion experiments, and the limits of detection of 
the SSNMR PRE and TEM studies. As we have previously demonstrated, binding ergosterol 
alone in the absence of channel activity is sufficient for cell killing.25 Specifically, the capacity 
for channel formation can be selectively eliminated while preserving the capacity for Erg binding 
and cell killing via deleting the C35 hydroxyl group appended to AmB.25 In the sterol sponge 
model, this result can be rationalized by invoking a selectively destabilizing influence of this 
deletion on the smaller membrane-inserted channel aggregates.  Future studies will aim to 
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determine whether this putative equilibrium between large extramembranous and small 
membrane-spanning aggregates can be alternatively shifted to favor ion channel formation, 
thereby maximizing potentially useful membrane-permeabilizing functions25 while minimizing 
cytotoxic sterol extracting activity.  
2-3 CURRENT UNDERSTANDING OF AMPHOTERICIN B’S ION CHANNEL ACTIVITY 
AmB, is the prototypical small molecule capable of forming ion channels in living 
systems.4-6,10,12,59-64 However, despite more than half a century of research, the structure of the 
AmB ion channel remains unknown. In the mid-1970’s, AmB was shown to form discrete ion 
channels in lipid bilayers.4 The AmB channel is capable of transporting both monovalent anions 
and cations60 and has been reported to be slightly cation selective in some studies.4,59,63,65-66 In 
addition, the AmB channel can be blocked by the bulky tetraalkylammonium ion61 like some 
potassium selective protein ion channels.67 However, the AmB channel has been suggested to be 
nearly 8Å in diameter in contrast to most protein ion channels.68 Leading modeling studies 
predict that AmB self-aggregates into multimeric “barrel-stave” structures.7-9, In these models, 
AmB’s polyene and mycosamine motifs interact with lipids and sterols while the polyol region 
lines the water-filled channel interior.  
Many features of protein ion channels have been elucidated through developing structure- 
activity relationships. Although protein ion channels are larger and more complex than AmB, the 
synthesis of protein analogs using techniques such as site directed mutagenesis is now routine.69 
In contrast, chemoselectively altering AmB’s structure in order to probe specific structure 
activity relationships is quite challenging.11 Because of these difficulties, there have been a 
limited number of studies investigating the roles of specific functional groups on AmB ion 
channel formation.25-27,62,70-71 
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Modeling studies predicted an intermolecular salt bridge between the C41 carboxylate and 
the C3’ ammonium of a neighboring AmB was critical for AmB channel stability.72 Removal of 
the entire mycosamine yielded a derivative incapable of either binding ergosterol or forming 
channels.27 Intriguingly, reduction of the C41 carboxylic acid to a methyl group did not preclude 
channel formation.26,27 Furthermore, the C35 hydroxyl group was predicted to stabilize both the 
single-barrel as well as double barrel ion channel models. Consistent with this model, a derivative 
lacking the C35 alcohol, C35deOAmB, did not permeabilize cell membranes.25 Thus, both the 
mycosamine appendage and C35 hydroxyl are required for ion channel formation, while oxidation 
at C41 is not. Despite these advances, the functional groups responsible for ion channel 
conductance and ion selectivity still remain unknown. As mentioned above, the polyol region of 
AmB is predicted to line the AmB channel interior, creating a hydrophilic environment for ions 
and water. Furthermore, the channel is predicted to be funnel shaped with a wide entrance near the 
C15 alcohol, tapering to its narrowest region near the C3 alcohol (Figure 2.13).72,73 This model 
therefore predicts that modifications at the C3 position would permit channel formation but alter 
ion conductance.  
 
Figure 2.13: A.) AmB and C3deOAmB structures. B.) AmB ion channel model funneling to narrowest region at 
C3-OH (highlighted in blue). 
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2-4 SYNTHESIS OF C3DEOXYAMB AND PROBING ITS ION CHANNEL PROPERTIES 
No derivatives with modifications at the polyol region of AmB have been studied using 
electrophysiological recordings, which are critical for characterizing differences in single ion 
channel conductances. This is likely in large part a consequence of the synthetic difficulties in 
obtaining such site-specifically modified AmB derivatives. Synthetic modification of the C13 
hemiketal,74,75 and genetic manipulations of the producing organism76-78 and related organisms79-
81 have yielded polyol modified derivatives. However, the impacts of these modifications on 
single ion channel conductance have not been reported. 
To test the hypothesis that the C3-hydroxyl group plays an important role in ion channel 
conductance, we targeted its chemoselective deletion.25-27,47 As one of 10 distinct hydroxyl 
groups appended to AmB, this represented a substantial synthetic challenge. We recognized, 
however, that the unique β-positioning of the C3 alcohol relative to the C1 carbonyl may provide 
an opportunity for selective elimination to form an alpha, beta-unsaturated macrolactone 
followed by chemoselective conjugate reduction.  
This plan was ultimately reduced to an efficient 9-step synthesis as shown in Scheme 1. 
Starting with the natural product, a series of functional group protections delivered intermediate 
1 (Scheme 2.1). Gratifyingly, exposure of 1 to NaHMDS at low temperatures chemoselectively 
eliminated the C3 p-methoxyphenylacetal, presumably via an E1cB type mechanism, yielding 
intermediate enone 2. Subsequent site-selective Stryker reduction82 of carbonyl-conjugated 
C3,C4 double bond provided deoxygenated intermediate 3. A final series of deprotections 
yielded the targeted single-atom modified variant, C3deOAmB.  
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It was unclear at the outset whether this functional group deletion would cause changes in 
macrocycle conformation, which in turn would complicate the analysis of voltage clamp 
electrophysiological recordings of the corresponding ion channels. Specifically, in the crystal 
structure of a derivative of AmB, the C3 hydroxyl group is involved in a hydrogen bonding 
network that includes both the C1 carbonyl and C5 hydroxyl group.83 Disruption of such a 
hydrogen bonding network might result in a change in macrocycle shape. To test this, we 
independently determined the ground state conformations of both AmB and C3deOAmB using 
stochastic conformation generation methods constrained by extensive NOESY and phase 
sensitive COSY NMR data processed using amplitude-constrained multiplet evaluation.84 
Optimization allowed us to perform these experiments without the use of solubilizing protective 
groups.  
We determined the lowest energy conformations of the AmB and C3deOAmB structures 
using the LowModeMD conformational search method85 with NOESY-based internuclear 
distance restraints and phase-sensitive COSY-based dihedral restraints.84 The structure-based 
alignment of the lowest energy conformation of the C3deOAmB skeleton with the lowest energy 
Scheme 2.1: Synthesis of C3deOAmB 
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conformer of AmB exhibits a heavy atom RMSD of 0.33 ± 0.03 Å, which is comparable to the 
precision of each structure (Figure 2.14). Thus, within the uncertainty of this NMR-based 
structure determination, the ground state conformations of these two compounds are identical. 
Further supporting this conclusion, both the 13C and 1H chemical shifts show excellent agreement 
between AmB and C3deOAmB, with the exception of the modified C3 site and its immediate 
neighbors, for which the chemical shifts change due to well understood electronegativity effects 
(See Materials and Methods below).86-88 
     
Finally, we tested the key hypothesis that removal of the C3 hydroxyl group would impact 
ion channel conductance. Specifically, HPLC-purified AmB and C3deOAmB were compared 
head-to-head in voltage-clamp single ion channel recording studies. Planar lipid bilayers were 
formed from a 70:30 ratio of DPhPC lipids to ergosterol at pH = 7.0. AmB or C3deOAmB were 
then added to both sides of the membrane as a solution in DMSO and channel activity was 
investigated. Shown in Figure 2.15A are representative single ion channel traces of both AmB 
(top) and C3deOAmB (bottom). The conductance of each molecule was determined by measuring 
the current of the single channels formed from each molecule at a range of voltages (Figure 2.15B). 
AmB has a single ion channel conductance of 17.2 ± 0.5 pS. Under identical conditions 
C3deOAmB also forms single ion channels, however, the conductance significantly decreases to 
5.2 ± 0.9 pS, a three-fold reduction (Figure 2.15C).   
Figure 2.14: Overlay of the lowest energy conformations of AmB and C3deOAmB. The heavy atom RMSD is 
0.33 ± 0.03 Å. 
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Despite extensive efforts, the ion selectivity of both AmB and C3deOAmB were unable to 
be determined in planar lipid bilayer experiments. To investigate a more qualitative method for 
determining relative ion selectivity for AmB and C3deOAmB channels, we focused on liposome 
efflux experiments. By comparing the rate of ion efflux from liposomes, a qualitative ion 
selectivity could be determined between AmB and C3deOAmB. These preliminary experiments 
in liposomes support differences in ion selectivity between AmB and C3deOAmB channels 
(Figure 2.16).  While these initial experiments only focused on potassium and proton efflux, future 
studies will examine efflux using a variety of ions including sodium, chloride, and bicarbonate.  
Figure 2.15: A.) Single ion channel activity of AmB (top) and C3deOAmB (bottom) in planar lipid bilayers. 
DPhPC lipids with 30% ergosterol. 1 M KCl pH = 7.0, 5 mM HEPES + 150 mV. B.) Current vs voltage 
response of AmB and C3deOAmB from 90 to 210 mV in 30 mV increments. 2 M KCl, pH = 7.0, 5 mM 
HEPES.14 AmB r2 = 0.9969. C3deOAmB r2 = 0.9174. C.) Bar plot illustrating the differences in ion channel 
conductance between AmB and C3deOAmB. **** p < 0.001. Graphs depict means ± SD. 
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2-5 SUMMARY 
For decades, scientists have widely accepted that membrane-spanning ion channels 
primarily contribute to the structure and antifungal activity of AmB.4-23 In contrast, we found that 
AmB primarily forms large extramembranous aggregates that extract Erg from lipid bilayers and 
thereby kill yeast. Membrane-inserted ion channels are relatively minor contributors, both 
structurally and functionally, to the antifungal action of this natural product. While previous 
studies have reported large aggregates of AmB or its derivatives,17,21 the interpretation of these 
findings has been in terms of the ion channel model. Here we describe PRE, 1H spin diffusion 
trajectory, and TEM studies that collectively demonstrate that AmB primarily exists in the form 
of large extramembranous aggregates.  Moreover, changes in PREs, 1H spin diffusion 
trajectories, T1 relaxation, order parameters, line widths, and chemical shift perturbations, as well 
as the observation of direct intermolecular crosspeaks and the results of cell-based Erg extraction 
experiments demonstrate that extramembranous aggregates of AmB directly bind Erg. 
Figure 2.16: A.-C.) Potassium efflux experiments with either 1 µM AmB or C3deOAmB. D.) Average half-
lives calculated using exponential decay fitting from potassium efflux experiments. E-G.) Proton efflux 
experiments with either 1 µM AmB or C3deOAmB. H.) Average half-lives calculated using exponential decay 
fitting from proton efflux experiments. DMSO vehicle was performed in triplicate and subtracted from AmB and 
C3deOAmB experiments to account for instrumental drift. N ≥ 5 for all experiments. Graphs depict means ± SD. 
NS, not significant. *** p < 0.01. 
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Collectively, these results strongly support the proposed sterol sponge model in which 
extramembranous aggregates of AmB extract Erg from phospholipid bilayers and thereby kill 
yeast. These findings also suggest that the cytotoxic and ion channel activity of AmB can be 
separated by simply adding AmB at low concentrations. Furthermore, the ability to form a less 
toxic AmB-Erg complex has important implications in the development of small molecule 
surrogates for missing or deficient protein ion channels. 
 Deletion of a single atom at the C3 position of AmB is synthetically accessible, does not 
cause a change in macrocycle conformation, and permits the retention of channel-forming activity 
yet changes the ion channel conductance by 3-fold. These findings are consistent with structural72 
and theoretical73 models for the AmB ion channel that place the C3 alcohol in the path of ion 
conductance. This structure activity relationship is the first step towards understanding the 
structure of the AmB ion channel. Furthermore, the demonstration that AmB’s ion channel 
conductance can be manipulated by modification of a polyol alcohol suggests that further polyol 
modifications could tune other channel properties, such as ion selectivity.  
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2-6 METHODS 
Materials 
Commercially available materials were purchased from Sigma-Aldrich, Alfa Aesar, 
Avanti Polar Lipids, Cambridge Isotope Laboratories, or Fisher Scientific and were used without 
further purification unless stated otherwise. Natural abundance amphotericin (AmB) was 
purchased from Sigma-Aldrich or a gift from Bristol-Myers Squibb Company. Unless stated 
otherwise, all solvents were dispensed from a solvent purification system that passes solvents 
through packed columns according to the method of Pangborn and coworkers52 (THF, Et2O, 
CH2Cl2, toluene, dioxane, hexanes: dry neutral alumina; DMSO, DMF, CH3OH : activated 
molecular sieves). Water was dispensed from a MilliQ water purification system (Millipore 
Corporation, Billerica, MA).  
Purification and Analysis 
Preparative scale HPLC purification was performed using an Agilent 1260 series 
instrument equipped with a multiple-wavelength detector and a Waters SunFire Prep C18 OBD 5 
µm 30 x 150 mm column at a flow rate of 25 mL/min. All HPLC solvents were filtered through 
0.2 μm Millipore filters prior to use. UV/Vis analyses were performed on a Shimadzu 
PharmaSpec UV-1700 spectrophotometer. Electrospray ionization mass spectra (ESI-MS) were 
obtained at the University of Illinois mass spectrometry facility.  
Amphotericin and Amphoteronolide B 
Due to light and air sensitivity of polyenes, all manipulations of AmB and 
amphoteronolide B (AmdeB) were carried out under low-light conditions and compounds were 
stored under a dry argon atmosphere at -20 ºC. AmdeB was prepared synthetically from natural 
abundance AmB as previously described.26,27 All AmB and AmdeB used for current experiments 
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were purified by preparative scale HPLC. All manipulations of HPLC-purified AmB and AmdeB 
were performed using either Optima MeOH, 0.2 µm-filtered HPLC grade solvents, or solvents 
dispensed from a solvent purification system.52 
For purification, solid AmB was dissolved in DMSO (10 mg/mL), filtered through Celite 
545 and purified (100 µL injections) with gradient of 5% to 65% MeCN / 5 mM ammonium 
acetate (NH4OAc) over 12 minutes with detection at 406 nm. The column was subsequently 
flushed with isocratic 95% MeCN / 5 mM NH4OAc for 2 min and re-equilibrated to 5% MeCN / 
5 mM NH4OAc prior to the next injection. The combined AmB solution was concentrated in 
vacuo, with filtered (0.2 µm) MeCN added back to the flask as needed for azeotropic removal of 
water. The resulting yellow solid was suspended via bath sonication in 1:1 MeCN:toluene and 
again concentrated in vacuo for azeotropic removal of residual NH4OAc. Residual solvent was 
removed under high vacuum for ≥ 8 h to furnish a pale yellow solid, which was stored under 
argon at -20 ºC. 
AmdeB was dissolved in DMF, filtered (Celite 545), injected, and eluted with a mobile 
phase gradient of 5% to 95% MeCN / 5 mM NH4OAc over 25 min.   
Ergosterol 
Natural abundance ergosterol (Erg) was purchased from Sigma-Aldrich and recrystallized 
from EtOH before use. Stock solutions of 4 mg/mL Erg in CHCl3 were stored under argon at -20 
°C for up to one month. 13C-skip-labeled Erg (13C-Erg) was prepared biosynthetically using the 
method previously described.19  
U-13C-Amphotericin Biosynthesis 
U-13C-Amphotericin (U-13C-AmB) (was prepared biosynthetically from cultures of the 
bacterium Streptomyces nodosus (American Type Culture Collection [ATCC], Manassas, VA, 
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cell line 14899) using a modified version of the protocol previously reported.18 In our modified 
protocol, the “FCA” medium66 was used, with substitution of U-13C-Glucose (U-13C-Glc) for 
natural abundance fructose. Inoculation of culture medium and pulse feeding U-13C-Glc were 
carried out in a Labconco Clean Bench (Labconco, Kansas City, MO) sterilized with 70% EtOH 
before and after each inoculation/feeding. S. nodosus starter cultures were prepared from ATCC 
14899 as previously described.66 Nine 250 mL baffled culture flasks, each containing 20 mL of 
the U-13C-Glc-enriched medium in 250 mL baffled flasks were inoculated with S. nodosus starter 
culture. Pulse feeding of cultures was done according to the schedule previously described,65 but 
with140 µL of aqueous 50% w/v U-13C-Glc added to each baffled flask. 
U-13C-Amphotericin Purification 
After work-up of the U-13C-AmB as previously described,65 if there remained any sign of 
residual Aliquat 336 (strong odor of Aliquat 336, dark yellow solid, sticky solid, not free 
flowing), then this material was further purified via C18 reverse phase flash chromatography as 
follows: AmB was dissolved in a minimum amount of DMF and Celite 545 was added to form a 
slurry. This slurry was concentrated in vacuo, thus adsorbing the AmB onto the Celite. This solid 
was loaded onto a flash column loaded with Silicycle C18 silica gel and equilibrated with 20% 
MeCN / 5 mM ammonium acetate. Purification proceeded with a gradient of 20% MeCN / 5 mM 
NH4OAc to 100% MeCN followed by 100% Optima MeOH (Fisher Scientific). The resulting 
yellow fractions were concentrated in vacuo and analyzed via 1H NMR in DMF-d7 for presence 
of residual Aliquat 336. If Aliquat 336 was still present, the material was purified again by C18 
flash column using the above protocol. Once removal of Aliquat 336 was confirmed, U-13C-
AmB was purified by preparative scale HPLC as described in General Methods above (Section 
 
 
38 
 
I). Prior to each experiment involving U-13C-AmB, the purity of the compound was confirmed 
by analytical HPLC (see representative chromatogram below). 
 
U-13C-Amphotericin Isotopic Enrichment 
For natural abundance AmB, the calculated mass for C47H74NO17 (M+H)
+ is 924.49. Average 
isotopic enrichment of U-13C-AmB was calculated from ESI-MS peak intensities. The average 
m/z (M+H)+ was 965.8.  Thus, on average, 41 of the 47 carbon atoms of AmB were 13C-enriched 
and the overall enrichment was thus approx. 87% (41/47 ≈ 0.87).18 
Solid-State NMR Spectroscopy 
SSNMR experiments were performed using a 600 MHz InfinityPlus spectrometer 
(Varian, now a subsidiary of Agilent Technologies, Inc.) equipped with a 3.2 mm T3 HXY MAS 
probe tuned to 1H-31P-13C mode. Pulse widths (π/2) for 1H, 13C, and 31P were 2-2.5 µs, 3.2 µs, 
and 3.2 µs, respectively. Spinning was controlled with a Varian MAS controller to 10,000  2 
Hz. SPINAL-64 decoupling (~75 to 80 kHz) was used during evolution and acquisition 
periods.58 The flow rate of sample cooling gas was maintained at 100 scfh at 20 °C, resulting in a 
calibrated sample temperature of 19.2 ± 1 °C. Chemical shifts were referenced externally with 
adamantane, with the downfield 13C resonance referenced to 40.48 ppm.53 
13C T1 and PRE Experiments  
T1 values were measured using standard T1 inversion recovery pulse sequence with a 5 
second pulse delay. Data were processed and fit with Varian Spinsight software version 4.3.2. 
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For each of the resolved methine and methylene in U-13C-labeled amphotericin (U-13C-AmB) 
and 13C skip labeled ergosterol (13C-Erg) the longitudinal 13C PRE was obtained by calculating 
the difference between the 13C R1 values for sample with and without 5 mol% of the DOXYL 
lipids, determined by modeling the individual relaxation trajectories as single exponential 
decays. T1 trajectories were fit using the integrated volume of a given peak as a function of delay 
time (tau_1); integration boundaries were set to at the linewidth half height. The average line 
width observed for POPC is ~40-60 Hz. The average linewidth observed for Erg in the absence 
of AmB is ~50 Hz, and 127 Hz in the presence of AmB (see Supplementary Table 3). The 
average linewidth observed for AmB is ~187 Hz.  
1H-13C Spin-Diffusion Experiments  
We performed 1H-13C spin-diffusion correlation experiments as previously described41 
using a 1 ms T2 filter, to detect interactions between the mobile 
1H signals of lipid acyl chains 
(1.35 ppm) and/or water (4.7 ppm) with the U-13C-AmB, and 13C-Erg in the presence and 
absence of AmB. 1H-13C polarization transfer trajectories were extracted from 1H-13C 2D spectra 
collected with 1H-13C mixing times ranging from 1 ms to 625 ms, by fitting peaks with a 
minimum signal to noise of 5, using a box integration method in Sparky. Trajectories were then 
normalized based on maximum observed intensity for a single resolved water or lipid 1H-13C 
cross peak after correction for 1H T1 relaxation, which was measured in a separate T1 inversion 
recovery experiment. Error bars are derived from the signal-to-noise ratios observed for each 
crosspeak.  
 
 
 
 
 
40 
 
 
 
 
 
 
Figure 2.17: T2-filtered (1 ms) spin diffusion studies of 40:0:1 POPC:AmB:13C-Erg MLVs show that in the 
absence of AmB Erg is embedded in the lipid membrane, with the C3 site on the A ring located close to the 
membrane water interface. The selected 1H-13C correlations were collected with 1 ms T2 filter and 1H-1H spin 
diffusion times of 1 ms to 400 ms. Cross peaks from the lipid acyl chain CH2 protons (~1.35 ppm) and water 
(~4.7 ppm) to all resolved sites of 13C-Erg are shown in red and blue, respectively. The polarization transfer is 
normalized based on the maximum observed intensity after correction of the 1H T1 relaxation. Spectra was 
acquired on a 600 MHz spectrometer, at 20 °C with and MAS rate of 10 kHz, and 75 kHz SPINAL 1H 
decoupling.53 
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Figure 2.18: T2-filtered (1 ms) spin diffusion studies of 40:4:1 POPC:AmB:13C-Erg MLVs show that in the 
presence of AmB Erg has been removed from the lipid bilayer, with the majority of Erg located more than 15-20 
Å away from the lipid acyl chains. The polarization transfer from water is very similar to that observed for AmB 
(Figure 2.3F), supporting the fact that the Erg has been absorbed by the AmB sterol sponge. The selected 1H-13C 
correlations were collected with 1 ms T2 filter and 1H-1H spin diffusion times of 1 ms to 400 ms. Cross peaks 
from the lipid acyl chain CH2 protons (~1.35 ppm) and water (~4.7 ppm) to all resolved sites of 13C-Erg are 
shown in red and blue, respectively. The polarization transfer is normalized based on the maximum observed 
intensity after correction of the 1H T1 relaxation. Spectra was acquired on a 600 MHz spectrometer, at 20 °C 
with and MAS rate of 10 kHz, and 75 kHz SPINAL 1H decoupling.53 
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Order Parameters from 1H-13C Dipolar Couplings  
Dipolar order parameters (S) were measured using the T-MREV pulse sequence44 at an 
MAS rate of 8.333 kHz (N=4 condition, 100 kHz 1H decoupling nutation frequency, 2.5 µs 1H 
π/2 pulse length). The T-MREV 13C-1H dephasing was incremented by 30 µs and a total of 25 
increments were recorded in t1. Fortran fitting routines
54 were used to determine the 13C-1H 
dipolar coupling, taking into account the effects of relaxation and contributions from weaker 
couplings from neighboring protons. We calibrated the scaling factor of the T-MREV sequence 
by measuring the 13C-1H dipolar coupling for crystalline N-acetyl-L-valine under the identical 
experimental conditions. 
 
 
 
Figure 2.19: 13C Line widths and order parameters 
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(1H)-13C-(1H-1H)-13C Correlation Spectra 
(1H)-13C-(1H-1H)-13C SSNMR experiments to yield performed at 10 °C, at an MAS rate 
11.628 kHz, with the heteronuclear contact time (tHC) set to 400 µs, and 
1H-1H mixing time of 
400 µs. These conditions reveal cross peaks for internuclear 13C-13C distances of ~4-6 Å.  In 
order to properly identify new intermolecular AmB-Erg crosspeaks the (1H)-13C-(1H-1H)-13C 
spectra were acquired back-to-back under identical conditions and signal averaged to 
approximately the same extent, adjusting the total measurement time based on the amount of 
material packed in each SSNMR rotor. The rotors of POPC:U-13C-AmB:Erg (10:1:1 molar ratio) 
and POPC:U-13C -AmB:13C-Erg (10:1:1 molar ratio) were packed with ~25 mg and the spectra 
signal averaged for 7.8 days each. The 10:1:1 POPC:AmB:13C-Erg sample was ~16 mg and 
therefore signal averaged for 13.6 days. The three spectra were all processed identically, with 40 
and 75 Hz 13C line broadening applied in the direct and indirect dimensions, respectively. 
Preparation of Stock Solutions for SSNMR Samples 
A fresh stock solution of HPLC-purified AmB (natural abundance or U-13C-AmB) was 
prepared for each experiment by dissolving AmB in a large volume of Optima methanol, 
typically 75-100 mL for 10 mg of AmB. Stock solution concentration was measured in triplicate 
by dilution in MeOH and measuring absorbance at 406 nm (ε406 = 164,000 M-1 cm-1).26 Unused 
stock solution was concentrated in vacuo and stored under a dry argon atmosphere at -20 ºC. 
Stock solutions of Erg were prepared by dissolving recrystallized (commercial) or HPLC-
purified (biosynthetic) Erg in a minimum volume of CHCl3 and the concentration determined by 
UV/Vis spectroscopy in a manner analogous to that used for AmB (ε282 = 10,400 M-1 cm-1).27 
Erg stock solutions were stored in I-Chem vials under a dry argon atmosphere at -20 ºC for up to 
1 month. 
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Phospholipids were purchased as stock solutions in CHCl3 and these solutions were used 
directly for liposome preparation. Unused phospholipid solutions were stored in vials/bottles 
under a dry argon atmosphere at -20 ºC. Stock solutions of unsaturated phospholipids were 
discarded after 1 month. 
Preparation of Liposome Vesicles for SSNMR Samples 
Liposomes were prepared using a modified version of the protocol previously reported.18 
A suspension of POPC/Erg/AmB in 1:1 CHCl3/MeOH was prepared as follows: The desired 
amount of AmB stock solution (typically 30-40 mL) was concentrated in vacuo to 2-3 mL and 
transferred to a 7 mL Wheaton vial, with three Optima MeOH washes to ensure complete 
transfer. This resulting AmB suspension was concentrated in vacuo. The desired amounts of 
stock solutions of phospholipid and Erg were then added via Hamilton gastight syringe, and an 
equivalent volume of Optima MeOH was added to resuspend the AmB. The vial was capped and 
this suspension was briefly vortexed and bath-sonicated until no AmB remained adherent to the 
sides of the vial (2-3 cycles). Solvent was removed under a gentle stream of nitrogen gas. 
Residual solvent was removed under high vacuum for ≥8 h.  
To the dried solid was added filter-sterilized 0.3 mM HEPES buffer, pH 7.0 to yield a 
final phospholipid concentration of 40 mM. This aqueous suspension was vortexed and sonicated 
3 times or until a homogeneous suspension was observed. Samples were then submitted to 5 
freeze/thaw cycles (liquid nitrogen, lukewarm tap water). Samples were again frozen in liquid 
nitrogen and lyophilized for ≥8 h. The lyophilization chamber was then back-filled with dry Ar 
to prevent samples from absorbing ambient water. Samples were immediately capped and 
packed into rotors for SSNMR as soon as possible.    
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Dry samples were packed in 3.2 mm diameter limited speed SSNMR rotors (Agilent 
Technologies, Inc.) and hydrated with 8-10 μL of MilliQ H2O. Rubber discs were used in the 
rotors to maintain hydration levels by creating a seal against which the rotor cap and drive tip 
were placed. Samples were placed at 4 °C for at least 24 hours to allow water to equilibrate. 
Electron Microscopy General Information 
LUVs were prepared by the method reported previously,25,27 and AmB was added to the 
LUV suspension as a freshly-prepared DMSO stock solution. Microscopy was performed using a 
120-keV FEI Spirit Transmission Electron Microscope. Images were recorded using a bottom 
mount TVIPS CMOS based camera system at nominal magnifications of 23,000-49,000x at the 
specimen level. Measurements were taken in ImageJ32 (v 1.47). 
Electron Microscopy Sample Preparation 
AmB was prepared as a stock DMSO solution (8.82 mM). 5 µL of the stock AmB 
solution was added to 95 µL of the 50x-diluted LUV solutions. For AmB-free samples, 5 µL of 
DMSO was added to 95 µL of the 50x-diluted LUV solutions. Samples were vortexed gently for 
5 seconds then incubated at 37 °C for 1 hour. EM samples were prepared as previously 
described55  with the following modifications. A 4 µL drop of the sample was applied to a 
negatively charged carbon-coated copper grid (Gilder 200 mesh, Ted Pella, Inc., Redding CA) 
for 30 seconds. Subsequently, two drops of freshly prepared 2% uranyl acetate were added to the 
sample and incubated for 1 minute before drying via aspiration. Samples were then screened on 
the electron microscope.  
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Growth Conditions for S. cerevisiae for In Vivo Sterol Extraction Studies and Membrane 
Isolation 
S. cerevisiae was grown in autoclave-sterilized yeast peptone dextrose (YPD) media 
consisting of 10 g/L yeast extract, 20 g/L peptone and 20 g/L of filter-sterilized dextrose added 
as a sterile 40% w/v solution in water. Solid media was prepared by pouring sterile media 
Figure 2.20: Supplemental transmission electron microscopy images. A.) 10:1 POPC:Erg liposomes. Average 
LUV size was ≈ 200 nm. B.) POPC:Erg 10:1 liposomes with 1 equivalent of added AmB. The average LUV size 
was ≈ 200 nm. C.) 1 equivalent AmB added in HEPES Buffer. 
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containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 mm polystyrene plates. Liquid 
cultures were incubated at 30 °C on a rotary shaker and solid cultures were maintained at 30 °C 
in an incubator. 
Sample Preparation for In Vivo Sterol Extraction Studies and Membrane Isolation 
750 mL overnight cultures of S. cerevisiae were grown to stationary phase (OD600 of ~1.7 as 
measured with a Shimadzu PharmaSpec UV-1700 UV/Vis spectrophotometer). This culture was 
divided equally into 50 mL Falcon centrifuge tubes.  
Stock solutions of AmdeB, AmB, and Erg were prepared in DMSO. Methyl-beta-
cyclodextrin (MBCD) were added directly to the liquid culture. Cells were treated with either a 
DMSO only control, 5 μM AmdeB, or 5 μM AmB for 1, 30, 60, or 120 minutes. Cells were 
treated with DMSO control, 500 mM MBCD, 25 μM Erg control, and the 5 μM AmB:25 μM Erg 
complex for 120 minutes. Treated tubes were incubated on the rotary shaker (200 rpm) at 30 oC 
for the time of exposure.  
For the quantification of colony forming units (CFUs), at the end of exposure, aliquots 
were taken from the samples, diluted, and plated on YPD agar plates. The plates were then 
incubated for 48 hours at 30 oC and colony-forming units were counted. 
For the quantification of percent ergosterol remaining, yeast membranes were isolated 
using a modified version of Haas’ spheroplasting and isosmotic cell lysis protocol and simple 
differential ultracentrifugation.45 At the end of the exposure time, tubes were removed from the 
shaker and centrifuged for 5 minutes at 3000 g at room temperature. The supernatant was poured 
off and 5 mL of wash buffer (dH2O, 1M DTT, 1M Tris-HCl, pH 9.4) was added. The tubes were 
vortexed to resuspend and incubated in a 30 oC water bath for 10 minutes. Tubes were then 
centrifuged again for 5 minutes at 3000 g and the supernatant poured off. 
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1 mL of spheroplasting buffer (1M KPi, YPD media, 4M Sorbitol) and 100 μL of a 5 
mg/mL solution of lyticase from Arthrobacter luteus (L2524 Sigma-Aldrich) was added to each 
tube, and each tube was then vortexed to resuspend. Tubes were incubated in a 30 oC water bath 
for 30 minutes, with occasional swirling. After incubation, tubes were centrifuged for 10 minutes 
at 1080 g at 4 oC and the supernatant poured off. 
1 mL of PBS buffer and 20 μL of a 0.4 mg/ml dextran in 8% Ficoll solution was added to 
each tube, mixed very gently to resuspend. This suspension was placed on ice for 4 minutes and 
then heat-shocked in a 30 oC water bath for 3 minutes.  
The suspensions were then transferred to Eppendorf tubes, vortexed to ensure complete 
lysis, and centrifuged at 15000 g at 4 oC for 15 minutes to remove un-lysed cells and cell debris. 
The resulting supernatants were transferred to thick-wall polycarbonate ultracentrifuge tubes (3.5 
mL, 13 x 51 mm, 349622 Beckman Coulter) and spun for 1 hour at 100,000 g at 4oC in a 
Beckman Coulter TLA-100.3 fixed-angle rotor in a Beckman TL-100 Ultracentrifuge. The 
supernatant was poured off. The remaining membrane pellet was resuspended in 1 mL PBS 
buffer and stored at -80 oC until further analysis. 
Gas Chromatography Quantification of Sterols 
750 μL of each membrane pellet sample and 20 μL of internal standard (4 mg/mL 
cholesterol in chloroform) were dissolved in 3 mL 2.5% ethanolic KOH in a 7 mL vial, which 
was then vortexed gently, capped, and heated in a heat block on a hot plate at 90oC for 1 hour. 
The vials were then removed from the heat source and allowed to cool to room temperature. 1 
mL of brine was added to the contents of each vial. Extraction was performed twice, each with 3 
mL of hexane. Organic layers were removed in both extractions, dried over magnesium sulfate, 
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filtered through Celite® 545 (Sigma-Aldrich), and transferred to another 7 mL vial. The contents 
of the vial were then concentrated in vacuo in a 30oC water bath.  
The resulting sterol films were resuspended in 100 μL pyridine and 100 μL N,O-Bis-
(trimethylsilyl)-trifluoroacetamide with 1% trimethylchlorosilane (T6381-10AMP Sigma-
Aldrich) by vortexing gently.56 This solution was heated at 60 oC for 1 hour. The vials were 
placed on ice and the solvent was evaporated off by nitrogen stream. Vials must be kept at a low 
temperature to prevent evaporation of the sterol TMS ethers along with the solvent. The resulting 
films were resuspended in 100 μL of decane, filtered and transferred to a GC vial insert for 
analysis.  
Gas chromatography analysis was carried out on an Agilent 7890A gas chromatograph 
equipped with a FID, an Agilent GC 7693 Autosampler, and a Dell computer running Microsoft 
XP that utilizes ChemStation v.B.04.02 SP1. Samples were separated on a 30 m, 0.320 mm ID, 
0.25 um film HP-5 capillary column (19091J-413 Agilent). Hydrogen was employed as a carrier 
gas with an average velocity of 84.8 cm/s. Nitrogen make-up gas, hydrogen and compressed air 
were used for the FID. A split/splitless injector was used in a 20:1 split. The injector volume was 
2 μL. The column temperature was initially held at 250 oC for 0.5 min, then ramped to 265 oC at 
a rate of 10 oC /min with a final hold time of 12.5 min. The injector and detector temperature 
were maintained at 270 oC and 290 oC, respectively. The value reported for each time point was 
calculated by dividing the value for the treatment group by the value for the DMSO control at the 
same time point, and then normalizing the DMSO control to 100%. 
Preparation of An Amphotericin-Ergosterol Complex   
Erg was prepared as a stock solution, 4 mg/mL in CHCl3, and the solvent removed under 
a gentle stream of nitrogen gas. Residual solvent was removed under high vacuum for at least 8 
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h. A DMSO solution of 5 μM AmB was then added to this solid Erg (25 μM final Erg 
concentration, 5:1 mole ratio Erg:AmB). The resulting suspension was gently vortexed and then 
heated to 80 oC for one hour in an aluminum heating block to allow Erg to fully dissolve. The 
resulting AmB/Erg solution was then allowed to cool to room temperature. This solution was left 
to complex at room temperature for another hour before use. 
The absorbance spectra of the two types of aggregate, (1) 5 μM AmB only in PBS buffer, 
(2) 5 μM AmB:25 μM Erg complex in PBS buffer, and the monomeric form of AmB (AmB in 
25% PBS buffer, 75% methanol) were investigated using a Shimadzu PharmaSpec UV-1700 
UV/Vis spectrophotometer.57 Figure 2.21 shows the distinct shift in UV spectra between the 
different forms of AmB and AmB bound to Erg in a complex.  
 
We further confirmed that the AmB aggregates we observed in our SSNMR, TEM, and cell-
based experiments are similar (Figure 2.22). 
Figure 2.21: Monomeric AmB in PBS:methanol and AmB aggregate in PBS buffer demonstrate spectral 
signatures by UV spectroscopy.60 
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C3deOAmB Materials 
Commercially available materials were purchased from Sigma-Aldrich Co. (Milwaukee, 
WI), Fisher Scientific (Hampton, NH), AK Scientific (Union City, CA) and used without further 
purifications unless noted otherwise. Camphorsulfonic acid was recrystallized from the ethyl 
acetate prior to use. All solvents were dispensed from a solvent purification system that passes 
solvents through packed columns according to the method of Pangborn and coworkers52 (THF, 
CH2Cl2, toluene, hexanes: dry neutral alumina; DMSO, DMF, CH3OH: activated molecular 
sieves). Triethylamine, N,N-diisopropylethylamine and pyridine were freshly distilled under 
nitrogen from CaH2. Water was double distilled or obtained from a Millipore MilliQ water 
purification system. 
C3deOAmB Reactions 
 Due to the light and air sensitivity of Amphotericin B, all manipulations were carried out 
under low light conditions and compounds were stored under an anaerobic atmosphere. All 
reactions were performed in oven- or flame-dried glassware under an atmosphere of argon unless 
otherwise indicated. Reactions were monitored by analytical thin layer chromatography 
Figure 2.22: 13C NMR and UV-Vis spectra of A.-B.) AmB precipitated in YPD buffer used for in vivo studies, 
C.-D.) AmB precipitated in HEPES buffer used for TEM studies, and E.-F.) 10:1 mole ratio of POPC:AmB 
MLVs lyophilized and rehydrated for SSNMR studies. 
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performed using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25 mm). 
Compounds were visualized using a UV (λ254) lamp or stained by KMnO4. Alternatively, 
reactions were monitored by RP-HPLC using an Agilent 1100 series HPLC system equipped 
with a Symmetry®C18 5 micron 4.6 x 150 mm column (Waters Corp. Milford, MA) with UV 
detection at 383 nm and the indicated eluent and flow rate of 1.2 mL/min. 
C3deOAmB Purification and Analysis 
 Flash chromatography was performed as described by Still and coworkers89 using the 
indicated solvent on E. Merck silica gel 60 230-400 mesh. 1H NMR spectra were recorded at 23 
oC on one of the following instruments: Varian Unity 500, Varian VXR 500, Agilent VNS 750. 
Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane and 
referenced internally to the residual protium in the NMR solvent (CD3C(O)CHD2, δ = 2.04, 
center line) or to added tetramethylsilane. Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, dd = doublet of doublets, 
app. = apparent), coupling constant (J) in Hertz (Hz) and integration. 13C spectra were recorded 
at 23 oC with Varian Unity 500 or Varian VXR 500. Chemical shift (δ) are reported downfield of 
tetramethylsilane and are referenced to the carbon resonances in the NMR solvent 
(CD3C(O)CD3, δ = 39.5, center line) or to added tetramethylsilane. High resolution mass spectra 
(HRMS) were obtained at the University of Illinois mass spectrometry facility. All synthesized 
compounds gave HRMS within 5 ppm of calculated values. 
Synthesis of AmB Derivatives 
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N-Alloc SI 1 
A round bottom flask was charged with Amphotericin B (4 g, 4.33 mmol, 1 eq) which were 
dissolved in a mixture of DMF: MeOH 2:1 (135 mL) at 23 oC. Pyridine (4 mL, 49.4 mmol, 11.4 
eq), Alloc-succinimide (2.4 g, 12.1 mmol, 2.8 eq) was subsequently added and the reaction was 
stirred overnight. The reaction mixture was then poured into diethyl ether (4 L). After stirring for 
15 minutes, the resulting yellow precipitate was isolated via Buchner filtration using Whatman 
50 filter paper and washed with diethyl ether to afford a yellow solid (4.32 g, 4.28 mmol, 99 %). 
This material was carried forward without further purification. 
 
HPLC (C18 SiO2; flow rate = 1.2 mL/min; MeCN: 25 mM NH4OAc in H2O 1:19  19:1 over 8 
minutes) 
  tR: 5.6 min 
 
HRMS (ESI) 
Calculated for C51H77NO19(M+Na
+): 1030.4987 
Found:                1030.4968 
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p-methoxybenzylideneacetal methyl ketal SI 2 
A round bottom flask was charged with SI 1 (6 g, 5.95 mmol, 1 eq) which was dissolved in a 
mixture of THF: MeOH 2:1 (198 mL) at 23 oC. Camphorsulfonic acid (350 mg, 1.51 mmol, 0.25 
eq) was added followed by anisaldehyde dimethyl acetal (10 mL, 58.7 mmol, 9.9 eq). The 
resulting mixture was quenched with triethylamine (240  mmol, 0.5 eq) after 45 minutes 
at 23 oC. The mixture was then concentrated in vacuo to form brown oil. Purification of the 
crude oil by flash chromatography (SiO2; methylene chloride: methanol 97:3  93:7, 0.1 % 
AcOH) furnished SI 2 as an orange solid (4.15 g, 3.30 mmol, 56 %). 
 
 
TLC (methylene chloride: MeOH 9:1, 0.1 %AcOH) 
  Rf = 0.44, visualized by UV 
1H NMR (500 MHz, acetone d-6) 
-6.85 (m, 4H), 6.50-6.17 (m, 11H), 6.03 
(app d, J = 8.8 Hz, 1H), 5.99-5.87 (m, 2H), 5.58 (dd, J = 9.4 Hz, J = 14.1 Hz, 1H), 5.53 (s, 1H), 
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5.46 (s, 1H), 5.31 (dd, J = 1.3 Hz, J = 17.5 Hz, 1H), 5.30-5.23 (m ,1H), 5.19-5.13 (m, 1H), 4.70 
(app t, J = 5.6 Hz, 1H), 4.64 (s, 1H), 4.58-4.48 (m, 2H), 4.23-4.13 (m, 2H), 3.99-3.91 (m, 2H), 
3.85-3.70 (m, 8H), 3.62-3.56 (m, 2H), 3.48-3.41 (m, 2H), 3.40-3.28 (m, 3H), 3.07 (s, 3H), 2.58 
(dd, J = 6.0 Hz, J = 6.0 Hz, 1H), 2.46-2.38 (m, 1H), 2.37-2.29 (m, 2H), 2.27-2.20 (m, 1H), 2.15-
2.10 (m, 1H), 1.94-1.81 (m, 3H), 1.78-1.60 (m, 3H), 1.60-1.43 (m, 4H), 1.39-1.32 (m, 2H), 1.24 
(d, J = 5.5 Hz, 3H), 1.23-1.22 (m, 1H), 1.19 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H), 1.02 (d, 
J = 7.1 Hz, 3H) 
13C NMR (125 MHz, acetone d-6) 
133.7, 133.1, 132.8, 132.7, 132.4, 130.0, 128.4 (2C), 117.3, 114.3, 114.0, 101.2, 100.9, 100.8, 
98.2, 95.0, 81.2, 78.2, 76.4, 74.8, 74.3, 73.4, 73.3, 73.1, 72.5, 72.3, 71.8, 71.1, 70.7, 69.3, 67.4, 
67.2, 65.8, 65.7, 57.9, 57.2, 55.6, 54.9, 48.7, 43.7, 42.8, 41.9, 41.7, 38.1, 37.0, 34.1, 33.3, 28.9, 
20.5, 18.8, 18.4 (2C), 17.6, 12.0 
HRMS (ESI) 
Calculated for C67H91NO21 (M+Na
+): 1280.5981 
Found:                           1280.5939 
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Pentatriethylsily ether SI 3 
SI 2 (4 g, 3.18 mmol, 1 eq) and imidazole (4.3 g, 63.6 mmol, 20 eq) were added into a round 
bottom flask which were then azeotropically dried via co-evaporation with toluene. The resulting 
solid was dissolved in methylene chloride (106 mL) and cooled to 0 oC. Triethylsilyl chloride 
(5.3 mL, 31.8 mmol, 10 eq) was added dropwise over 3 minutes. The resulting yellow 
suspension was warmed to 23 oC and stirred for 4 hours. The mixture was then quenched at 0 oC 
with saturated aqueous sodium bicarbonate (106 mL), which was then diluted with diethyl ether 
(1 L) and the layers were separated. The organic layer was washed with water: saturated aqueous 
sodium bicarbonate 1:1 (3 x 250 mL) and brine (1 x 250 mL), dried over sodium sulfate and 
concentrated in vacuo. Purification of the crude brown oil by flash chromatography (SiO2; 
hexanes: ethyl acetate 19:1 4:1, 0.1 % AcOH) furnished SI 3 as an orange solid (1.92 g, 1.87 
mmol, 59 %). 
 
TLC (hexane:ethyl acetate 7:3, 0.1 % AcOH) 
  Rf=0.71, visualized by UV 
1H NMR (500 MHz, acetone d-6) 
-7.34 (m, 4H), 6.93-6.85 (m,4H), 6.49-6.05 (m, 12H), 6.00-5.91 (m,1H), 5.87 (app dd, J = 
5.6 Hz, J = 14.7 Hz, 1H), 5.66 (dd, J = 9.3 Hz, J = 15.1 Hz, 1H), 5.46 (app s, 2H), 5.42-5.38 (m, 
1H), 5.37-5.30 (m, 1H), 5.22-5.15 (m, 1H), 4.99-4.90 (m, 1H), 4.72-4.67 (m, 1H), 4.62-4.49 (m, 
3H), 4.27 (dt, J = 4.5 Hz, J = 10.5 Hz, 1H), 4.23-4.14 (m, 1H), 3.97-3.87 (m, 3H), 3.79 (s, 3H), 
3.81-3.67 (m, 7H), 3.63-3.56 (m, 1H), 3.48 (app t, J = 9.0 Hz, 1H), 3.36-3.28 (m, 1H), 3.08 (s, 
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3H), 2.54 (dd, J = 7.4 Hz, J = 17.5 Hz, 1H), 2.45-2.37 (m, 1H), 2.33-2.23 (m, 3H), 2.13-2.07 (m, 
1H), 1.96-1.84 (m, 3H), 1.79-1.53 (m, 4H), 1.53-1.41 (m, 4H), 1.36-1.26 (m, 1H), 1.25 (d, J = 
6.1 Hz, 3H), 1.23-1.20 (m, 1H), 1.19 (d, J = 6.1 Hz, 3H), 1.09-0.76 (m, 49H), 0.76-0.40 (m, 32H) 
13C NMR (125 MHz, acetone d-6) 
133.4, 133.1, 132.9, 132.8, 132.7, 131.5, 131.2, 128.7, 128.4, 117.4, 114.3，114.0, 113.9, 101.8, 
101.2, 101.0, 98.3, 81.7, 76.3, 75.3, 75.2, 74.6, 74.0, 73.4, 73.2, 73.0, 71.9，68.8, 67.8, 65.9, 
58.3, 57.2, 55.6, 48.5, 44.1, 43.4, 41.4, 41.2, 38.0, 36.6, 33.7, 33.0, 28.4, 19.0, 18.6, 18.3, 7.5, 7.3 
(2C), 7.2, 7.1, 7.0, 6.7, 6.2, 6.0 (2C), 5.9 (2C), 5.8, 5.7, 5.6 
 
 
HRMS (ESI) 
  Calculated for C98H161NO21Si5 (M+Na
+):1851.0305 
  Found :          1851.0310 
 
 
 
Allyl ester 1 
To a stirred solution of SI 3 (1.62 g, 0.885 mmol, 1 eq) in dimethylformamide (29.5 mL) was 
added allyl bromide (3.1 mL, 35.4 mmol, 40 eq) and N,N-diisopropylethylamine (0.62 mL, 3.54 
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mmol, 4 eq). The solution was stirred for 4 hours at 23 oC and then diluted with diethyl ether 
(300 mL). The resulting mixture was washed with water: saturated aqueous ammonium chloride 
1:1 (3 x 75 mL) and brine (1 x 75 mL). The organic layer was dried over sodium sulfate and then 
concentrated in vacuo. Purification by flash chromatography (SiO2; hexanes: ethyl acetate 
19:1 9:1) afforded 1 as an orange solid (1.42 g, 0.763 mmol, 86 %). 
 
 
 
TLC (hexanes: ethyl acetate 7:3) 
  Rf = 0.78, visualized by UV 
1H NMR (500 MHz, acetone d-6) 
-7.35 (m, 4H), 6.93-6.85 (m, 4H), 6.52-6.17 (m, 11H), 6.12 (dd, J = 9.8 Hz, J = 15.0 Hz, 
1H), 6.05-5.90 (m, 2H), 5.90-5.83 (m, 1H), 5.66 (dd, J = 9.2 Hz, J = 14.9 Hz, 1H), 5.54-5.26 (m, 
6H), 5.23-5.16 (m, 1H), 5.00-4.92 (m, 1H), 4.76-4.51 (m, 5H), 4.50 (s, 1H), 4.28 (dt, J = 4.6 Hz, 
J = 10.6 Hz, 1H), 4.25-4.16 (m, 1H), 3.97-3.87 (m, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.77-3.67 (m, 
4H), 3.65 (app dt, J = 3.2 Hz, J = 9.6 Hz, 1H), 3.48 (t, J = 8.9 Hz, 1H), 3.38-3.29 (m, 1H), 3.08 
(s, 3H), 2.54 (dd, J = 7.3 Hz, J = 17.5 Hz, 1H), 2.46-2.39 (m, 1H), 2.36-2.25 (m, 3H), 2.04-1.98 
(m, 1H), 1.97-1.84 (m, 3H), 1.80-1.53 (m, 6H), 1.53-1.40 (m, 2H), 1.37-1.28 (m, 2H), 1.24 (d, J 
= 6.2 Hz, 3H), 1.19 (d, J = 6.2 Hz, 3H), 1.08-0.86 (m, 49H), 0.76-0.37 (m, 32H) 
13C NMR (125 MHz, acetone d-6) 
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133.3, 133.1, 132.7, 132.5, 132.4, 131.4, 131.0, 128.5, 128.2, 128.0 (2C), 127.9, 118.9, 117.3, 
114.1, 113.8, 113.7, 101.7, 101.0, 100.7, 98.7, 81.5, 75.9, 75.7, 74.9, 74.5, 73.7, 73.0, 72.7, 71.6, 
68.7, 67.5, 65.7 (2C), 58.1, 57.7, 55.5, 55.4 (2C), 48.4, 43.8, 43.1, 41.3, 37.8, 36.6, 33.4, 32.7, 
28.0, 19.0, 18.5, 18.4, 11.3, 7.6, 7.4 (2C), 7.3 (2C), 7.2, 7.1, 6.2, 6.1 (2C), 6.0, 5.9 (2C),5.8, 5.7, 
5.6 (3C), 5.5, 5.2 
HRMS (ESI) 
  Calculated for C101H165NO21Si5 (M+Na
+): 1891.0618 
  Found:      1891.0547 
 
 
 
α,β-unsaturated lactone 2 
Prior to the reaction, 1 (1.63 g, 0.872 mmol, 1 eq) was azeotropically dried via coevaporation 
with toluene. The resulting orange solid was dissolved in THF (14.5 mL) and cooled to -78 oC. 
Sodium bis(trimethylsilyl)amide (800 mg, 4.36 mmol, 5 eq) in THF (14.5 mL) was cooled to -78 
oC and added dropwise into the solution of 1 over 5 minutes via syringe. The mixture was stirred 
for 1 hour at -78 oC and quenched with saturated aqueous ammonium chloride (29 mL) at -78 oC, 
which was then extracted with diethyl ether (300 mL). The organic layer was washed with water: 
saturated aqueous ammonium chloride 1:1 (3 x 75 mL) and brine (1 x 75 mL), dried over sodium 
sulfate, and concentrated in vacuo. Purification of the crude orange oil by flash chromatography 
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(SiO2; hexanes: ethyl acetate 19:1 17:3) afforded 2 as a yellow solid (1.14 g, 0.658 mmol, 75 
%). 
 
 
TLC (hexanes: ethyl acetate 7:3) 
  Rf=0.74, visualized by UV 
 
1H NMR (500 MHz, acetone d-6) 
2H), 6.47-6.07 (m, 12H), 6.04-5.85 (m, 3H), 5.80 (d, J = 15.6 Hz, 1H), 5.62 (dd, J = 8.9 Hz, J = 
14.0 Hz, 1H), 5.47 (s, 1H), 5.46-5.25 (m, 4H), 5.19 (dq, J = 10.5 Hz, J = 4.6 Hz, 1H), 5.12-5.05 
(m, 1H), 4.69 (dd, J = 6.0 Hz, J = 13.6 Hz, 1H), 4.66-4.53 (m, 4H), 4.52 (s, 1H), 4.28 (dt, J = 4.7 
Hz, J = 10.6 Hz, 1H), 3.99-3.89 (m, 3H), 3.81-3.73 (m, 4H), 3.72-3.67 (m, 2H), 3.68-3.60 (m, 
2H), 3.48 (t, J = 8.9 Hz, 1H), 3.34-3.27 (m, 1H), 3.13 (s,3H), 2.49-2.25 (m, 6H), 2.03-1.89 (m, 
4H), 1.88-1.80 (m, 1H), 1.73-1.43 (m, 5H), 1.40-1.32 (m, 1H), 1.22 (d, J = 6.2 Hz, 3H), 1.20 (d, 
J = 6.1 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H), 1.05-0.77 (m, 46H), 0.75-0.38 (m, 32H) 
13C NMR (125 MHz, acetone d-6) 
, 133.5, 
133.3, 133.2, 132.8, 132.6, 132.4, 131.8, 130.4, 128.5, 123.5, 118.9, 117.2, 113.7, 101.6, 100.8, 
98.7, 81.4, 78.9, 75.9, 75.1, 74.4, 73.7, 73.2, 73.0, 70.7, 70.3, 68.6, 67.5, 65.7, 65.6, 58.1, 57.1, 
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55.4, 48.5, 43.8, 42.9, 41.9, 37.2, 34.3, 33.2, 28.9, 18.9, 18.6, 18.1, 12.2, 7.4 (2C), 7.3, 7.2, 7.0, 
5.8, 5.7 (2C), 5.4 
HRMS (ESI) 
  Calculated for C93H157NO19Si5 (M+Na
+): 1755.0094 
  Found:      1755.0094 
 
 
 
Lactone 3 
A round bottom flask was purged with argon and charged with 2 (500 mg, 0.288 mmol, 1 eq) 
and Stryker’s reagent (566 mg, 0.288 mmol, 1 eq). Toluene (14.4 mL) and water (45 
subsequently added and the mixture was stirred for 14 hours at 23 oC. The mixture was then 
stirred under air for 30 minutes before it was filtered through celite plug with ethyl acetate (600 
mL). The filtrate was washed with water: saturated aqueous ammonium chloride 1:1 (2 x 150 
mL), water: saturated aqueous sodium bicarbonate 1:1 (2 x 150 mL) and brine (1 x 150 mL). The 
organic layer was dried over sodium sulfate and concentrated in vacuo. Purification by flash 
chromatography (SiO2; hexanes: ethyl acetate 19:1 17:3) afforded 3 as a yellow solid (424 mg, 
0.244 mmol, 85 %). 
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TLC (hexanes: ethyl acetate 7:3) 
  Rf=0.68, visualized by UV 
1H NMR (500 MHz, acetone d-6) 
 Hz, 2H), 6.90 (d, J=8.7 Hz, 2H), 6.46-6.08 (m, 12H), 6.05-5.92 (m,2H), 5.89 
(m, 1H), 5.61 (dd, J=9.2 Hz, J=14.5 Hz, 1H), 5.47 (s, 1H), 5.46-5.26 (m, 4H), 5.19 (app dd, 
J=1.5 Hz, J=10.5 Hz, 1H), 4.98 (m, 1H), 4.69 (dd, J=5.8 Hz, J=13.4 Hz, 1H), 4.66-4.52 (m, 4H), 
4.50 (s, 1H), 4.28 (dt, J=4.6 Hz, J=10.7 Hz, 1H), 3.98-3.88 (m, 3H), 3.79 (s, 3H), 3.77-3.67 (m, 
4H), 3.64 (m, 1H), 3.48 (t, J= 8.9 Hz, 1H), 3.31 (m, 1H), 3.11 (s, 3H), 2.42 (m, 1H), 2.34-2.18 
(m, 4H), 2.15(m, 1H), 2.12 (m, 1H), 2.01 (m, 1H), 1.95 (m, 1H), 1.90-1.82 (m, 4H), 1.80-1.58 
(m, 5H), 1.55-1.48 (m, 3H), 1.24 (d, J=6.0 Hz, 3H), 1.18 (d, J=6.2 Hz, 3H), 1.06 (d, J=6.7 Hz, 
3H), 1.04-0.78 (m, 46H), 0.76-0.36 (m, 32H) 
13C NMR (125 MHz, acetone d-6) 
, 160.9, 156.3, 138.5, 136.7, 134.5, 134.2, 134.1, 134.0, 133.8, 133.7, 133.6, 
133.5 (2C), 132.9, 132.8, 132.7, 132.6, 131.5, 130.5, 129.5, 129.4, 128.7, 126.1, 119.0, 117.3, 
113.9, 110.6, 101.9, 101.0, 98.9, 81.8, 78.4, 76.0, 75.3, 74.7, 73.9, 73.4, 73.3, 71.2, 71.1, 68.8, 
67.8, 65.9, 65.8, 58.4, 57.4, 55.6, 48.6, 44.1, 43.2, 41.3, 39.2, 37.4, 35.2, 34.5, 33.4, 29.1, 21.7, 
19.0, 18.6, 18.4, 11.8, 7.4 (2C), 7.3, 7.1, 6.0 (2C), 5.9(2C), 5.6 
HRMS (ESI) 
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  Calculated for C93H159NO19Si5 (M+Na
+): 1757.0250 
  Found:      1757.0303 
 
 
 
Polyol SI 4 
A plastic bottle was charged with 3 (1 g, 0.576 mmol, 1 eq), which was dissolved in THF (20 
mL) and cooled to 0 oC. A pyridine (36.8 mL) and THF (60 mL) mixture in another plastic bottle 
was cooled to 0 oC. 70 % HF-pyridine was added to another plastic bottle containing pyridine 
(36.8 mL) and THF (60 mL) at 0 oC. The resulting solution was then cannula transferred slowly 
to the THF solution of 3 and the reaction was allowed to stir at 23 oC. After 12 hours the reaction 
was quenched at 0 oC with saturated aqueous sodium bicarbonate and diluted with methylene 
chloride (1.2 L). The organic layer was washed with water: saturated aqueous sodium 
bicarbonate 1:1 (2 x 600 mL) and brine (600 mL). The organic layer was dried with sodium 
sulfate and concentrated in vacuo. Purification by flash chromatography (SiO2; methylene 
chloride: MeOH 99:1 95:5) afforded SI 4 as a yellow solid (587.2 mg, 0.504 mmol, 88 %). 
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TLC (methylene chloride: MeOH 9:1) 
  Rf = 0.46, visualized by UV 
1H NMR (500 MHz, acetone d-6) 
-6.29 (m, 9H), 6.27-6.17 (m, 3H), 6.08 
(app d, J = 8.8 Hz,1H), 6.03-5.90 (m, 3H), 5.59 (dd, J = 9.1 Hz, J = 14.3 Hz, 1H), 5.54 (s, 1H), 
5.43 (app dd, J = 1.6 Hz, J = 17.2 Hz, 1H), 5.32 (app dd, J = 1.4 Hz, J = 17.2 Hz, 1H), 5.26 (app 
dd, J = 1.4 Hz, J = 10.6 Hz, 1H), 5.22-5.14 (m, 2H), 5.16 (dq, J = 10.6 Hz, J = 1.5 Hz, 1H), 4.72-
4.62 (m, 3H), 4.59 (s, 1H), 4.56-4.49 (m, 2H), 4.19 (dt, J = 4.8 Hz, J = 10.1 Hz, 1H), 4.01-3.90 
(m, 2H), 3.84 (app d, J = 2.0 Hz, 1H), 3.79 (s, 3H), 3.77-3.72 (m, 1H), 3.67-3.59 (m, 1H), 3.48-
3.28 (m, 5H), 3.11 (s, 3H), 2.48-2.34 (m, 2H), 2.31 (app t, J = 10.1 Hz, 1H), 2.26-2.18 (m, 2H), 
2.18-2.11 (m, 2H), 2.04-1.99 (m, 1H), 1.92-1.83 (m, 3H), 1.80-1.71 (m, 2H), 1.66-1.58 (m, 1H), 
1.57-1.45 (m, 3H), 1.43-1.31 (m, 3H), 1.26 (d, J = 5.2 Hz, 3H), 1.20 (d, J = 6.0 Hz, 3H), 1.13 (d, 
J= 6.4 Hz, 3H), 1.02 (d, J = 7.2 Hz, 3H) 
13C NMR (125 MHz, acetone d-6) 
134.6, 134.5, 134.1, 134.0, 133.9 (2C), 133.8 (2C), 
133.6 (2C), 132.8, 132.7, 132.5, 132.2, 129.5, 128.4, 118.5, 117.1, 113.9, 101.0, 100.8, 98.3, 
81.2, 78.3, 74.9, 74.3, 74.2, 73.1, 72.1, 71.9, 71.2, 70.2, 67.3, 67.2, 65.7, 65.6 (2C), 58.0, 57.5, 
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55.5, 48.9, 43.6, 43.5, 42.6, 41.6, 39.1, 37.4, 35.7, 35.3, 33.9, 30.6, 27.2, 22.1, 18.8, 18.4, 17.6, 
12.2 
HRMS (ESI) 
  Calculated for C63H89NO19 (M+Na
+): 1186.5926 
  Found:     1186.5951 
 
 
 
Hemi ketal SI 5 
A round bottom flask was charged with SI 4 (200 mg, 0.194 mmol, 1 eq). THF: H2O 2:1 (6.5 
mL) was added followed by camphorsulfonic acid (345 mg, 1.49 mmol, 7.7 eq). The reaction 
was allowed to stir at 23 oC for 3 hours before quenching with triethylamine (414 L, 2.98 
mmol, 15.4 eq). The reaction was dried over sodium sulfate and then concentrated in vacuo. 
Purification of the resulting residue by flash chromatography (SiO2: methylene chloride: MeOH 
99:1 90:10) afforded SI 5 as a yellow solid (80.9 mg, 0.078 mmol, 40 %). 
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TLC (methylene chloride: MeOH 9:1) 
  Rf=0.24, visualized by UV 
1H NMR (750 MHz, pyridine d-5: CD3OD 1:1) 
-6.27 (m, 13H), 6.09-6.03 (m, 1H), 5.97-5.90 (m, 1H), 5.65 (app q, J = 6.6 Hz, 1H), 5.52 
(app d, J = 17.3 Hz, 1H), 5.46 (dd, J = 10.4 Hz, J = 15.2 Hz, 1H), 5.32 (app dd, J = 1.1 Hz, J = 
17.4 Hz, 1H), 5.28(app d, J = 10.3 Hz, 1H), 5.14 (app d, J = 10.4 Hz, 1H), 4.91-4.86 (m, 1H), 
4.77 (s, 1H), 4.76-4.70 (m, 5H), 4.66 (app t, J = 11.0 Hz, 1H), 4.62-4.55 (m, 1H), 4.22 (app d, J = 
3.1 Hz, 1H), 4.05 (dd, J = 3.0 Hz, J = -10.2 Hz, 1H), 3.88 (app d, J = 11.1 Hz, 1H), 3.73 (t, J = 
9.6 Hz, 1H), 3.65-3.61 (m, 1H), 3.60-3.55 (m, 1H), 3.48-3.45 (m, 1H), 3.34 (app d, J = 9.3 Hz, 
1H), 2.62-2.55 (m, 2H), 2.36-2.29 (m, 2H), 2.30-2.16 (m, 3H), 2.06-1.98 (m, 2H), 1.89 (app dd, J 
= 11.0 Hz, J = 15.2 Hz, 1H), 1.85 (app dd, J = 11.3 Hz, J = 14.3 Hz, 1H), 1.83-1.78 (m, 2H), 1.69 
(app dd, J = 2.0 Hz, J = 13.8 Hz, 1H), 1.64-1.52 (m, 4H), 1.48 (d, J = 6.1 Hz, 3H), 1.47-1.39 (m, 
3H), 1.37 (d, J = 6.6 Hz, 3H), 1.24 (d, J = 6.4 Hz, 3H), 1.19 (d, J = 7.1 Hz, 3H) 
13C NMR (125 MHz, acetone d-6) 
133.7, 133.5 (2C), 133.3, 133.0, 118.2, 117.1, 98.5, 98.4, 98.0, 79.3, 79.1, 77.1, 76.9, 74.4, 70.2, 
69.4, 67.0, 66.1, 65.7 (2C), 65.6, 58.6, 58.0, 47.3, 45.5, 43.9, 40.9, 40.8, 39.6, 38.8, 36.5, 35.2, 
32.8, 22.8, 18.9, 18.4, 17.1, 12.5 
HRMS (ESI) 
  Calculated for C54H81NO18 (M+Na
+): 1054.5351 
  Found:     1054.5387 
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C3deOAmB 
A round bottom flask was charged with SI 5 (35 mg, 0.034 mmol, 1 eq), thiosalicylic acid (26.1 
mg, 0.170 mmol, 5 eq) and palladium tetrakis(triphenylphosphine) (11.6 mg, 0.0100 mmol, 0.3 
eq). DMF (1.75 mL) was added and the reaction was allowed to stir at 23 oC for 15 minutes 
before poured into diethyl ether (35 mL). The reaction mixture was then transferred to a 50 mL 
centrifuge tube and centrifuged at 3700g for 5 minutes. The red pellet was dissolved in DMSO (4 
mL) and purified by preparative RP-HPLC (Waters SunFire Prep C18 OBD 5 micron 30 x 150 
mm; 25 mL/min flow rate, MeCN: 15 mM NH4OAc in H2O 1:19  19:1 over 9 minutes, 
MeCN: 15 mM NH4OAc in H2O 19:1 for 1 minute, MeCN: 15 mM NH4OAc in H2O 19:1  
1:19 over 2 minutes) to afford C3deOAmB (16.2 mg, 0.018 mmol, 53 %) as a yellow solid. 
 
 
 
 
HPLC (analytical, C18 SiO2; flow rate = 1.2 mL/min; MeCN: 25 mM NH4OAc in H2O 1:19  
19:1 over 8 minutes) 
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  tR: 5.1 min 
 
 
 
1H NMR (750 MHz, pyridine d-5: CD3OD 1:1) 
 = 
11.3 Hz, J = 14.6 Hz, 1H), 6.51 (dd, J = 11.4 Hz. J = 13.4 Hz, 1H), 6.47-6.35 (m, 7H), 6.33-6.25 
(m, 2H), 5.69-5.63 (m, 1H), 5.50-5.45 (m, 1H), 5.03 (s, 1H), 4.87 (t, J = 10.7 Hz, 1H), 4.79-4.73 
(m, 2H), 4.69 (app t, J = 10.7 Hz, 1H), 4.57 (app d, J = 3.2 Hz, 1H), 3.87 (app d, J = 11.0 Hz, 
1H), 3.85 (t, J = 9.8 Hz, 1H), 3.70-3.68 (m, 2H), 3.65-3.59 (m, 1H), 3.47-3.45 (m, 1H), 3.36-3.31 
(m, 1H), 2.82 (app dd, J = 4.5 Hz, J = 15.2 Hz, 1H), 2.62-2.55 (m, 1H), 2.46 (t, J = 10.4 Hz, 1H), 
2.34-2.16 (m, 4H), 2.05-1.97 (m, 3H), 1.92-1.86 (m, J = 9.1 Hz, J = 14.0 Hz, 1H), 1.86-1.78 (m, 
2H), 1.66 (app dd, J = 2.3 Hz, J = 13.9 Hz, 1H), 1.64-1.51 (m, 4H), 1.46 (d, J = 6.2 Hz, 3H), 
1.45-1.38 (m, 3H), 1.37 (d, J = 6.5 Hz, 3H), 1.14 (d, JH = 6.4 Hz, 3H), 1.19 (d, J = 7.1 Hz, 3H) 
13C NMR (187.5 MHz, pyridine d-5:CD3OD 1:1) 
133.0, 130.3, 98.4, 79.3, 78.6, 76.7, 75.1, 74.4, 72.3, 70.6, 70.0, 69.8, 69.1, 67.5, 66.9, 61.5, 57.3, 
49.1, 47.8, 45.4, 44.1, 41.2, 40.7, 39.5, 38.9, 36.5, 35.3, 32.2, 30.8, 22.9, 19.1, 18.2, 17.2, 12.7 
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HRMS (ESI) 
  Calculated for C47H73NO16 (M+H
+): 908.5008 
  Found:     908.5007 
 
General Information for Planar Lipid Bilayer Experiments 
All data were acquired using a Warner Instruments (Hamden, CT) BC-535 amplifier and 
the data were filtered using a built in 4 pole Bessel filter with a cutoff frequency of 5 kHz. The 
headstage and delrin cell were housed within a Warner Instruments model FC-1 Faraday cage. 
The solutions were stirred using a Warner Instruments SUNstir-3 stirplate. The signal was passed 
through a Warner Instruments low pass 8 pole Bessel filter with a frequency cutoff of 1 kHz. The 
filtered data were sampled at a rate of 10 kHz using a Molecular Devices (Sunnyvale, CA) 
Digidata 1440 data acquisition system and the data were analyzed using Molecular Devices 
pClamp 10 software. Salt bridges were prepared monthly and were fabricated from 1.5 mm OD, 
0.86 mm ID borosilicate capillary tubing and were filled with 1 M aqueous KCl with 2.5 % agar. 
Prior to a day’s experiments, silver electrodes were plated by submerging in commercial bleach 
for 15 to 30 minutes. The electrodes were plated periodically throughout the day. 
Preparation of Lipid Solution for Planar Lipid Bilayer Experiments 
Lipids were obtained from Avanti Polar Lipids as 10 mg/mL solutions in CHCl3. The 
solutions were stored at -20 °C under dry argon and used within 3 months. A 4 mg/mL solution 
of ergosterol in CHCl3 was prepared monthly and stored at -20 °C under dry argon. Lipid films 
were prepared by charging a 1.5 mL vial with 60 µL DPhPC, and 30 µL ergosterol. The solvent 
was removed with a gentle stream of nitrogen. The lipid film was then dissolved in 30 µL n-
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decane to give the 20 mg/mL solution of lipids used for the electrophysiology experiments. The 
decane solutions were used within 3 hours of preparation. 
Formation of Planar Lipid Bilayers 
Custom manufactured polysulfone cups were machined with a 150 μm aperture (modeled 
after Warner Instruments model 64-0416, Hamden, CT). The area around the hole was then 
primed with 1 μL of the decane lipid solution. The primed cup was left to stand for 
approximately 10 minutes such that most of the decane evaporated. Then 1 mL of a 1 M KCl, 5 
mM HEPES at pH = 7.0 was added to each chamber. The membrane was formed by sequential 
vertical swabs across the hole using a flame polished glass applicator that had been previously 
dipped into the lipid solution. The formation of a membrane was detected by a reduction in the 
current to 0 pA. The integrity of this membrane was confirmed by applying a potential of 150 
mV for approximately one minute. If the current increased by >1 pA upon voltage introduction, 
the membrane was rejected. Membranes were between 45 and 105 pF in size. 
Interrogating Channel Formation  
If the membrane was acceptable, 0.25 - 1 μL of a compound in DMSO was added to both 
chambers and the solutions were stirred with zero applied potential for 3 minutes. After 3 
minutes the stirring was stopped, and a potential was applied across the membrane. The 
formation of single AmB channels under similar conditions has been well documented.4 The 
concentration of AmB and C3deOAmB required to observe channel activity varied from 
membrane to membrane and appeared to depend on the membrane capacitance. For both AmB 
and C3deOAmB, single channel formation was observed at concentrations between 0.25 and 5 
nM.  
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A standardized protocol was used to perform these experiments with both AmB and 
C3deOAmB. Each compound was initially added to both sides of the lipid bilayer at 0.5 nM and 
then channel activity was investigated for 10 minutes. If no channel activity was observed, a 
small amount of additional compound was added to both sides of the membrane to increase the 
concentration by 0.5 nM and then channel activity was investigated for 10 minutes again. This 
process was repeated until single channel activity was observed, or until we reached a 
concentration of 5 nM, observed multi-channel formation (data not used) or observed membrane 
rupture. For both AmB and C3deOAmB, single channel data were typically recorded at 0.5 nM. 
To measure conductance of AmB and C3deOAmB the same basic experimental setup was used 
with the following slight modifications. A 2 M KCl, 5 mM HEPES pH = 7.0 bathing solution 
was used instead of the 1 M KCl, 5 mM HEPES pH = 7.0 solution. Upon bilayer formation and 
addition of compound to both sides of the membrane channel activity was investigated at 90, 
120, 150, 180, and 210 mV applied potential.  
Single Channel Characterization 
All data processing was performed within the pClamp v10 software suite. Following 
acquisition, the data was digitally filtered to 20 Hz. Then using the single channel search feature 
(ignore short level changes of 40 ms or less, update baseline automatically) the amplitude of the 
open and closed states was determined. The delta between the open and closed levels represents 
the single channel current at the given applied voltage. Dwell times were calculated from single 
ion channel traces. 
Best-fit lines of the current vs. voltage plot of both AmB and C3deOAmB single ion 
channels were determined via linear regression. The slope is equal to the conductance of the 
corresponding channel based on Ohm’s Law. Errors were determined from the standard error of 
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the linear regression. The p value of equivalent AmB and C3deOAmB single ion channel 
conductances was calculated to be less than 0.0001. 
 
 
Figure 2.23: A.) Representative traces of AmB single ion channel activity in planar lipids bilayers. DPhPC 
Lipids with 30% Ergosterol. 1 M KCl pH = 7.0, 5 mM HEPES +150 mV. Each representative trace contains one 
minute of recording. B.) Corresponding amplitude diagrams with Gaussian fits for each of the AmB single ion 
channel traces. Average dwell times for AmB single ion channel activity were 135.2 ± 65.03 ms. 
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General Information for Liposome Efflux Experiments 
Potassium selective measurements were obtained using a Denver Instruments (Denver, 
CO) Model 225 pH meter equipped with a World Precision Instruments (Sarasota, FL) potassium 
selective electrode inside a Faraday cage. The electrode was filled with 1000 ppm KCl standard 
solution and conditioned in a 1000 ppm KCl standard solution for 15 minutes prior to potassium 
selective measurements. Measurements were made on 3 mL solutions that were magnetically 
stirred in 7 mL vials incubated at 23 °C. The instrument was calibrated daily with KCl standard 
solutions to 10, 100, and 1000 ppm potassium. The potassium concentration was sampled every 
Figure 2.24: A.) Representative traces of C3deOAmB single ion channel activity in planar lipids bilayers. 
DPhPC Lipids with 30% Ergosterol. 1 M KCl pH = 7.0, 5 mM HEPES +150 mV. Each representative trace 
contains one minute of recording. B.) Corresponding amplitude diagrams with Gaussian fits for each of the 
C3deOAmB single ion channel traces. Average dwell times for C3deOAmB single ion channel activity were 
1265 ± 363.1 ms. 
 
 
74 
 
10 seconds throughout the course of the efflux experiments. Proton selective measurements were 
obtained using a Fisher Scientific (Hampton, NH) micro pH electrode. Measurements were made 
on 3 mL solutions that were magnetically stirred in 7 mL vials incubated at 23 °C. The 
instrument was calibrated daily with pH standard solutions of 4, 7, and 10. The pH was sampled 
every 30 seconds throughout the course of the efflux experiments.  
Liposome preparation for Liposome Efflux Experiments 
Palmitoyl oleoyl phosphatidylcholine (POPC) was obtained as a 25 mg/mL solution in 
CHCl3 from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 ºC under an atmosphere 
of dry argon and used within 3 months. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at 4 ºC under an atmosphere of dry argon. Prior to preparing a lipid film, the 
solutions were warmed to ambient temperature to prevent condensation from contaminating the 
solutions. A 7 mL vial was charged with 640 μL POPC and 230 μL of the ergosterol solution. 
The solvent was removed with a gentle stream of nitrogen and the resulting lipid film was stored 
under high vacuum for a minimum of eight hours prior to use. For potassium efflux experiments, 
the film was then hydrated with 1 mL of 150 mM KCl, 5 mM HEPES buffer pH 7.4 and 
vortexed vigorously for approximately 3 minutes to form a suspension of multilamellar vesicles 
(MLVs). For proton efflux experiments, the film was hydrated with 1 mL of 400 mM Sodium 
Phosphate buffer pH 5.5. The resulting lipid suspension was pulled into a Hamilton (Reno, NV) 
1 mL gastight syringe and the syringe was placed in an Avanti Polar Lipids Mini-Extruder. The 
lipid solution was then passed through a 0.20 μm Millipore (Billerica, MA) polycarbonate filter 
21 times, the newly formed large unilamellar vesicle (LUV) suspension being collected in the 
syringe that did not contain the original suspension of MLVs to prevent the carryover of MLVs 
into the LUV solution. To obtain a sufficient quantity of LUVs, three independent 1 mL 
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preparations were pooled together for the dialysis and subsequent efflux experiments. The newly 
formed LUVs were dialyzed using Pierce (Rockford, IL) Slide-A-Lyzer MWCO 3,500 dialysis 
cassettes. For potassium efflux experiments, the samples were dialyzed three times against 600 
mL of 150 mM NaCl, 5 mM HEPES buffer pH 7.4. For proton efflux experiments, the samples 
were dialyzed three times against 600 mL of 400 mM Sodium Sulfate pH 7.5. The first two 
dialyses were two hours long, while the final dialysis was performed overnight. 
Determination of Phosphorus Content for Liposome Efflux Experiments 
Determination of total phosphorus was adapted from the report of Chen and coworkers.90 
The LUV solution was diluted tenfold with either 150 mM NaCl, 5 mM HEPES buffer pH 7.4 
(potassium efflux experiments) or 400 mM Sodium Sulfate pH 7.5 (proton efflux experiments). 
Three 10 μL samples of the diluted LUV suspension were added to three separate 7 mL vials. 
Subsequently, the solvent was removed with a stream of N2. To each dried LUV film, including 
a fourth vial containing no lipids that was used as a blank, was added 450 μL of 8.9 M H2SO4. 
The four samples were incubated open to ambient atmosphere in a 225 °C aluminum heating 
block for 25 min and then removed to 23 °C and cooled for 5 minutes. After cooling, 150 μL of 
30% w/v aqueous hydrogen peroxide was added to each sample, and the vials were returned to 
the 225 °C heating block for 30 minutes. The samples were then removed to 23 °C and cooled 
for 5 minutes before the addition of 3.9 mL water. Then 500 μL of 2.5% w/v ammonium 
molybdate was added to each vial and the resulting mixtures were then vortexed briefly and 
vigorously five times. Subsequently, 500 μL of 10% w/v ascorbic acid was added to each vial 
and the resulting mixtures were then vortexed briefly and vigorously five times. The vials were 
enclosed with a PTFE lined cap and then placed in a 100 °C aluminum heating block for 7 
minutes. The samples were removed to 23 °C and cooled for approximately 15 minutes prior to 
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analysis by UV/Vis spectroscopy. Total phosphorus was determined by observing the absorbance 
at 820 nm and comparing this value to a standard curve obtained through this method and a 
standard phosphorus solution of known concentration. 
Efflux from LUVs 
The LUV solutions were adjusted to 1 mM using either 150 mM NaCl, 5 mM HEPES 
buffer pH 7.4 (potassium efflux experiments) or 400 mM Sodium Sulfate pH 7.5 (proton efflux 
experiments). 3 mL of the 1 mM LUV suspension was added to a 7 mL vial, and the solution 
was gently stirred. The appropriate probe was inserted, and data were collected for one minute 
prior to addition of compound. Then 30 µL of a 0.1 mM DMSO solution of the compound was 
added, and data were collected until there was no change in efflux for at least 3 data points. T 
effect complete ion release, 30 µL of a 10% v/v solution of triton X-100 was added, and data 
were collected for an additional five minutes. 
Data Analysis 
The data from each run was normalized to the percent of total ion release from 0 to 
100%. Thus for each experiment a scaling factor S was calculated. For example, the scaling 
factor for potassium efflux was calculated using the following relationship: 
[
[K +]𝑓𝑖𝑛𝑎𝑙
[K +]𝑖𝑛𝑖𝑡𝑖𝑎𝑙
− 1] ∙ 𝑆 = 100 
 
Each concentration data point was then multiplied by S before plotting as a function of time. To 
calculate half-life (time to reach half of the maximum efflux), each efflux experiment was 
plotted in Origin Pro and fitted using an exponential decay function.  
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H-H NOESY NMR Spectra for C3deOAmB 
750 MHz spectra were acquired at room temperature with 2218 points, 512 increments, 
and 64 transients per increment. Spectra were processed using nmrPipe91 as follows: the Sparky 
program92 was used for peak-picking and integration of crosspeaks (see Table S2). The following 
formula was used to convert peak intensity to distance: 
𝑟𝑥 =  (
𝑉𝑥
𝑉𝑠𝑡𝑑
)
−1 6⁄
∗  𝑟𝑠𝑡𝑑 
where rstd and Vstd are based off of the integration values for H31-H33 proton – proton distance.   
Phase-Sensitive COSY (COSYPS) NMR Spectra for C3deOAmB 
750 MHz spectra were acquired at room temperature with 2218 points, 720 increments, 
and 16 transients per increment. Spectra were processed using nmrPipe91 as described by Delagio 
et al.84 All COSYPS spectra were acquired with sufficient interscan delay to allow for full spin-
relaxation (d1 = 10 seconds for AmB and 15 for C3deOAmB, as determined by T1 relaxation 
experiments). 
HSQC for C3deOAmB 
A gradient HSQC spectrum was acquired at room temperature on a 750 MHz 
spectrometer with 2218 points, 512 increments, and 8 transients per increment.  
COSYPS processing and 3J determination for C3deOAmB 
Raw COSYPS data were processed as described by Delagio et al.84 to produce a 
diagonal-suppressed spectrum and a diagonal-only spectrum. Amplitude-constrained multiplet 
evaluation (ACME)84 was used to determine the 3J H-H coupling constants (see Figure 2.24 for 
 
 
78 
 
all coupling constants calculated by ACME). 
 
Figure 2.25: Coupling constants yielded from ACME analysis and the corresponding dihedral values for both 
AmB and C3deOAmB. The dihedral angles of the crystal structure are also listed for comparison. 
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Crosspeak Fitting for C3deOAmB 
The ACME method for determining J values from the COSYPS spectra is described at 
length by Delagio et al.84 The values are determined as described by Palacios et al.26 Dihedral 
angles are calculated from the 3J H-H coupling constants generated by the ACME program using 
the MestReJ software.93 Each 3J H-H constant will yield 4 possible solutions to the Karplus 
equation. The angle chosen was consistent with the angles of the crystal structure. The selected 
dihedral angles (± 30°) were used as restraints in LowModeMD conformational searches. 
Computational Conformational Search with Energy Minimization Calculations 
LowModeMD conformational searches85 were performed using the Molecular Operating 
Environment suite (MOE), Version 2014.09,94 with the empirical MMFF94x force field and a 
distance solvation model. In brief, conformations were perturbed along a molecular dynamics 
trajectory, with kinetic energy variations in the low frequency vibrational modes, followed by 
energy minimization.85 Initial atomic coordinates and structure files for both AmB and 
C3deOAmB were generated from the AmB crystal structure (CCDC 866798)83 using MOE. 
NMR-derived distance and dihedral angle restraints were applied with weight factors of 2 
kcal/mol/Å and 0.02 kcal/mol/deg, respectively. The conformational searches were performed 
with an iteration limit of 10,000 and a rejection limit up to 500. Default values were used for all 
other parameters.   
Each H-C-C-H dihedral angle was restrained to the selected value ± 30° (see Table S1). 
Consistent with the standard convention for dihedral angles, dihedral angle values were defined 
using the following range, -180° < θ ≤ 180°.  The π-bonds in the polyene moiety were 
constrained to 180 ± 10°. 
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Interproton distances were restrained for proton pairs exhibiting NOE correlations, with 
the lower limit set at 1.8 Å and the upper limit set at 2.5 Å, 3.5 Å, or 5.0 Å for strong, medium, 
and weak correlations, respectively. In the case of a proton pairing with a proton from a methyl 
group, that proton-proton distance was defined between the proton and the carbon atom of the 
methyl group with an expanded distance range, and weighted half as much. The top conformers 
for both AmB and C3deOAmB were imported into VMD95 and aligned using the RMSD 
Calculator Tool. Only the heavy atoms pictured below were used for the alignment and RMSD 
calculation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.26: Structure-based alignment of the lowest energy conformation of the AmB skeleton with the 
crystal structure. RMSD of the best conformer is 0.2868 ± 0.0005 Å. 
Figure 2.27: Structure-based alignment of the lowest energy conformation of the C3deOAmB skeleton 
with the crystal structure. RMSD of best conformer is 0.55 ± 0.02 Å. 
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Figure 2.29: Plot of 13C chemical shift values for C3deOAmB versus AmB molecule with the outliers C2, C3 and 
C4 removed. R2 is 0.99998. 
Figure 2.28: Plot of 13C chemical shifts for C3deOAmB versus AmB molecule. The outliers are C2, C4 and C3.   
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Table S1: Coupling constants yielded from ACME analysis and the corresponding dihedral 
values for both AmB and C3deOAmB. The dihedral angles of the crystal structure are also listed 
for comparison. 
Figure 2.31: Plot of 1H chemical shift values for C3deOAmB versus AmB molecule with the outliers H2A – H5 
removed. R2 is 0.99988. 
Figure 2.30: Plot of 1H chemical shifts for C3deOAmB versus AmB molecule. The outliers are H2A, H2B, H3A, 
H3B, H4A, H4B, H5. 
R² = 0.99988 
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Chapter 3 
Amphotericin B Restores Physiology in Protein-Deficient Yeast and Lung Epithelia 
Deficiencies of protein ion channels underlie many currently incurable human diseases. 
Some small molecules can perform ion channel-like functions, suggesting the possibility of 
replacing missing protein ion channels with small molecule mimics. However, closely replicating 
the functions of ion selective and tightly regulated protein channels with small molecules is 
challenging. Robust networks of pumps and channels are usually responsible for the directional 
movement of specific ions in organisms ranging from microbes to humans. We thus questioned 
whether minimally selective small molecule mimics of missing protein channels might be capable 
of collaborating with the corresponding protein ion pumps to restore physiology. We first tested 
whether the natural product Amphotericin B could restore growth in ion transporter-deficient 
yeast. We determined that this natural product could vigorously and sustainably restore yeast cell 
growth. We further provided evidence that this tolerance for imperfect mimicry is attributable to 
collaboration between the channel-forming small molecule and protein ion pumps. Encouraged by 
the results in yeast, my colleague Katrina Diaz and I asked whether the same small molecule could 
restore physiology in human lung epithelia lacking the cystic fibrosis transmembrane conductance 
regulator (CFTR). We observed restoration of physiology in CFTR-deficient human epithelia. 
These results illuminate a mechanistic framework for pursuing small molecule replacements for 
deficient protein ion channels that underlie a range of challenging human diseases. 
Jenn Hou performed cell viability and chemical sensitivity experiments. Katrina Diaz and 
I performed ASL height experiments. Tony Grillo synthesized compounds 2-4, and Katrina Diaz 
performed Ussing Chamber experiments. Portions of this chapter were adapted from Cioffi, et al., 
Journal of the American Chemical Society, 2015 and Diaz, et al., manuscript in preparation. 
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3-1 THE PROSPECT OF MOLECULAR PROSTHETICS IN YEAST 
There are many currently incurable human diseases that are caused by missing protein 
ion channels, including cystic fibrosis, Bartter syndrome, Dravet syndrome, and Dent’s 
disease.1,2  Like many other human diseases caused by missing proteins, these diseases are 
difficult to treat, and new approaches are needed. Some small molecules can perform ion 
channel-like functions,3-11 suggesting the possibility of replacing missing protein ion channels 
with small molecule mimics. Closely replicating the functions of ion selective and tightly 
regulated protein channels with small molecules is challenging. However, robust protein 
networks comprised of pumps and channels drive targeted ions in targeted directions throughout 
the spectrum of living systems.12 We thus questioned whether relatively unselective and 
unregulated small molecule mimics of missing protein channels might be capable of 
collaborating with the corresponding protein ion pumps to restore physiology.  
Yeast represent an excellent model system for studying eukaryotic physiology.13,14 
Moreover, deficiencies of specific protein ion transporters in yeast are known to lead to dramatic 
no growth phenotypes, thus providing a unique opportunity for using cell growth as a readout for 
physiology restoration. In yeast, ATP-driven V-ATPase and Pma1 proton pumps in the vacuolar 
and plasma membranes, respectively, collaborate with passive Trk potassium transporters in the 
plasma membrane to achieve intracellular movement of potassium required for cell growth 
(Figure 3.1A, left).15 Loss of Trk transporters impairs this uptake of environmental potassium 
and results in a no growth phenotype (Figure 3.1A, middle).16-18 Because the primary drivers of 
ion movement, the corresponding ATP-driven pumps, are still active in such yeast, we 
hypothesized that a small molecule ion channel permeable to potassium could collaborate with 
V-ATPase and Pma1 to restore cell growth (Figure 3.1A, right). 
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 The ion channel-forming natural product amphotericin B (Figure 3.1B, AmB) was 
identified as a small molecule that could enable testing of this hypothesis.3 AmB can 
permeabilize yeast cells to potassium and other ions.19,20 AmB is also highly toxic to yeast, and 
this toxicity was thought to be inextricably linked to its membrane permeabilization. However, 
we found a synthesized derivative of AmB lacking a single oxygen atom at C35 (C35deOAmB) 
(Figure 3.1B) does not form ion channels and yet still maintains potent fungicidal activity.21 
Further studies revealed that AmB primarily kills yeast by binding and extracting sterols from 
membranes and is only cytotoxic when the amount of AmB exceeds that of ergosterol.22,23 This 
all suggested the channel activity of AmB might be separated from its cytocidal activity by 
simply adding this compound at low concentrations. Moreover, AmB and C35deOAmB, which 
differ via a single atom, represent a unique pair of probes for determining the impact of small 
molecule-mediated ion channel activity on organismal physiology. 
 
 
 
Figure 3.1: A.) Prospect of replacing missing protein ion transporters with small molecule mimics. B.) 
Chemical structures of the archetypical ion channel-forming small molecule amphotericin B and its single atom-
deficient and channel-inactivated derivative C35-deoxy amphotericin B (C35deOAmB). 
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3-2 AMB RESTORES PHYSIOLOGY IN PROTEIN-DEFICIENT YEAST 
 We thus tested the hypothesis that AmB could restore cell growth in potassium 
transporter-deficient yeast with a modified functional complementation experiment.24 Consistent 
with prior reports,16,17 growth was observed when wild type Saccharomyces cerevisiae were 
streaked onto agar plates containing normal concentrations of potassium (10 mM) (Figure 3.2A, 
left), and no growth was observed for the potassium transporter-deficient strain (trk1Δtrk2Δ) 
under the same conditions (Figure 3.2A, middle). Strikingly, the addition of a low concentration 
of AmB (125 nM) to an otherwise identical agar plate vigorously restored growth of the 
trk1Δtrk2Δ mutant (Figure 3.2A, right).  
A series of additional experiments confirmed the observed resto-ration of cell growth is 
caused by the small molecule-based ion channel activity. A disc diffusion assay visually revealed 
the predicted dependence of this growth rescue on the concentration of AmB (Figure 3.2B). To 
quantify this concentration dependence and eliminate the potentially complicating issue of 
plating efficiency,25 we also measured trk1Δtrk2Δ yeast cell growth in a broth dilution assay 
using media containing a normal concentration of potassium (10 mM) (Figure 3.2C). Consistent 
with the disc diffusion results, no cell growth was observed in the absence of AmB, a dose-
dependent increase of growth was observed at intermediate concentrations, and no growth was 
observed at or above the minimum inhibitory concentration of this antifungal agent. Further 
ruling out any type of generic hormetic effects,26 no growth stimulatory effects were observed 
when wild type cells or trk1Δtrk2Δ cells grown under per-missive conditions were treated with 
AmB (Figure 3.3). AmB at 125 nM also did not cause any toxicity in these experiments.  
To directly probe the importance of the ion channel activity of AmB, we also tested the 
single atom-deficient variant C35deOAmB, which does not form ion channels (Figure 3.1B).21  
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Figure 3.2: A.) Restoration of yeast cell growth under normal potassium conditions (10 mM) with a small 
molecule mimic of missing protein potassium transporters. B.) Disc diffusion with AmB on a plate of 
trk1Δtrk2Δ cells. C.) AmB restores cell growth at concentrations below its minimum inhibitory concentration, 
while C35deOAmB does not restore growth. D.) Tetraethylammonium diminishes AmBmediated growth 
restoration in trk1Δtrk2Δ cells but has no effect on trk1Δtrk2Δ cells grown under permissive conditions (100 
mM KCl). E.) AmB restores uptake of extracellular 86Rb+ in trk1Δtrk2Δ cells, but C35deOAmB does not. F.) 
Vigorous restoration of cell growth is observed upon treating trk1Δtrk2Δ cells with AmB. G.) Similar to wild 
type cells, AmB-rescued trk1Δtrk2Δ cells show sustained growth over a period of >40 days. H.) A preformed 
AmB-ergosterol complex dramatically increases the range of concentrations over which physiology is restored. 
NS, not significant. ***P ≤ 0.0001. Graphs depict means ± SEM. 
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This derivative failed to restore growth in trk1Δtrk2Δ cells at any tested concentration (Figure 
3.2C). In a complementary experiment, we utilized the sterically bulky tetraethylammonium 
cation to block the AmB-based ion channel.27 This cation inhibited the functional 
complementation observed with AmB in a dose-dependent manner without causing general 
toxicity (Figure 3.2D). We also monitored uptake of radioactive 86Rb+ as a reporter of 
transmembrane potassium movement (Figure 3.2E).28 86Rb+ uptake was observed in wild type 
yeast but not in the trk1Δtrk2Δ mutant, and no uptake was observed when the trk1Δtrk2Δ mutant 
was treated with the channel-inactivated derivative C35deOAmB. In contrast, 86Rb+ uptake was 
restored when trk1Δtrk2Δ cells were treated with AmB. 
 
Figure 3.3: A.) AmB does not cause growth stimulatory effects in wild type cells grown in the presence of 100 
mM KCl. Curves represent AmB concentrations of 0 nM, 62.5 nM, and 125 nM. No growth is observed at or 
above the minimum inhibitory concentration of 500 nM AmB. B.) AmB does not cause growth stimulatory 
effects on trk1Δtrk2Δ cells grown under permissive conditions (100 mM KCl). Curves represent AmB 
concentrations of 0 nM, 62.5 nM, and 125 nM. No growth is observed at or above the minimum inhibitory 
concentration of 500 nM AmB. C.) Wild type and AmB-rescued (125 nM) trk1Δtrk2Δ yeast growth curve for 24 
hours. The same potassium concentration (10 mM) was used in both experiments. The doubling time for wild 
type and AmB-rescued trk1Δtrk2Δ yeast was 86 ± 2.4 minutes and 144 ± 2.8 minutes, respectively. D.) AmB-
treated wild type and AmB-rescued trk1Δtrk2Δ cells show no decrease in cell viability compared to wild type as 
judged by propidium iodide staining. NS, not significant. Graph depicts means ± SEM.  
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We further quantified the vigor and sustainability of this AmB ion channel-mediated 
restoration of yeast cell growth. AmB-treated trk1Δtrk2Δ cells reached a maximum cell density 
that matched that of the wild type (Figure 3.2F), and the doubling time for AmB-rescued 
trk1Δtrk2Δ cells was only 1.7 times longer (Figure 3.3C). We also observed equivalent levels of 
cell viability in wild type yeast, wild type yeast treated with 125 nM AmB, and trk1Δtrk2Δ cells 
rescued with 125 nM AmB (Figure 3.3D). To probe the sustain-ability of this rescue effect, we 
reiterated the max cell density and doubling time experiments for over a month. Like wild type 
cells, the AmB-rescued trk1Δtrk2Δ cells showed sustained vigorous cell growth throughout this 
entire period of time (Figure 3.2G). Removing AmB from the media at any point resulted in 
rapid loss of growth for the trk1Δtrk2Δ cells. We further confirmed the mechanism-based 
hypothesis that a pre-formed AmB-ergosterol complex should retain the capacity to permeabilize 
yeast cells (Figure 3.4) but show substantially decreased cell killing.22 This pre-formed complex 
dramatically extended the range of concentrations over which rescue was observed (Figure 
3.2H). 
 
Figure 3.4: Potassium efflux in wild type S. cerevisiae. AmB readily permeabilizes wild type S. cerevisiae 
compared to DMSO vehicle. A pre-formed AmB-ergosterol complex still permeabilizes yeast cells. Experiment 
was performed in triplicate. Plot is representative of each replicate. 
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To probe the scope and limitations of this tolerance for imperfect mimicry of missing proteins 
with small molecules, a series of additional ion transporting natural products were evaluated. 
Vigorous restoration of trk1Δtrk2Δ cell growth was observed with other small molecules that 
form potassium ion channels, including nystatin, candicidin, and mepartricin, but not with those 
that selectively transport NH4
+ (nonactin), Cl- (prodigiosin), and Ca2+ (calcimycin) (Figure 3.5). 
Interestingly, the potassium ion carrier valinomycin29 is unable to restore cell growth (Figure 
3.6A). As a further control, the polyene macrolide natural product natamycin, which binds 
ergosterol but does not form channels,21 is also unable to restore cell growth (Figure 3.6B). 
 
Figure 3.5: A.) Series of potassium-transporting polyene macrolide natural products restore vigorous cell 
growth in trk1Δtrk2Δ yeast, whereas no growth is observed upon treating with other small molecules that 
selectively transport other ions. B.-D.) Nystatin, candicidin, and mepartricin were similarly able to restore 
physiology in a liquid broth dilution assay over a variety of concentrations. Graphs depict means ± SEM. 
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 Finally, we tested the mechanistic hypothesis that these potassium channel-forming 
small molecules restore physiology by collaborating with the V-ATPase and Pma1 proton 
pumps. Such a model predicts selective sensitivity of the small molecule-rescued mutants to 
chemical inhibition of these pumps. As a negative control, AmB-treated wild type and AmB-
rescued trk1Δtrk2Δ cells were equally sensitive to nocodazole, an off-pathway inhibitor of 
microtubule dynamics (Figure 3.7A). In contrast, AmB-rescued trk1Δtrk2Δ cells were 
exceptionally sensitive to inhibition of V-ATPase with bafilomycin (Figure 3.7B) and Pma1 with 
ebselen (Figure 3.7C). Similar results were observed with nystatin-, candicidin-, and mepartricin-
rescued trk1Δtrk2Δ cells (Figure 3.7D-F). 
 
 
 
 
Figure 3.6: A.) Disc diffusion assay with valinomycin (4 mg/mL) on an agar plate containing 10 mM potassium 
and streaked with trk1Δtrk2Δ cells. B.) Broth microdilution assay with valinomycin. C.) Disc diffusion assay 
with natamycin (4 mg/mL) on an agar plate containing 10 mM potassium and streaked with trk1Δtrk2Δ cells. 
D.) Broth microdilution assay with natamycin.Graphs depict means ± SEM. 
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3-3 THE PROSPECT OF MOLECULAR PROSTHETICS IN HUMAN LUNG EPITHELIA 
 With the confirmation of AmB efficacy in yeast cells, we hypothesized that this approach 
could restore physiology in a human disease-relevant system. Most of the morbidity/mortality in 
cystic fibrosis is caused by deficiencies of CFTR in lung epithelia (Figure 3.8).In a leading 
model, CFTR functions primarily as an apical channel for chloride and other anions, thereby 
maintaining proper airway surface liquid (ASL) that protects against lung infections.30,31 
Chloride ions are driven into lung epithelia by the basolateral Na+/K+-ATPase and sodium 
potassium chloride cotransporter (NKCC). We thus hypothesized that anion-permeable channels 
formed in the apical membrane by AmB could work in concert with these basolateral pumps and 
channels to achieve restored physiology in CFTR-deficient human lung epithelia.  
Figure 3.7: A.) AmB-treated wild type S. cerevisiae and trk1Δtrk2Δ cells are equally sensitive to the off-
pathway microtubule inhibitor nocodazole. B.) AmB-rescued trk1Δtrk2Δ cells are substantially more sensitive to 
the V-ATPase inhibitor bafilomycin compared to wild type cells. C.) AmB-rescued trk1Δtrk2Δ cells are 
substantially more sensitive to the Pma1 inhibitor ebselen than wild type cells. D.-F.) EC50 values for various 
inhibitors of cell growth against wild type (black bars) and trk1Δtrk2Δ cells (white bars) treated with optimum 
rescue concentrations of potassium-transporting polyene macrolide natural products AmB, nystatin, candicidin, 
and mepartricin. NS, not significant. *P ≤ 0.05. **P ≤ 0.001. ***P ≤ 0.0001. Graphs depict means ± SEM. 
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Similar to trk1Δtrk2Δ cells, in human lung epithelia the Na+/K+-ATPase pump12 in the 
basolateral membrane generates the driving force for moving chloride ions into epithelial cells, 
and CFTR in the apical membrane mediates the passive release of these ions to the airway 
surface.32 This, in turn, maintains airway surface hydration and thus mucociliary motion that 
protects against lung infections33 (Figure 3.8A). Deficiencies of these protein ion channels can 
cause dramatic phenotypes. Loss of CFTR in humans causes the common and fatal genetic 
disease cystic fibrosis. The leading model invokes that the apical release of intracellular chloride 
is compromised leading to airway surface dehydration, loss of mucociliary motion, and chronic 
infections33 (Figure 3.8B). Importantly, in both of these cases the primary drivers of ion 
movement, the corresponding ATP-driven pumps, are still active. We thus hypothesized that a 
small molecule ion channel permeable to both potassium and chloride could collaborate with the 
respective protein ion pumps in each system to restore physiology (Figure 3.8C). 
 
 
 
Figure 3.8: A.) Monolayers of normal human lung epithelia (NuLi).26 In one of the leading models, the 
basolateral Na+/K+ ATPase pumps create an electrochemical driving force for chloride movement into the cells, 
and CFTR promotes the passive release of chloride to the apical surface. This, in turn, hydrates the surface 
leading to normal mucociliary motion. B.) CFTR (ΔF508/ΔF508) human lung epithelia (CuFi). Lack of CFTR 
prevents chloride efflux leading to dehydration, lack of mucociliary motion, and chronic infections. C.) AmB is 
hypothesized to collaborate with Na+/K+ ATPase pumps to restore transepithelial transport of chloride, apical 
surface hydration, and mucociliary motion. 
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3-4 AMB RESTORES PHYSIOLOGY IN CFTR-DEFICIENT HUMAN LUNG EPITHELIA 
 We first determined via Ussing chamber experiments that AmB (0.5 µM) can 
permeabilize fully differentiated human lung epithelia derived from a cystic fibrosis patient with 
the most common F508del/F508del mutation (CuFi) (Figure 3.9B, Figure 3.9C). This result is 
especially remarkable because differentiated lung epithelia have barriers to small molecule-
mediated permeabilization.32 We also tested a range of synthetic small molecules previously 
reported to permeabilize model membranes and/or cells4,6-8 and observed little or no 
permeabilization of these same epithelia even at high micromolar concentrations (Figure 3.9A, 
Figure 3.9C). Importantly, C35deOAmB causes no such permeabilization, making this single 
atom-modifed variant of AmB a unique and critical probe for determining whether any observed 
impacts of the natural product are specifically mediated by its ion channel activity (Figure 3.9C). 
Having observed AmB-mediated restoration of cell growth in potassium channel-
deficient yeast, we next tested whether the same small molecule could restore ASL height, an 
important marker for physiology in cystic fibrosis cell line epithelial monolayers, via confocal 
fluorescence microscopy.34,35 NuLi epithelial monolayers (cell line derived from normal human 
lung epithelia) were treated with vehicle, and CuFi-1 epithelial monolayers (cell line derived 
from a patient with the most common ΔF508/ΔF508 mutation) were treated with vehicle or 
AmB.36 CuFi-1 epithelia were markedly dehydrated relative to NuLi epithelia, consistent with 
prior reports for ASL height for these cell lines (Figure 3.10A). Upon treatment of CuFi-1 
epithelia with AmB (500 nM), normal ASL volume was restored (Figure 3.10A). 
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Demonstrating that this restoration is specifically caused by AmB permeabilizing the apical 
membrane, no increase in ASL height was observed upon treatment with the channel-inactivated 
derivative C35deOAmB, nor by adding AmB to the basolateral surface. These results were 
quantitatively confirmed using automated ImageJ analysis (Figure 3.10B).39 Finally, to test the 
hypothesis that AmB-mediated restoration of ASL taps into the endogenous network of 
collaborating proteins, basolateral bumetanide was administered to inhibit NKCC. This 
Figure 3.9: A.) AmB and its channel-inactivated derivative C35deOAmB along with small molecules 1-4 
previously reported to permeabilize planar lipid bilayers, liposomes and/or cells to chloride. B.) AmB (solid line) 
permeabilizes fully differentiated lung epithelia at 500 nM while the channel-inactivated derivative 
C35deOAmB (dashed line) does not. Black arrow indicates time of compound addition. C.) Short circuit current 
across human CF lung epithelia via Ussing chamber experiments. Values represent mean area under the curve 
over 15 minutes following compound addition. DMSO vehicle alone does not permeabilize. 1 does not 
permeabilize at 35 µM or 350 µM. 2 does not permeabilize at 1 µM or 10 µM. 3 does not permeabilize at 80 µM 
or 800 µM. 4 causes little or no permeabilization at 50 µM or 500 µM. Experiments were run in triplicate.  
NS, not significant. ** P ≤ 0.01. 
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restoration of ASL can be blocked with the basolateral addition of bumetanide to inhibit NKCC, 
which has also been shown previously to reduce ASL in normal lung epithelia (Figure 3.10C).40 
ASL restoration by AmB is observed in a dose-dependent fashion, with the optimal dose at 
0.5µM AmB (Figure 3.11). 
 
 The discovery that a less ion-selective small molecule surrogate restores physiology can 
in part be attributable to the complexity of living systems. Both yeast and human lung epithelia 
have evolved protein ion pumps and channels to drive targeted ions in targeted directions, and 
feedback regulation and functional redundancy allows for these proteins to collaborate with each 
other to achieve physiology even in the case of imperfect selectivity. For example, the selectivity 
of CFTR for chloride over potassium is only 10:1,41 suggesting that a small molecule that is 
minimally selective might be able to collaborate with endogenous pumps and channels to 
achieve physiology. Furthermore, AmB is not completely unselective, as its channel cannot 
transport divalent cations and has a chloride to potassium selectivity of 1:7.42 We have provided 
Figure 3.10: AmB restores ASL height in human CF lung epithelia. A.) Confocal microscope images showing 
normal lung epithelia (NuLi) exhibiting normal ASL volume while CF lung epithelia (CuFi) exhibit a relatively 
low ASL. The addition of 500 nM AmB restores hydration to CF human lung epithelia. Scale bar = 10 µm. B.) 
Quantification of ASL height using ImageJ analysis. Apical addition of AmB restores ASL height, but the 
channel-inactivated derivative C35deOAmB and basolateral addition of AmB do not. C.) AmB-mediated 
restoration of hydration can be blocked by inhibiting basolateral NKCC with bumetanide. (C) AmB is able to 
promote ASL height in a dose-dependent manner. NS, not significant. **** P ≤ 0.0001. Graphs depict means ± 
SEM.  
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evidence that these endogenous pumps can collaborate with a less selective mimic of a protein 
ion channel to restore physiology. We intend to now further explore in the human lung epithelia 
system the interface of our small molecule and these protein networks, invoking the concept of a 
bionic cell equipped with small molecule prosthetics to facilitate normal function. 
 
 
Small molecule potentiators and correctors such as Ivacaftor have dramatically increased 
patient quality of life through improving lung function.43,44 These recent advances provide 
compelling evidence that small molecules hold substantial potential for the treatment of diseases 
caused by missing proteins. However, Ivacaftor and other CFTR corrector/potentiators are 
inherently mutation specific, targeting only certain genotypes. In contrast, the approach 
described herein, in which a small molecule autonomously replicates the function of a missing 
protein, is mutation independent. With the ΔF508/ΔF508 mutation affecting more than 70% of 
CF patients, this strategy potentially holds substantial benefit to patients suffering from any 
CFTR mutation. Furthermore, aerosolized AmB is an FDA-approved treatment for lung fungal 
infections, and this local delivery has been shown to be minimally toxic.  
Figure 3.11: AmB is able to promote ASL height in a dose-dependent manner. Graph depicts means ± SEM.  
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 It is also interesting to remark on the differences in timespan for observing restoration of 
physiology in human lung epithelia. For example, Ussing chamber data was typically collected 
over 15 minutes while ASL height data was collected after 48-72 hours. We hypothesize that the 
AmB-mediated restoration of physiology is a slow process, taking at least 48 hours before 
markers of restored physiology are observed. We think this effect is due to the time required for 
AmB to effectively collaborate with the endogenous pumps to achieve physiology. It is 
encouraging to note that in their preclinical trials, Vertex also observed relatively long necessary 
incubation times with Ivacaftor before moving into clinical trials.45  
In addition to its potential clinical impact, AmB represents a possible probe for better 
understanding the pathophysiology of CF. While AmB can imperfectly replicate the channel 
activity of CFTR, it is highly unlikely that it can replicate CFTR’s proposed roles in signaling 
and regulation of other protein ion channels. Additionally, CFTR maintains other aspects of lung 
physiology such as ASL pH and antimicrobial activity, and mucociliary transport (MCT).46,47 
Future studies will focus on determining if AmB can restore ASL composition and MCT in CF 
lung tissues. It has also been shown that stressful cellular environments may contribute to CFTR 
misfolding.48,49 We will determine if, alternatively, AmB restores physiology by ameliorating the 
stress caused by the loss of ion transport and dehydration of the apical surface, and therefore 
allows for more correctly folded ∆F508 CFTR to reach the cell surface, leading to normal 
function. 
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3-5 SUMMARY 
Thus, imperfect small molecule mimics of missing protein ion transporters can restore 
physiology in yeast, and evidence supports that this phenomenon is attributable to functional 
collaboration between small molecule channels and protein ion pumps. A common channels and 
pumps architecture is responsible for directional ion movement in organisms from yeast to 
humans,12 suggesting that the same type of functional collaboration observed herein might 
enable small molecule surrogates for missing protein ion channels to impact on human disease. 
Thus, the same unselective channel-forming small molecule can replace different protein 
channels and thereby restore physiology in growth-deficient yeast and human CF lung epithelia. 
These findings brighten the prospect of developing small molecule-based ion channels to address 
cystic fibrosis and other challenging diseases caused by missing proteins.  
While these studies have focused on the restoration of ion channel function, the inherent 
robustness of human physiology suggests a similar approach may be impactful for other 
functional deficiencies as well. Recent studies have revealed that most humans have lost the 
function of ~20 proteins yet have no disease phenotype.50 Even some people with mutations that 
typically cause catastrophic genetic diseases live symptom-free,51 demonstrating an inherent 
robustness of living systems that could be leveraged with small molecules with protein-like 
functions. Our findings brighten the prospect of discovering and using functional small 
molecules as replacements for missing proteins that underlie currently incurable human diseases. 
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3-6 METHODS 
Yeast Culture Conditions 
Wild-type S. cerevisiae (ATCC 9763) were maintained with yeast peptone adenine 
dextrose (YPAD) growth media consisting of 10 g/L yeast extract, 20 g/L peptone, 20 g/L 
dextrose, 0.015 g/L adenine hemisulfate salt (final potassium concentration = 10 mM) and the 
media was adjusted to pH 5.0 using citric acid. As described below, all growth restoration 
experiments, including the disc diffusion and broth microdilution assays, were performed using 
the same normal concentration of potassium (10 mM) for both wild type and trk1∆trk2∆ S. 
cerevisiae (SGY 1528). However, as previously described,52 to culture trk1∆trk2∆ prior to 
performing these experiments, additional potassium was added in the form of potassium chloride 
(100 mM KCl) to the same (YPAD) growth media. For culturing on solid media, 20 g/L agar 
was added to these same mixtures. After autoclave sterilization, dextrose was subsequently 
added as a sterile 40% w/v solution in water (dextrose solutions were filter-sterilized using a 0.22 
µm filter). Liquid cultures were incubated at 30 °C on a rotary shaker (200 rpm). Solid cultures 
were maintained at 30 °C in an incubator.  
Growth Rescue Assay on Solid Media 
These growth rescue experiments were performed using solid media prepared as 
described above containing normal concentrations of potassium (10 mM). For solid media 
containing AmB (AK Scientific), the same media was allowed to cool for 15 minutes before 
addition of AmB as a solution in DMSO to provide a final concentration of 125 nM AmB. 
Cultured yeast diluted to an OD600
 of 0.1 were streaked onto these plates, and plates were 
examined for growth after 24-48 hours of incubation.  
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Disc Diffusion Assay 
The assay was performed using a previously described protocol.53 Discs containing either 
DMSO vehicle or the indicated small molecule (4 mg/mL) were added. A normal media 
concentration of potassium (10 mM) was used for all experiments. 
Broth Microdilution Assay 
The protocol was adapted from the minimum inhibitory concentration assay described in 
the Clinical and Laboratory Standards Institute document M27-A254,55 with the following 
modifications: After culturing as described above, wild type or trk1∆trk2∆ yeast were transferred 
to normal potassium (10 mM) YPAD liquid media adjusted to pH 5.0 using citric acid containing 
DMSO vehicle or the indicated concentration of the indicated small molecule and growth was 
monitored at 24 h via UV/Vis spectroscopy (OD600). The experiments in Figure 3.3A and Figure 
3.3B were performed the same way but using media to which was added 100mM KCl. 
Tetraethylammonium Block Assay 
The broth microdilution assay described above was performed with the addition of the 
indicated concentration of tetraethylammonium to trk1∆trk2∆ yeast in YPAD media containing 
the normal concentration of potassium (10 mM) and 125 nM AmB. The control experiment was 
performed by adding the indicated concentration of tetraethylammonium to trk1∆trk2∆ yeast in 
YPAD media to which was added KCl (100 mM). 
86Rb+ Uptake Assay 
The procedure for 86Rb+ uptake was adapted from Mulet and coworkers.56 Yeast were 
cultured overnight as described above. After centrifugation, the supernatant was poured off, and 
the cells were resuspended in sterile water. This wash was repeated two more times. The cells 
were then resuspended in 40 mL of the potassium starvation/uptake buffer (50 mM succinic acid, 
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2% glucose, adjusted to pH 5.5 with Tris). The same buffer was used for all experiments for both 
trk1∆trk2∆ and wild type yeast. After 3 hour incubation in the potassium starvation buffer, cells 
were centrifuged and washed twice with sterile water. Cells were resuspended in 1 mL of the 
potassium starvation/uptake buffer. Cell concentration was determined using an INCYTO 
Neubauer disposable hemocytometer, and wild type S. cerevisiae and trk1Δtrk2Δ cells were 
diluted to the same cell density (3x107 cells/mL). 700 µL of the yeast suspension was added to a 
1.5 mL Eppendorf tube. After a 5 minute pre-incubation in the potassium starvation/uptake 
medium, trk1∆trk2∆ yeast were then treated with DMSO solutions of AmB or C35deOAmB 
(final concentration 3 µM). 86RbCl (1.1 µCi) was then added to the reaction mixtures. Reaction 
mixtures were vortexed to ensure a homogeneous solution. At the indicated times, the uptake 
reaction was stopped by taking a 100 µL aliquot from the reaction mixture and diluting with 10 
mL of ice-cold 20 mM MgCl2. Cells were then collected via vacuum filtration through a 0.45-
µm-pore-size nitrocellulose filter (Millipore HAWP). Cells were washed with two 15 mL 
aliquots of 20 mM ice-cold MgCl2. Moist filters were transferred to plastic vials for measuring 
radioactivity. Radioactivity was monitored using a Perkin Elmer Wizard2 automatic gamma 
counter. Results are reported in counts per minute as an average of three biological replicates.  
Cell Viability Assay 
Assay was adapted from Corliss and coworkers.57 Wild type and trk1Δtrk2Δ cells were 
inoculated in high potassium (100 mM KCl) YPAD media. Starter cultures were grown at 30 °C 
for 14-15 hours. Cells were then cultured in high potassium YPAD at 30 °C for 2-2.5 hours. 100 
µL of a 0.25 mg/mL propidium iodide (PI, Sigma-Aldrich P4864) solution was prepared. After 
2-2.5 hours, cells were centrifuged at 23 °C at 800g for 5 minutes. The supernatant was decanted, 
cells were resuspended in 40 mL of high potassium YPAD, vortexed, and centrifuged. The wash 
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step was repeated. After pouring off the supernatant, cells were resuspended in 15 mL of high 
potassium YPAD, vortexed, and diluted to an OD600 of 0.5. To set one (WT, WT + PI, 
trk1Δtrk2Δ, and trk1Δtrk2Δ + PI) and set two (WT + PI + AmB, trk1Δtrk2Δ + PI + AmB), 26.4 
µL of DMSO were added to 1 mL aliquots of WT and trk1Δtrk2Δ, and incubated at 30 °C for 30 
minutes. A 1% w/v low gelling temperature agarose (Sigma-Aldrich A9414) was prepared in 
normal potassium (10 mM) YPAD. When set one incubation completed, cells were pulse 
centrifuged, supernatant was removed, and cells were resuspended in normal potassium YPAD 
to wash. Cells were centrifuged and resuspended in 250 µL of normal potassium YPAD. 
Afterwards, 1 µL of 0.25 mg/mL PI dye was added to appropriate samples and 250 µL of 1% 
agarose was added. Samples were plated onto microscope slides with cover slips and were 
incubated in humidity chambers for 24 hours at 30°C. For set two, cells were resuspended in 
normal potassium YPAD containing 125 nM AmB. Cells were resuspended in 250 µL of normal 
potassium YPAD containing 250 nM AmB before adding to 1% agarose (to obtain 125 nM AmB 
final). Confocal microscope (Zeiss LSM700) images were taken at 40x where ~15 random 
images were taken per slide, per treatment group, per experiment. The total number of PI stained 
cells was subtracted from the total cells recorded, and divided by total cells to give % viability. 
At least 200 cells were recorded per treatment group and 4 independent sets of data were 
obtained. 
Doubling Time and Sustainable Restoration of Cell Growth Assay 
Wild type and trk1∆trk2∆ yeast were treated as described in the broth microdilution assay 
described above, with the trk1∆trk2∆ yeast treated with 125 nM AmB. The OD600 was measured 
at time zero and then every hour for 24 hours. Wild type yeast were then streaked onto normal 
potassium (10 mM) YPAD agar plates and AmB-rescued trk1∆trk2∆ yeast were streaked onto 
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AmB-containing (125 nM) normal potassium (10 mM) YPAD agar plates. These agar plates 
were then incubated at 30 °C for about 48 hours. The same procedure was then repeated for over 
42 days, measuring the max OD600 and doubling time every three days. Doubling time was 
determined using the following equation: Td = (t2-t1) x [log(2)/log (q2/q1)], where t2 and t1 
represent the time at the two points and q2 and q1 represent the OD600 values in the exponential 
phase of growth (OD600 from 0.2 to 0.6).  
Preparation of Amphotericin-Ergosterol Complex 
This complex was prepared and characterized as previously described.22 Broth 
microdilution experiments were performed as described above.  
Potassium Efflux Assay 
Performed as previously described.21 
Sensitivities to Chemical Inhibitors Assay 
Broth microdilution assays were performed as described above with the following 
changes: prior to harvesting cells, small molecules AmB, nystatin A1 (Riedel-de-Haen), 
candicidin (TOKU-E), or mepartricin B (Santa Cruz Biotechnology) and chemical inhibitors 
nocodazole (Sigma-Aldrich), ebselen (Cayman Chemical), or bafilomycin B1 (Santa Cruz 
Biotechnology)  were prepared as stock solutions in DMSO. Saturated cell cultures were 
centrifuged for 5 minutes at 1000g. The supernatant was poured off, and cells were resuspended 
in sterile MilliQ water. Cells were centrifuged again, and supernatant was poured off. The wash 
step was repeated. The supernatant was poured off, and cells were resuspended in normal 
potassium (10 mM) YPAD. Cells were diluted with normal potassium (10 mM) YPAD to an 
OD600 of 0.01. Next, an appropriate volume of AmB, nystatin A1, candicidin, or mepartricin B 
solution was added to give a final rescuing concentration of 125 nM, 1000 nM, 8 nM, and 8 nM, 
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respectively. A control was prepared by adding the corresponding volume of DMSO to 
trk1∆trk2∆ cells. 195 uL of WT + small molecule, 195 uL of trk1∆trk2∆ + small molecule, and 
195 uL of trk1∆trk2∆ + DMSO were added to a 96 well plate. Next, 5 µL of DMSO or chemical 
inhibitor was added to each well, with each concentration tested in triplicate for both WT and 
trk1∆trk2∆. The plate was covered and incubated at 30 °C for 24 hours. A BioTek Synergy H1 
Hybrid Reader was used to measure the OD600. Utilizing GraphPad PRISM, data were fitted by 
nonlinear regression, inhibition dose response, variable slope (four parameters) to yield EC50 
values with SEM. For statistical analysis, EC50 values from the two treatment groups were 
compared by unpaired t-test. 
Airway Surface Liquid (ASL) Height Studies 
ASL height was studied using an established fluorescent dye assay.34 Mature, 
differentiated membranes were grown on Millicell 0.1 µm polyethylene terephthalate hanging 
cell culture inserts. Wild type (NuLi) lung epithelia were treated with perfluorocarbon (FC-72) 
vehicle (Acros Organics), and CuFi epithelia were treated with vehicle or 500 nM AmB and 
incubated for 24 hours at 37oC. On the day of imaging, 2.5 µL of a 70kDa Texas Red-dextran 
conjugate (Molecular Probes) solution in PBS was added to the apical side of the membranes, 
followed by 100 µL of FC-770 (Sigma-Aldrich) to prevent evaporation. These were placed on 
100 µL of PBS on a 10mm glass bottom Fluorodish for imaging (World Precision Instruments). 
Membranes were imaged immediately after dye addition and again at 24 hours to examine dye 
absorption. Three Z-stack images per membrane in biological n = 6 were taken on a Zeiss 
LSM700 confocal microscope at 40x oil immersion. These images were analyzed using ImageJ39 
to determine the area of fluorescence in the left hand 200-micron width of each image to ensure 
equal size analysis. Images were converted to 8-bit, Gaussian Blur was applied, and made binary. 
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The parameters for Analyze Particles were particles from 1-Infinity µm2 in size and from 0%-
100% circularity. This was done for all images, and areas were averaged and plotted. 
Synthesis General Information 
 Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, or 
Steraloids, and were used without further purification unless otherwise noted. Solvents were 
purified via passage through packed columns as described by Pangborn and coworkers (THF, 
MeOH, CH2Cl2: dry neutral alumina; DMF: activated molecular sieves).
58 All water was 
deionized prior to use. Triethylamine was freshly distilled under an atmosphere of nitrogen from 
CaH2 before use. 1 was commercially available through Sigma-Aldrich. The following 
compounds were prepared according to known literature procedures: 2,6,59,60 3,61-63 and 4.8,64 
Their full spectroscopic analysis can be found below.  
Reactions were monitored by analytical thin layer chromatography (TLC) performed 
using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25 mm). Compounds were 
visualized by exposure to a UV lamp (λ = 254 nm or 366 nm), and/or a solution of KMnO4 stain, 
followed by heating using a Varitemp heat gun. Flash column chromatography was performed 
using Merck silica gel grade 9385 60Å (230-240 mesh). 
1HNMR and 13CNMR were recorded at 20°C on Varian Unity 400, Unity Inova 400, Unity 
Inova 500NB, Varian XR500, or Unity 500 instruments. Chemical shifts (δ) are reported in parts 
per million (ppm) downfield from tetramethylsilane and referenced to residual protium in the 
NMR solvent (CHCl3, δ=7.26; MeOH, δ=3.31, center line; acetone, δ=2.05, center line) or to 
added tetramethylsilane (δ=0.00). Data are reported as follows: chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad, app=apparent), coupling 
constant (J) in Hertz (Hz), and integration. 13CNMR are referenced to carbon resonances in the 
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NMR solvent (CDCl3, δ=77.16, center line; MeOH, δ=49.00, center line; acetone, δ=29.84, 
center line). High resolution mass spectra (HRMS) were performed at the University of Illinois, 
School of Chemical Sciences Mass Spectrometry Laboratory. HPLC characterization were 
performed using an Agilent 1260 Infinity series analytical HPLC with a 3.5 µm C18 column 
(Agilent Technologies).  
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Synthesis of Hydroxybisnorcholenic-spermine-sulfonate, (2)  
 
 
2 was prepared according to literature precedent in 19.6% overall yield starting from 
Fernholtz Acid.6,59,60 Characterization of this compound was consistent with previously 
reported data.6,59,60 
 
TLC (8:2:1 CHCl3:MeOH:NH4OH) 
Rf = 0.58, visualized by KMnO4 stain 
 
1HNMR (500 MHz, CD3OD) 
δ 5.40-5.36 (m, 1H), 4.18-4.11 (m, 1H), 3.29-3.19 (m, 2H), 2.77 (app t, J = 7.0 Hz, 
2H), 2.71 (app t, J = 7.2 Hz, 2H), 2.69-2.63 (m, 6H), 2.38-2.31 (m, 1H), 2.31-2.21 
(m, 2H), 2.09-2.04 (m, 1H), 2.04-1.95 (m, 2H), 1.91-1.84 (m, 1H), 1.79-1.69 (m, 
6H), 1.63-1.54 (m, 4H), 1.54-1.46 (m, 4H), 1.36-1.24 (m, 3H), 1.15 (d, J = 6.8 Hz, 
3H), 1.14-1.06 (m, 2H), 1.03 (s, 3H), 1.00-0.93 (m, 2H), 0.75 (s, 3H) 
 
13CNMR (125 MHz, CD3OD) 
δ 179.8, 142.2, 122.3, 72.4, 57.9, 54.0, 51.7, 50.1, 49.9, 48.0, 47.5, 45.1, 43.4, 43.0, 
41.0, 40.4, 38.6, 37.7, 37.6, 33.3, 33.0, 32.3, 31.6, 29.8, 28.5, 27.8, 27.8, 25.4, 22.2, 
19.9, 18.0, 12.5 
 
HRMS (ESI+) 
            Calculated for C32H59N4O5S [M+H
+]+: 611.4206  
            Observed:  611.4205 
 
 HPLC (0.1% TFA in H2O to MeCN gradient, 214 nm) 
 
  
DMSO 
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Synthesis of Methyl 3α-acetoxy-7α,12α-di[(4-nitrophenylaminocarbonyl)amino]-5β-cholan-
24-oate (3) 
 
 
 
3 was prepared according to literature precedent in 14.9% overall yield starting from 
cholic acid.61-63 Characterization of this compound was consistent with previously 
reported data.61-63 
 
TLC (1:2 Hexanes:Ethyl Acetate) 
Rf = 0.40, visualized by UV (254 nm and/or 366 nm) and/or KMnO4 stain 
 
1HNMR (500 MHz, Acetone-d6) 
δ 8.85 (br s, 1H), 8.66 (br s, 1H), 8.15 (app d, J = 8.8 Hz, 4H), 7.73 (app d, J = 9.3 
Hz, 4H), 6.24-6.14 (app br s, 2H), 4.56-4.47 (m, 1H), 4.21-4.16 (m, 1H), 4.12-4.06 
(m, 1H), 3.55 (s, 3H), 2.29-2.23 (m, 4H), 2.20-2.09 (m, 2H), 2.02-1.94 (m, 4H), 
1.91 (s, 3H), 1.89-1.77 (m, 4H), 1.75-1.55 (m, 4H), 1.52-1.22 (m, 6H), 0.91 (s, 3H), 
0.89 (s, 3H), 0.87 (s, 3H) 
 
13CNMR (125 MHz, Acetone-d6) 
δ 174.4, 170.2, 154.5, 148.0, 148.0, 147.9, 142.2, 142.1, 125.9, 117.7, 117.7, 74.6, 
53.9, 51.5, 49.1, 47.0, 45.6, 42.1, 38.0, 35.8, 35.8, 35.5, 33.4, 31.5, 31.2, 27.9, 27.6, 
27.3, 24.0, 23.2, 21.3, 17.5, 14.0 
 
HRMS (ESI+) 
            Calculated for C41H55N6O10 [M+H
+]+: 791.3980  
            Observed: 791.3977 
 
Analytical HPLC (H2O to MeCN gradient, 360 nm) 
 
  
DMSO 
114 
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Synthesis of N1,N3-bis(((R)-1-( isobutylamino)-4-methyl-1-oxopentan-2-yl)oxy)isophthalamide 
(4) 
 
4 was prepared according to literature precedent in 37.3% overall yield starting from 
leucine.8,64 Characterization of this compound was consistent with previously reported 
data.8,64  
 
TLC (1:1 Hexanes:Ethyl Acetate) 
Rf = 0.33, visualized by UV (254 nm) and/or KMnO4 stain 
 
1HNMR (500 MHz, CDCl3) 
δ 11.06 (br s, 2H), 8.16 (app br s, 3H), 8.01 (app d, J = 7.7 Hz, 2H), 7.51 (t, J = 7.8 
Hz, 1H), 4.39 (dd, J = 9.4, 3.2 Hz, 2H), 2.99 (app dt, J = 13.0, 6.4 Hz, 2H), 2.87 
(app dt, J = 13.0, 6.4 Hz, 2H), 1.84-1.77 (m, 2H), 1.75-1.60 (m, 4H), 1.56 (m, 2H), 
0.87 (app d, J = 6.6 Hz, 12H), 0.80 (d, J = 6.6 Hz, 6H), 0.74 (d, J = 6.6 Hz, 6H) 
 
13CNMR (125 MHz, CDCl3) 
δ 172.3, 166.1, 131.9, 131.4, 129.5, 125.3, 85.4, 46.8, 41.3, 28.4, 24.9, 23.3, 21.9, 
20.1, 20.1 
 
HRMS (ESI+) 
            Calculated for C28H47N4O6 [M+H
+]+: 535.3496  
                       Observed:                                            535.3497 
 
Analytical HPLC (H2O to MeCN gradient, 254 nm)  
 
 
DMSO 
116 
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Chapter 4 
Hinokitiol Restores Physiology in Protein-Deficient Yeast and Colorectal Epithelia 
Multiple human diseases are caused by hereditary or acquired deficiencies of iron 
transporting proteins and/or their functions, which reduce transmembrane iron flux in distinct 
sites and directions. Because other iron-transport proteins remain active, labile iron gradients 
likely build-up across the corresponding protein-deficient membranes. We hypothesized that a 
small molecule that autonomously transports iron might be able to harness these labile iron 
gradients to restore physiology in the setting of iron transporter deficiencies. Using iron 
transporter-deficient yeast, we discovered that a small molecule natural product, hinokitiol, can 
harness such gradients to restore iron transport into, within, and/or out of cells. My colleagues 
Tony Grillo and Anna SantaMaria then went on to test hinokitiol in vivo. They determined that 
the same compound promotes gut iron absorption in DMT1-deficient rats and ferroportin-
deficient mice, as well as hemoglobinization in both DMT1- and mitoferrin-deficient zebrafish.. 
These results suggest small molecules that partially mimic the function of missing protein 
transporters of iron, and possibly other ions, may have potential in treating human diseases. 
Tony Grillo, Anna SantaMaria, and I worked together on yeast cells and the 
development/maintenance of the Caco-2 cell line. Tony Grillo synthesized C2deOHino. Tony 
Grillo, Anna SantaMaria, and I worked together on biophysical studies. Tony Grillo and Anna 
SantaMaria performed Caco-2 uptake and transport experiments. Tony Grillo and Anna 
SantaMaria then went on to perform all animal studies with collaborators. Portions of this 
chapter were adapted from Grillo et al., Restored iron transport by a small molecule promotes 
gut absorption and hemoglobinization, submitted. 
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4-1 IRON TRANSPORTERS AND THEIR ROLE IN IRON HOMEOSTASIS 
 Site- and direction-selective transmembrane ion transport is achieved in most living 
systems via the concerted action of active ion-transport proteins that generate localized 
electrochemical gradients and the passive ion-transport proteins that use them.1 Deficiencies of 
passive ion-transport proteins cause many human diseases including anemias, cystic fibrosis, 
arrhythmias, and neurological, skeletal muscle, endocrine, and renal disorders.2-5 Because the 
corresponding active ion transporters typically remain active, the loss of ion transporters may 
yield a build-up of ion gradients upstream of the membranes that normally host them (Figure 
4.1). We hypothesized that small molecules capable of promoting ion transport could utilize such 
gradients to restore transmembrane ion flux in a site- and direction-selective manner. 
 Iron homeostasis, in particular, is maintained by dynamic networks of pumps, 
transporters, and regulators that permit essential use yet minimized toxicity of this redox-active 
metal.2 No known regulatory mechanisms of iron excretion exist,6 and thus systemic iron levels 
are primarily controlled through rigorous regulation of dietary iron absorption by tunable 
transporters and regulators.2,6 Deficiencies and/or dysfunction of proteins involved in iron 
transport, homeostasis, and/or metabolism often impede the movement of iron into, within, 
and/or out of cells (Figure 4.1), being associated with more than twenty-five Mendelian 
diseases.6-9 We questioned whether a small molecule iron transporter could utilize accumulated 
transmembrane gradients of the labile iron pool2 that selectively build-up in an iron transporter 
deficiency to restore iron movement into, within, and/or out of cells and thereby enable its use in 
endogenous iron-dependent physiological processes (Figure 4.1). 
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4-2 HINOKITIOL RESTORES PHYSIOLOGY IN YEAST   
 To test this, we chose to study three disease-relevant iron transporter deficiencies that 
disrupt iron movement in different directions, cellular locations, and tissues.2,6 Deficiencies of 
divalent metal transporter 1 (DMT1, Nramp2, DCT1, SLC11A2) reduce apical ferrous iron 
uptake into duodenal enterocytes (Figure 4.2A) and prevent endosomal iron release in red blood 
cell progenitors (Figure 4.2B).2,6 Mitoferrin (Mfrn1, SLC25A37) deficiencies in the inner 
mitochondrial membrane impair iron import into the mitochondrial matrix (Figure 4.2C).10,11 
Ferroportin (FPN1, IReg1, MTP1, SLC40A1) deficiencies reduce iron efflux from gut 
epithelium (Figure 4.2D) and from reticuloendothelial macrophages (Figure 4.2E).12-15  
 Previous reports suggest high doses of hydrophilic iron chelators, such as deferiprone and 
pyridoxal isonicotinoyl hydrazone (PIH), as well as more lipophilic derivates such as 
salicylaldehyde isonicotinoyl hydrazone (SIH), may bind and relocate excess iron.16,17 However, 
Figure 4.1: A small molecule that autonomously performs transmembrane iron transport is hypothesized to 
harness local ion gradients of the labile iron pool that selectively accumulate in the setting of missing protein 
iron transporters. Brown spheres represent labile iron, which includes both ionic iron and iron weakly bound to 
small molecules such as citrate. 
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the corresponding complexes of many of these chelators show limited membrane permeation and 
may require the action of co-localized proteins to achieve iron mobilization.18,19 We alternatively 
sought to identify a lipophilic small molecule that can autonomously perform transmembrane 
iron transport to promote physiology in cells and animals missing each of the aforementioned 
proteins. 
 To find such a molecule, we designed a modified functional complementation 
experiment,20 in which candidate metallophores were tested for their capacity to restore growth 
to a strain of Saccharomyces cerevisiae missing the iron transporting complex FetFtr1 
Figure 4.2: Simplified Schematics for Iron Transporter Deficiencies. A.) DMT1-deficient gut epithelia exhibit 
reduced dietary iron absorption across the apical membrane resulting in decreased transport to the basolateral 
fluid via FPN1. B.) DMT1 deficiencies impair normal differentiation of red blood cell progenitors by precluding 
endosomal iron release to the cytosol for mitochondrial hemoglobinization. C.) Mfrn1 deficiencies lead to 
impaired mitochondrial iron import and reduced hemoglobinization and differentiation in developing erythrons. 
D.) FPN1 deficiencies prevent the proper release of iron from gut enterocytes leading to reduced transport to the 
basolateral fluid. E.) FPN1 deficiencies also preclude the release of labile iron from reticuloendothelial 
macrophages in the liver. F.) Yeast missing the iron transporting complex Fet3Ftr1 are iron-deficient and cannot 
grow under iron-limiting conditions. 
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(fet3Δftr1Δ, Figure 4.2F).21 The natural product hinokitiol (Hino, β-thujaplicin, Figure 4.3A), 
originally isolated by Nozoe from essential oil of the Chamaecyparis taiwanensis (Taiwan 
Hinoki) tree,22 vigorously restored cell growth (Figure 4.3B-D). This natural product has 
previously been characterized as a potent chelator of iron and other metals23-26  and exerts a 
range of biological activities.25-31 Hinokitiol restored growth to iron transporter-deficient yeast 
under fermentative and respiratory conditions (Figure 4.3E) and independent of known 
siderophore transporters (Figure 4.3F).21,32 Hinokitiol sustainably (Figure 4.3G) restores growth 
to wild type levels (Figure 4.3D) with similar doubling times (Figure 4.3H and Figure 4.3I). In 
contrast, hydrophilic iron chelators, such as deferiprone, PIH, and SIH, showed no growth rescue 
(Figure 4.4). 
 Synthetic deletion of the C-2 oxygen atom yielded C2-deoxy hinokitiol (C2deOHino, 
Figure 4.3A and Figure 4.5A), which cannot bind iron (Figure 4.5B) and thus served as a 
negative control. Hinokitiol dose-dependently restores yeast growth while C2deOHino does not 
(Figure 4.5C). Hinokitiol, but not C2deOHino, also restores iron influx (Figure 4.5D) and 
hinokitiol-mediated growth is iron-dependent (Figure 4.5E and Figure 4.5F). Unlike water 
soluble complexes of iron chelators,17 the complex of iron and hinokitiol is lipid soluble and 
predominantly partitions into non-polar solvents over water (Figure 4.5G). In this vein, growth 
restoration was observed with other lipophilic (Figure 4.4A), but not hydrophilic (Figure 4.4B), 
α-hydroxy ketones, nor small molecules that transport other ions (Figure 4.4C).  
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Figure 4.3: Restoring Physiology to Iron Transporter-Deficient Organisms. A.) Structures of hinokitiol (Hino) 
and the transport-inactive derivative C2-deoxy hinokitiol (C2deOHino). B.) Disc diffusion with hinokitiol of 
fet3Δftr1Δ cells streaked on a low iron SD-agar plate containing 10 µM FeCl3 restored yeast cell growth at 
intermediate concentrations of small molecule. C.) In the absence of hinokitiol, reduced fet3Δftr1Δ yeast cell 
growth was observed on low iron SD-agar plates containing 10 µM FeCl3 by serial 10-fold dilution plating (from 
OD600 = 1.0). Under identical conditions, restored cell growth was observed on the same low iron SD-agar plates 
containing 10 µM hinokitiol. D.) Yeast cell growth in liquid SD media containing 10 µM FeCl3 in the absence or 
presence of 10 µM hinokitiol. E.) 10-fold serial dilution plating (from OD600 = 1.0) of iron-deficient yeast 
(fet3Δftr1Δ) on low iron SG-agar plates containing 10 µM FeCl3 in the absence or presence of hinokitiol (10 
µM). F.) Hinokitiol (10 µM) also restores growth to iron-deficient yeast missing all known siderophore protein 
transporters (fet3Δarn1-4Δ) on low iron SD-agar plates containing 10 µM FeCl3. G.) Growth restoration to 
fet3Δftr1Δ yeast can be sustained for >100 days with continued reliance on hinokitiol. H.) and I.) Doubling 
times of hinokitiol-treated fet3Δftr1Δ yeast are similar to wild type yeast. NS, not significant. **** P ≤ 0.0001. 
Graphs depict means ± SEM.  
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4-3 CHARACTERIZATION OF HINOKITIOL BINDING AND TRANSPORT  
 Several biophysical experiments were performed to better understand the capacity for 
hinokitiol to bind and transport ferrous and ferric iron across lipid membranes. This natural 
product rapidly binds iron to form a hinokitiol:iron complex, as evidenced by an immediate 
change in color and UV-Vis spectra upon addition of ferric or ferrous iron (Figure 4.6A-D). 
Unlike water soluble iron chelators,17 hinokitiol:iron complexes predominantly partition into 
non-polar solvents over water (Figure 4.6A and Figure 4.5G), consistent with quantitative 
extraction of iron from the aqueous to the organic layer as determined via ICP-MS analysis 
(Figure 4.6E). Hinokitiol strongly binds ferrous and ferric iron with a KA = 5.3x10
15 for ferrous 
iron and KA = 5.8x10
25
 for ferric iron, which is more than an order of magnitude stronger than 
deferiprone (Figure 4.6F and Figure 4.6G). Consistent with its high affinity, hinokitiol can 
remove iron from iron-citrate complexes that compose the labile iron pool (Figure 4.6C), and 
Figure 4.4: Small Molecule-Mediated Growth is General to Lipophilic Carriers. A.) Hinokitiol and other 
lipophilic α-hydroxy ketones restore growth to fet3Δftr1Δ yeast streaked onto low iron SD-agar plates 
containing 10 µM FeCl3 while B.) other iron chelators and C.) small molecule transporters of other ions do not 
restore growth under identical conditions. 
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from iron binding proteins transferrin and ferritin (Figure 4.6H and Figure 4.6I). Moreover, 56Fe 
bound to hinokitiol readily exchanges with 55Fe in solution (Figure 4.6J). Thus, the binding of 
iron by hinokitiol under physiological conditions is expected to be dynamic, which may allow 
for the release of iron from hinokitiol complexes and its subsequent utilization in iron-related 
physiological processes. 
 
Hinokitiol autonomously transports both ferrous and ferric iron across model liposomal 
membranes while C2deOHino, deferiprone, and PIH show minimal transport (Figure 4.7A and 
Figure 4.7B). While the transport-active complex remains to be identified, speciation studies are 
consistent with the predominant formation of a 3:1 Hino:FeIII complex in aqueous buffer (Figure 
4.7C and Figure 4.7D). X-ray crystallography of tris(hinacolato) iron (III) revealed a pair of C1-
symmetric complexes, each composed of a lipophilic outer shell encasing a hydrophilic and iron 
Figure 4.5: Hinokitiol Restores Growth to Iron-Deficient Yeast. A.) The transport inactive derivative, C2-deoxy 
hinokitiol (C2deOHino), was synthesized on multi-gram scale in two steps from hinokitiol. B.) C2deOHino does 
not bind iron. C.) Hinokitiol restored growth of fet3Δftr1Δ yeast while C2deOHino did not. D.) Hinokitiol 
increases 55Fe influx into fet3Δftr1Δ yeast while C2deOHino does not. E.) Hinokitiol-promoted growth 
restoration of fet3Δftr1Δ yeast is dependent on iron levels in the media. F.) Increased environmental iron levels 
broaden the rescue window where hinokitiol-promoted growth is observed before toxicity alternatively occurs. 
No growth was observed for fet3Δftr1Δ yeast in the absence of hinokitiol at any tested iron concentration. G.) 
Octanol/water partition coefficients of the iron complexes of other iron chelators that do or do not restore growth 
to fet3Δftr1Δ yeast. The logP of the iron complex of SIH was not determined due to the low stability of SIH in 
acidic aqueous solutions as determined by 1H NMR analysis. Graphs depict means ± SEM. 
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binding central core (Figure 4.7E). To test the selectivity of divalent cation transport, we 
performed a liposomal assay using the fluorescent probe PhenGreen. Upon binding divalent 
cations, PhenGreen fluorescence is quenched. Hinokitiol was observed to be a broad spectrum 
metallophore capable of binding and transporting multiple divalent metals (Figure 4.8). 
Substantial selectivity of hinokitiol for binding and transporting iron is expected in biological 
systems due to the high metallomic abundance of iron.33,34 
 
4-4 HINOKITIOL RESTORES PHYSIOLOGY IN HUMAN COLORECTAL EPITHELIA  
 Encouraged by these results, we thus asked whether hinokitiol could promote iron 
movement into, within, and/or out of mammalian cells deficient in iron transporters. We first 
studied iron uptake and transepithelial transport in differentiated DMT1-deficient Caco-2 gut 
Figure 4.6: Physical Characteristics of Hinokitiol Binding and Transport. A.) Opposite to water soluble 
chelators, such as deferiprone, the hinokitiol-iron complex partitions into non-polar solvents. B.) UV titration 
study of hinokitiol with increasing FeCl3 indicates hinokitiol binds iron. Arrows indicate changes in UV 
spectrum with increasing iron from 0:1 Fe:Hino to 6:1 Fe:Hino. C.) Hinokitiol binds iron (III) using a source of 
ionic iron (III) and iron (III) weakly bound to small molecules. D.) Hinokitiol similarly forms a complex with 
iron (II). E.) The iron is quantitatively bound to hinokitiol in solution at pH=7.0 as determined by iron content in 
the organic layer after extraction of hinokitiol-bound iron by ICP-MS. F.) UV-Vis spectra of hinokitiol bound to 
iron (III) with increasing doses of the competitive chelator EDTA. High doses of EDTA largely remove iron 
from hinokitiol. G.) Hinokitiol strongly binds iron (III) relative to deferiprone as determined by the EC50 values 
obtained from an EDTA competition study. Hinokitiol removes iron from H.) transferrin (1 nM) and I.) ferritin 
(3.3 ng ferritin/mL) in a dose-dependent fashion using 55Fe as a radiotracer. J.) Stoichiometric ionic 55Fe was 
added to a solution containing a pre-formed 56Fe-hinokitiol complex in 10 mM Mes/Tris buffer at pH=7.0. 
Equilibrium between the 55Fe-hinokitiol complex and the 56Fe-hinokitiol complex was achieved within one hour. 
NS, not significant. Graphs depict means ± SEM. 
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epithelia monolayers35,36  (Figure 4.2A) established through stable shRNA transfection (Figure 
4.9A-C). DMT1-deficient monolayers showed reduced iron uptake into cells and reduced 
transepithelial iron transport to the basolateral fluid after apical addition of 55FeCl3 (Figure 4.9D 
and Figure 4.9E). Addition of hinokitiol (500 nM) restored uptake and transport (Figure 4.9D 
and Figure 4.9E). Furthermore, the time course of hinokitiol-mediated transport was 
commensurate with dwell times in the gut (Figure 4.9F). 
 
Hinokitiol did not disrupt monolayer integrity (Figure 4.9G), and did not affect basal 
DMT1 expression (Figure 4.9B and Figure 4.9C). Hinokitiol-mediated transport occurs at 
multiple pHs found throughout the duodenum (Figure 4.9H). While hinokitiol promotes uptake 
and transport over a wide range of concentrations, C2deOHino and sub-toxic concentrations of 
iron chelators deferiprone, deferoxamine, PIH, and SIH did not similarly promote both uptake 
Figure 4.7: Physical Characteristics of Hinokitiol Binding and Transport. A. and B.) In contrast to water soluble 
iron chelators and C2deOHino, hinokitiol autonomously promotes the efflux of A.) ferrous and B.) ferric iron 
from model POPC liposomes. C. and D.) Titration studies with iron and hinokitiol support that a 3:1 Hino:Fe 
complex is predominantly formed in 10 mM Mes/Tris buffer at pH=7.0 as indicated by saturation of the C.) λmax 
and the D.) absorbance at 420 nm at 3:1 Hino:Fe ratios. Increased amounts of iron led to no changes in the UV-
Vis spectra. E.) X-ray crystal structures of two C1-symmetric Fe(Hino)3 complexes. 
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and transport (Figure 4.9I and Figure 4.9J). In contrast to hinokitiol, high concentrations of these 
iron chelators decreased iron uptake into DMT1-deficient monolayers (Figure 4.9I).  
We next probed the mechanistic hypothesis that hinokitiol promotes site- and direction-
selective iron movement by harnessing built-up transmembrane iron gradients in transporter-
deficient systems (Figure 4.1).  We first tested this hypothesis in liposomes where the 
concentration of both iron and hinokitiol could be easily modified. We observed that hinokitiol-
mediated iron (II) and iron (III) efflux from liposomes is directly proportional to the extracellular 
iron and/or hinokitiol levels (Figure 4.10A-F). Finally, we asked whether endogenous networks 
of other ion-transport proteins and regulators2 in iron transporter-deficient cells can collaborate 
with the small molecule hinokitiol to help promote restoration of site- and direction-selective 
iron transport. In yeast, the intracellular movement and storage of iron is dependent on a proton 
gradient known as the proton motive force, which is generated by the ATP-dependent active ion-
transport proteins Pma1 and V-ATPase in the plasma and vacuolar membranes, respectively.21,43 
This model predicts selective sensitivity of the small molecule-rescued mutants to chemical 
inhibition of these pumps. Consistent with the dependence of hinokitiol-mediated iron transport 
on this proton motive force, hinokitiol-rescued fet3Δftr1Δ yeast are exceptionally sensitive to 
chemical inhibition of Pma1 and V-ATPase, but not to off-pathway inhibitors (Figure 4.11). 
My colleagues Tony Grillo and Anna SantaMaria then went on to ask whether hinokitiol 
could restore gut iron absorption and hemoglobinization in animal models of iron transporter 
deficiencies. DMT1- and FPN1-deficiencies in duodenal enterocytes reduce rates of iron 
absorption in the gut by disrupting apical iron uptake into cells and basolateral efflux into the  
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Figure 4.8: Selectivity of Hinokitiol-Mediated Binding and Transport with Divalent Cations. A.) Metal content 
in aqueous layer before extraction (black bars) and the organic layer after extraction with 1:1 Hex:EtOAc (white 
bars) using 10:1 Hino:Metal indicates hinokitiol forms organic soluble complexes with each individual metal. 
No metal was detected in the organic layer in the absence of hinokitiol. B.) Stoichiometric competition 
experiments with 1 mM of each divalent metal and 1 mM hinokitiol in a 10 mM Mes/Tris buffer in 1:1 
MeOH:H2O at pH=7.0. Hinokitiol binds many metals by ICP-MS quantification of extracted hinokitiol-bound 
metal. The metal in the organic layer was determined to be in the order of Cu > Fe > Mn ≈ Zn > Co > Ni. ND = 
Not detected. C.) Hinokitiol (10 µM) rapidly promotes the efflux of multiple divalent metals from POPC 
liposomes as determined by a PhenGreen assay. In these studies, hinokitiol was unable to transport MnII to any 
observable degree. Quantification of metal release was done by comparison of fluorescence quenching to a 
standard curve for each metal. The reciprocal half-lives for efflux were determined to be in the order of Cu > Zn 
> Co > Ni > Fe >> Mn. D.-I.) Fluorescence quenching of PhenGreen (10 µM) after addition of DMSO (black) or 
hinokitiol (blue, 2 µM), indicated by the arrow, to a suspension of liposomes containing 5 mM D.) FeII, E.) MnII, 
F.) CoII, G.) NiII, H.) ZnII, I.) or CuII. PhenGreen fluorescence quenching indicating efflux of metal from 
liposomes. Lysis with Triton X was performed at t = 60 min, where fluorescence quenching was observed for 
each metal treated with DMSO. The levels of fluorescence quenching after lysis of the DMSO-treated liposomes 
were similar to that for hinokitiol-treated liposomes before lysis (t = 60 min), except for manganese where no 
transport was observed. 
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Figure 4.9: Hinokitiol Promotes Uptake and Transport in DMT1-Deficient Caco-2 Cells. A.) Dmt1 mRNA 
levels, quantified via qRT-PCR, are reduced in shDMT1 Caco-2 monolayers as compared to the shControl cell 
monolayers. B. and C.) Quantitative densitometric analysis of western blots indicated decreased DMT1 protein 
levels in shDMT1 Caco-2 monolayers. Hinokitiol (500 nM) treatment did not induce DMT1 expression. D.) 55Fe 
uptake into DMT1-deficient Caco-2 monolayers and E.) transepithelial transport (apical to basolateral) indicated 
hinokitiol (500 nM) restored normal iron absorption. F.) Hinokitiol-promoted 55Fe transport occurs on times 
commensurate with dwell times in the gut. G.) TransEpithelial electrical resistance (TEER) values of Caco-2 
monolayers treated with DMSO, hinokitiol (500 nM), or C2deOHino (500 nM) remain consistent over the 
course of the experiment. H.) Hinokitiol (500 nM) promotes transport in shDMT1 Caco-2 monolayers at a range 
of pHs found throughout the duodenum. I. and J.) In contrast to hinokitiol, the iron chelators deferiprone, PIH, 
SIH, and deferoxamine do not restore I.) uptake into or J.) transcellular transport across DMT1-deficient Caco-2 
monolayers under identical conditions (pH = 5.5 apical, pH = 7.4 basolateral). Dotted line represents shControl 
levels. While a slight increase in transport was observed in SIH treated cells, reduced uptake was observed, 
consistent with paracellular, and not transcellular, iron transport. Concentrations used for each small molecule 
were 0, 0.01, 0.1, 1, and 10 µM. **** P ≤ 0.0001. Graphs depict means ± SEM.  
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blood, respectively.2,6,12-15 They tested gut iron absorption in DMT1-deficient Belgrade (b/b) 
rats6 and FPN1-deficient Flatiron (ffe/+) mice.14,15 They also tested whether chronic treatment 
with hinokitiol could restore hemoglobinization in DMT1- and Mfrn1-deficient zebrafish. 
Strikingly, they observed that hinokitiol promoted gut iron absorption in DMT1-deficient rats 
and ferroportin-deficient mice, as well as hemoglobinization in both DMT1- and mitoferrin-
deficient zebrafish. 
 
 
 
Figure 4.10: Hinokitiol Transport as a Function of the Iron Gradient. A. and D.) Increased intraliposomal A.) 
ferrous iron and D.) ferric iron leads to increased rates of iron efflux in the presence of hinokitiol (10 µM). No 
efflux was observed in the absence of hinokitiol. B. and E.) The rate of iron release from hinokitiol-treated (10 
µM) POPC liposomes also increases as a function of the amount of B.) ferrous and E.) ferric iron inside of the 
liposomes. C. and F.) Hinokitiol increases the release of C.) ferrous and F.) ferric iron from POPC liposomes in 
a dose-dependent fashion with a constant concentration of iron (30 mM).  
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4-5 SUMMARY  
 Thus, a small molecule can restore site- and direction-selective iron transport in different 
cells deficient in three distinct iron-transport proteins, and the same compound can promote 
dietary gut iron absorption or peripheral hemoglobinization in corresponding animal models. 
Mechanistic studies support the role of transmembrane ion gradients that build-up in the setting 
of missing iron transporters, enabling hinokitiol to restore site- and direction-selective 
transmembrane iron transport. 
 
These findings provide a conceptual framework and proof-of-concept demonstration to 
support the pursuit of small molecule surrogates for missing or dysfunctional iron-transport 
proteins that underlie many human diseases. Notably, it has recently been recognized that 
acquired deficiencies of FPN1 underlie the anemia of chronic inflammation that frequently 
Figure 4.11: Endogenous Proteins Involved in Iron Uptake and Transport. A and D.) As expected, wild type and 
fet3Δftr1Δ yeast grown in the presence of hinokitiol (10 µM) are equisensitive to an inhibitor of cell wall 
biosynthesis, caspofungin, which is off-pathway of iron uptake. B. and E.) Inhibition of the proton-motive force 
generating pump Pma1 with ebselen leads to increased sensitivity of hinokitiol-rescued fet3Δftr1Δ yeast relative 
to hinokitiol-treated wild type yeast. C. and F.) Inhibition of the proton-motive force generating pump V-ATPase 
with bafilomycin leads to increased sensitivity of hinokitiol-rescued fet3Δftr1Δ yeast relative to hinokitiol-
treated wild type yeast. This suggests these proteins play a role in hinokitiol-mediated restoration of yeast cell 
growth. 
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occurs in patients suffering from many common diseases, including rheumatoid arthritis, 
systemic lupus erythematosus, and inflammatory bowel disease.9 Further, this approach may 
have potential in promoting the rapid excretion of excess iron that builds up in tissues (e.g. liver 
or brain) in many diverse iron overload disorders.  
Because networks of active and passive ion-transport proteins similarly underlie the 
directional movement of many other ions in most living systems, including humans, these 
findings may also have even broader scientific and therapeutic implications. 
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4-6 METHODS 
Cell lines and Growth Conditions 
Wild type (DEY1457) and isogenic fet3Δftr1Δ S. cerevisiae were obtained from D. 
Kosman.44 Wild type (YPH499) and isogenic fet3Δarn1-4Δ S. cerevisiae were obtained from C. 
Philpott.45 Yeast were maintained on standard YPD media containing 10 g/L yeast extract, 20 
g/L peptone, and 20 g/L dextrose without (liquid media) or with (solid media) 20 g/L agar. 
Growth-restoration assays in yeast used SD media consisting of 1.91 g/L iron-free YNB-FeCl3 
(ForMedium CYN 1201), 0.79 g/L Complete Supplement Mixture (Sunrise Science Products 
1001-010), 5 g/L ammonium sulfate (Sigma A4418), 20 g/L dextrose, and 10 µM FeCl3 (Sigma 
451649) at pH=7.0 in 50 mM MES/Tris buffer without (liquid media) or with (solid media) 20 
g/L agar unless otherwise noted. Dextrose and FeCl3 were added after autoclave sterilization 
from a filter-sterilized 40% w/v dextrose solution in water and from a freshly prepared 10 mM 
FeCl3 stock in sterile water, respectively. Non-fermentable growth restoration used the same 
synthetic medium except for the use of 30 g/L glycerol instead of dextrose.  
Human Caco-2 cells (HTB-37) were obtained from ATCC and cultured with DMEM 
(Gibco 10313-021) containing 10% HI FBS (Gibco 16000-036), 4 mM glutamine (Lonza BE17-
605E), 100 µg/mL PEN-STREP (Lonza DE17-602E), and 1% MEM NEAA (Fisher 11140-050). 
Transfected Caco-2 cell lines were maintained on this media containing 800 mg/L G418 (Santa 
Cruz sc-29065B).  
Caco-2 cells (passage 18-50) were grown in T75 flasks to ≥90% confluency before 
trypsinization with 0.25% trypsin-EDTA (Fisher 25200-056) and passaging at 10:1 dilution in 
Caco-2 media without (wild type) or with G418 (transfected). Monolayers were grown by 
seeding Caco-2 cells (passage 20-50) onto 0.4 µm PET cell culture inserts (Fisher 08-771) in 6-
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well companion plates (Fisher 08-771-24) at 2x105 cells/well and allowed to fully differentiate 
for 21-28 days before experiments were performed with changing of media every 3-4 days. 
Growth Rescue of Iron-Deficient Yeast with Small Molecules on Agar Plates  
Growth rescue in yeast was performed similar to previously reported20 using 10 µM 
hinokitiol on SD-agar plates containing 10 µM FeCl3 and 2% agarose gel. Wild type and 
fet3Δftr1Δ or fet3Δarn1-4Δ controls treated with vehicle (DMSO) were performed under 
identical conditions using the same low-iron SD media containing 10 µM FeCl3. Yeast were 
grown overnight in YPD media and diluted at an optical density at 600 nm (OD600) of 0.1 in SD 
media before streaking onto agar plates. Disc diffusion assays were performed using ≥10 mM 
stock solutions (in DMSO) of tropolone (Sigma T89702), α-dolabrin (Specs Compound 
Handling AN-584/43416897), maltol (Sigma H43407), deferiprone (DFP, Sigma 379409), 
pyridoxal isonicotinoyl hydrazone (PIH, Santa Cruz sc-204192), comenic acid (COMA, kindly 
donated by Obiter Research, LLC), amphotericin B (AK Scientific L970), nonactin (Sigma 
N2286), and calcimycin (Sigma C7522) (10 µL per paper disc) on SD-agar plates containing 10 
µM FeCl3 streaked with the appropriate yeast strain (OD600 = 0.1). Growth restoration under non-
fermentable conditions was performed using 3% glycerol instead of 2% dextrose. Images were 
taken 48-72 hours after inoculation unless otherwise noted. 
Serial 10-fold dilution plating growth restoration assays were performed on these same 
SD-agar plates in the absence or presence of hinokitiol by serial 10-fold dilution of a yeast 
suspension at OD600 = 1.0. The yeast suspension was inoculated onto these plates (10 µL per 
dot). 
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Growth Rescue of fet3Δftr1Δ Yeast with Small Molecules in Liquid Media  
Growth rescue in yeast was performed similar to previously reported20 using 10 µM 
hinokitiol in SD liquid media containing 10 µM FeCl3 in a 96-well plate unless otherwise noted. 
Wild type and fet3Δftr1Δ controls treated with vehicle (DMSO) were performed under identical 
conditions in the absence of hinokitiol. Yeast were grown overnight in YPD media and diluted at 
an OD600 of 0.1 in SD media, diluted 10-fold, and incubated at 30 °C with continuous shaking 
(200 rpm). The OD600 was obtained 24-48 hours after inoculation unless otherwise noted. Small 
molecule dose-response with hinokitiol and C2-deoxy hinokitiol (C2deOHino) was determined 
by addition of the small molecule (40X stock solution in DMSO) to give the indicated final 
concentrations. Iron dose-response studies were performed in the same SD media without FeCl3 
containing 10 µM hinokitiol (from a 40X stock solution in DMSO), with FeCl3 (40X stock 
solution in water) added to the give the indicated final concentrations up to 10 µM FeCl3. For 
dose-dependent hinokitiol-promoted rescue at increasing dosages of FeCl3, SD media was made 
containing either 10, 25, 50, or 100 µM FeCl3 from a 10 mM FeCl3 stock before adding 
hinokitiol (40X stock solution in DMSO) to give the indicated final concentrations. 
Sustainability Assay 
Sustainable hinokitiol-promoted growth restoration of fet3Δftr1Δ yeast was performed 
similar to previously reported20 by inoculation of hinokitiol-rescued yeast from SD-agar plates 
containing 10 µM hinokitiol and 10 µM FeCl3 into SD liquid media containing 10 µM hinokitiol 
and 10 µM FeCl3, then streaking of the yeast suspension (diluted to OD600 of 0.1) onto agar 
plates. This process was repeated for >100 days. 
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Doubling Time of fet3Δftr1Δ Yeast Treated with Hinokitiol  
Doubling times of wild type and hinokitiol-rescued fet3Δftr1Δ yeast were determined 
similar to previously reported20 by tracking the OD600 every hour over 48 hours in the same SD 
media containing 10 µM hinokitiol and applying the equation Td = (t2-t1) x [log(2)/log(q2/q1)] 
during exponential phase. 
Chemical Inhibition of Yeast Cell Growth with Inhibitors of Pma1, V-ATPase 
Chemical inhibition of hinokitiol-treated and hinokitiol-rescued wild type and fet3Δftr1Δ 
yeast cell growth, respectively, was performed as previously reported20 with increasing dosages 
of caspofungin (Sigma SML0425), ebselen (Sigma 70530), and bafilomycin B1 (Santa Cruz sc-
202072) (40X stocks in DMSO). EC50 values were determined from fitting of yeast growth 
curves using GraphPad PRISM. 
55Fe3+ Uptake Assay in Yeast  
Iron (III) uptake into wild type and fet3Δftr1Δ yeast was adapted from Kosman and 
coworkers.46 Overnight yeast cultures were repeatedly centrifuged and rinsed with water. The 
cell pellet was resuspended in MilliQ water, and diluted in SD media without FeCl3. The cells 
were incubated at 30 °C for 3 hours, centrifuged and rinsed with water twice. The cells were then 
suspended to 3x107 cells/mL in SD media containing 50 mM sodium citrate and 2% glucose. 
Hinokitiol or C2deOHino (from 40X stocks in DMSO) was added to a final concentration of 100 
µM before 55FeCl3 (1.1 µCi) was then added to the yeast suspensions. The suspension was 
continuously homogenized before aliquots were taken and diluted with 10 mL of room 
temperature water. Cells were then collected via vacuum filtration through a 0.45 µm 
nitrocellulose filter (Millipore HAWP), and rinsed with room temperature water (x5 of 100mL). 
The filters were then transferred to a scintillation vial containing 3 mL of scintillation cocktail 
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for measuring radioactivity using a liquid scintillation counter. Hinokitiol showed a dose-
dependent increase in 55Fe uptake from 5 to 100 µM while C2deOHino showed no uptake up to 
100 µM. 
Lipophilicity Determination for Small Molecule Iron Chelates 
Octanol-water partition coefficients were obtained as previously reported47 with 100 µM 
small molecule and 33 µM FeCl3 (50 µM FeCl3 for PIH as it forms a 2:1 complex) using equal 
volumes of equilibrated pH=5 water and octanol. Concentrations of small molecule in water 
were determined via UV-Vis spectroscopy compared to known initial standards.  
Hexane-water partition was obtained similar to above with 500 µM small molecule and 
50 µM FeCl3 using equal volumes of 50 mM Mes-Tris buffer at pH=7.0 and hexanes. 
Crystal Structure of Fe(Hino)3  
An x-ray quality crystal of synthesized Fe(Hino)3 was obtained from a recrystallization of 
Fe(Hino)3 (10 mg) in acetone (2 mL) and benzene (0.2 mL) in an uncapped 1 mL vial by 
allowing the solvent to slowly evaporate undisturbed overnight. X-Ray single crystal analysis 
was performed by the University of Illinois X-Ray facility. 
The optical rotation of Fe(Hino)3 in solution was determined with a polarimeter using 
Determination of Iron Efflux from Liposomes 
Iron (III) efflux from POPC liposomes was determined similar to previously reported.48 
POPC liposomes were prepared as similarly reported49 using 30 mM FeCl3, 62.5 mM citrate at 
pH=7.0 in 25 mM Mes/Tris buffer. External iron was removed by size exclusion 
chromatography using Sephadex G-50 and eluting with external buffer. External buffer consisted 
of 62.5 mM ascorbate at pH=7.0 in 25 mM Mes/Tris buffer. The liposomes were diluted to 1 
mM phosphorus in this buffer. Ferrozine (Sigma 160601) was added (100X stock in external 
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buffer) to a final concentration of 500 µM. Liposomal suspension was then transferred to a 96-
well plate, and either DMSO or 5 µM hinokitiol, C2deOHino, deferiprone, or PIH (40X stock 
solution in DMSO) were added to initiate the experiment. The OD562 was determined every 
minute over the course of 2 hours using a plate-reader with continuous shaking at 30 °C to detect 
the relative amounts of external ferrozine-iron chelate at the indicated times. After 2 hours, 
liposomes were lysed with triton-X to give 100% iron efflux. Hinokitiol dose- and temperature-
dependently promoted iron (III) efflux from POPC liposomes while C2deOHino showed no 
efflux up to 100 µM. 
Iron (II) efflux was performed as described above, however, the internal buffer 
alternatively consisted of 30 mM FeSO4, 62.5 mM ascorbate at pH=7.0 in 25 mM Mes/Tris 
buffer and triton-X lysis was performed after 1 hour. 
Determination of Divalent Cation Selectivity for Transport in Liposomes 
Hinokitiol-promoted transport into liposomes with varying metals and iron 
concentrations was performed by tracking the quenching of PhenGreen (Fisher P14312). 
Liposomes were prepared as described above with an internal buffer containing either 10 mM 
ascorbate at pH=7.0 in 5 mM Mes/Tris buffer (for Fe2+ transport), 10 mM citrate at pH=7.0 in 5 
mM Mes/Tris buffer (for Cu2+ transport), or 5 mM Mes/Tris buffer at pH=7.0 (for Mn2+, Co2+, 
Zn2+, and Ni2+ transport).  The external buffer consisted of either 10 mM ascorbate at pH=7.0 in 
5 mM Mes/Tris buffer (for Fe2+ transport) or 5 mM Mes/Tris buffer at pH=7.0 (for Cu2+, Mn2+, 
Co2+, Zn2+, and Ni2+ transport). In all cases liposomes were prepared using 5 mM of either FeCl2, 
MnCl2, NiCl2, CoCl2, ZnCl2, or CuCl2 added to the internal buffer. The liposome suspension was 
diluted to 1 mM, and PhenGreen was added to a final concentration of 10 µM (from a 10 mM 
stock in DMSO). The liposome suspension was then transferred to a 96-well plate, and the 
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fluorescence was monitored with excitation at 500 nm and emission at 530 nm for two minutes 
to obtain baseline fluorescence. After two minutes, DMSO or hinokitiol (from a 40X stock to a 
final concentration of 2 µM) was added. The fluorescence continued to be monitored for 1 hour 
after addition.  
The total amount of metal efflux was determined using standard curves in external buffer 
with 10 µM PhenGreen and known concentrations of metal. The t1/2 values were calculated using 
an asymptotic fit in Origin Pro. The t1/2 values indicate the time required to reach half of the 
maximum metal efflux.  
Exchangeability of Ferric Iron Bound to Hinokitiol 
Non-radioactive FeCl3 (100 nM, referred to as 
56Fe) was added to hinokitiol (100 nM) in 
25 mM MES/Tris buffer at pH=7.0. The solution was equilibrated for 1 hour at 37 °C, and then 
an equal amount of 55FeCl3 (100 nM) was added from a 100 µM stock. . The solution was 
incubated at 37 °C, and 100uL aliquots were taken at 5, 10, 20, 40, and 60 minutes and extracted 
complex with 1:1 EtOAc:H2O, and added 500 uL of the 2mL of EtOAc to a scintillation vial. A 
100uL aliquot was taken and put directly into scintillation counter for 2x total 55Fe possible.the 
indicated time points an aliquot was taken and added to water. The percent equilibrium was then 
determined by normalizing the radioactive counts from the theoretical maximum 55Fe found in 
the hinokitiol complex (1:1 55Fe:56Fe at equilibrium). 
Transfection of Caco-2 Cells Against DMT1. 
Caco-2 cells were transfected as previously reported35 using lipofectamine LTX 
(Invitrogen 15338-100) and Plus reagent (Invitrogen 11514-015) with 10 µg/well of either non-
targeting control shRNA or four other shRNA constructs targeting human DMT1 (Qiagen 
KH05760N) 24 hours after seeding 2x105 cells/well in 6-well plates (~30% confluent). The 
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transfection agents were removed, and the cells were allowed to recover for 24 hours before 
treatment with Caco-2 Complete media containing 0.8 g/L G418. Cells were incubated in G418 
media for ~2 weeks to promote selection of transfected cells while complete cell death was 
observed with non-transfected cells. Non-targeting control construct = 5’-
GGAATCTCATTCGATGCATAC-3’; shDMT1 construct (Clone 4) = 5’-
AACCTATTCTGGCCAGTTTGT-3’. 
qRT-PCR Conditions 
DMT1 mRNA levels were determined via qRT-PCR using SYBR Green (Agilent 
600825) following manufacturer protocols after undergoing treatment as described below. For 
determination of DMT1 mRNA levels in differentiated Caco-2 monolayers (21-28 days post 
seeding), mRNA was isolated using RNeasy Mini Kit (Qiagen 74104) according to manufacturer 
instructions. The threshold cycle (Ct) values of DMT1 were normalized to internal control actin 
using primers against DMT1 (Origene HP200584) and actin (Origene HP204660) using the 
Pfaffl Method and were then normalized to shControl levels. 
Western Blotting Conditions 
Caco-2 monolayers underwent treatment as described in rescue experiments before lysis 
with RIPA buffer (Thermo 89901) containing protease inhibitors (Thermo 88266). Protein 
concentrations were determined by a BCA kit (Thermo 23225) and diluted to 2 mg/mL in the 
same RIPA buffer. Relative protein levels were then determined through western blotting of 20 
µg of protein lysate blocking for 2 hours at room temperature with 5% BSA and using primary 
antibodies consisting of either human anti-DMT1 (1:3,000 dilution, Santa Cruz sc-30120) or 
human anti-actin HRP conjugate (1:10,000 dilution, Cell Signaling 5125S) in 5% BSA overnight 
at 5 °C before rinsing thoroughly with TBST and incubation (if non-HRP conjugated) with 
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secondary antibody consisting of anti-rabbit IgG HRP conjugate (1:5,000 dilution, Cell Signaling 
7074, in 5% milk) at room temperature for two hours. Blots were thoroughly rinsed with TBST 
and imaged after addition of Femto Chemluminescence solution according to manufacturer 
instructions (Thermo Fisher 34095). 
55Fe Uptake and Transport in Differentiated Caco-2 Monolayers  
Media from differentiated Caco-2 monolayers (P25-50, 21-28 days post seeding) grown 
on PET inserts in 6-well plates was aspirated, and monolayers were rinsed with PBS. 2 mL of 
basolateral fluid (serum-free DMEM at pH=7.4 in 10 mM HEPES buffer) was added to the 
basolateral side, and 1 mL of apical fluid (serum-free DMEM at pH=5.5 in 10 mM MES buffer) 
containing 200 nM 55FeCl3 and either DMSO vehicle, hinokitiol, C2deOHino, deferiprone, PIH, 
SIH or deferoxamine mesylate (Sigma D9533) (500 nM Hino/C2deOHino for DMT1-deficiency, 
1 µM Hino/C2deOHino for FPN1-deficiency, or indicated concentration from a 1000X stock in 
DMSO) was added to the apical side via addition on the wall of the membrane insert without 
disrupting the cell monolayer. The monolayers were then incubated for four hours at 37 °C 
unless otherwise noted. A 100 µL aliquot of the basolateral fluid was removed, diluted in 
scintillation cocktail, and radioactivity was determined on a liquid scintillation counter to 
quantify relative amounts of 55Fe transport. To determine intracellular 55Fe, the basolateral and 
apical media was removed, and the monolayer was rinsed with PBS (x2). The cells were then 
lysed with 500 µL of 200 mM NaOH with nutator mixing overnight, and radioactivity was 
determined on a liquid scintillation counter after diluting the cell lysate in scintillation cocktail. 
All values were normalized to shControl monolayers unless otherwise noted. Absolute iron 
levels were determined through calibration of 55Fe radioactivity levels with known standards and 
average mg of protein per membrane was determined by protein lysis with RIPA buffer 
144 
 
containing protease inhibitors and quantified through a BCA kit according to manufacturer 
instructions. Determination of 55Fe transport as a function of pH used the protocol described 
above except for the use of apical fluid containing either 10 mM PIPES (pH=6.5) or 10 mM 
HEPES (pH=7.4) in DMEM. 
TEER Determination in Caco-2 Monolayers  
To determine Caco-2 membrane integrity, transport studies were performed as described 
above, except for the use of non-radioactive iron instead of 55FeCl3. At the indicated time points, 
the transepithelial electrical resistance (TEER) was determined with an epithelial voltohmmeter 
and compared to the TEER of the membrane at the beginning of the experiment. 
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